Treatment of Diffuse Cutaneous Systemic Sclerosis with Hyperimmune Caprine Serum by Quillinan, NP
1 
 
 
  
Treatment of Diffuse 
Cutaneous Systemic Sclerosis 
with Hyperimmune Caprine 
Serum 
 
DR. NIAMH PATRICIA QUILLINAN 
University College London (UCL) 
MD (Res) Degree 
2 
 
Declaration 
 
I, Niamh Patricia Quillinan, confirm that the work presented in this thesis is my 
own. Where information has been derived from other sources, I confirm that this 
has been indicated in the thesis. 
 
 
Signed: ___________________________________    Date: 17/03/2016  
3 
 
Abstract 
Systemic sclerosis (SSc) is a multisystem autoimmune rheumatic disorder with 
high morbidity and the highest case specific mortality of the rheumatic diseases. 
There is no currently approved unequivocally effective treatment for SSc and 
therefore there is a huge unmet medical need for novel and effective therapies. 
Hyperimmune caprine serum (HCS) is a goat serum extract derivative produced 
from goats vaccinated with a detergent-inactivated HIV viral lysate. It contains 
caprine immunoglobulins and small molecular weight proteins as well as a 
CRH, α-2 macroglobulin (α-2M) and lipoprotein-related peptide-1 complex.  
 
In this thesis we explore the hypothesis that hyperimmune caprine serum 
improves skin and other measures of disease severity in established dcSSc by 
modulating immunological function that determines persistence of clinical 
disease. This hypothesis is explored through 1) a prospective clinical trial, 2) 
long-term clinical use and 3) detailed assessment of serum growth factors and 
cytokines, as well as established and exploratory markers of disease. 
 
The primary objective of the clinical trial was to explore safety and tolerability of 
HCS in established diffuse cutaneous systemic sclerosis (dcSSc). Secondary 
objectives included assessment of potential efficacy and biological activity and 
exploration of candidate biomarkers. 
There were no safety concerns and frequency of adverse events was not 
different between HCS and placebo group. MRSS improved in the HCS group 
and worsened in the placebo group, with more responders in the HCS group at 
26 weeks. Neuropathic pain improved in the HCS group compared to placebo. 
There was a trend to benefit for lung function indices. Cluster analysis revealed 
changes in a number of cytokines in the HCS group compared to placebo, in 
parallel with the skin changes. In particular, α-MSH and ACTH were significantly 
increased in the HCS group leading use to hypothesise that improvement in 
MRSS may have been mediated through the melanocortin system. 
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patients who decided not to go on compassionate HCS, D) Placebo patients 
who started compassionate HCS for 6 months. 
Figure 5.25: Graphic representation of Fractalkine levels from baseline to week 
26. 
Figure 5.26: Graphic representation of combined 26 week post hoc data, 
Fractalkine levels from baseline to week 26. 
Figure 5.27: Graphic representation of Fractalkine levels at baseline, week 26 
and week 52; A) HCS continuing on compassionate HCS for a further 6 months, 
B) HCS treatment discontinued after 6 month double-blind period, C) Placebo 
patients who decided not to go on compassionate HCS, D) Placebo patients 
who started compassionate HCS for 6 months. 
Figure 5.28: Graphic representation of COMP levels from baseline to week 26. 
Figure 5.29: Graphic representation of combined 26 week post hoc data, 
COMP levels from baseline to week 26. 
Figure 5.30: Graphic representation of COMP levels at baseline, week 26 and 
week 52; A) HCS continuing on compassionate HCS for a further 6 months, B) 
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HCS treatment discontinued after 6 month double-blind period, C) Placebo 
patients who decided not to go on compassionate HCS, D) Placebo patients 
who started compassionate HCS for 6 months. 
Figure 5.31: Graphic representation of GROα levels from baseline to week 26. 
Figure 5.32: Graphic representation of combined 26 week post hoc data, 
GROα levels from baseline to week 26. 
Figure 5.33: Graphic representation of GROα levels at baseline, week 26 and 
week 52; A) HCS continuing on compassionate HCS for a further 6 months, B) 
HCS treatment discontinued after 6 month double-blind period, C) Placebo 
patients who decided not to go on compassionate HCS, D) Placebo patients 
who started compassionate HCS for 6 months. 
Figure 5.34: Unsupervised cluster analysis heat map, baseline, 10 HCS 
patients and 10 placebo patients. 
Figure 5.35: Unsupervised cluster analysis heat map, Week 26, 10 HCS 
patients and 10 placebo patients. 
Figure 5.36: Unsupervised cluster analysis heat map, difference between 
baseline and Week 26, 10 HCS patients and 10 placebo patients. 
Figure 3.37: Supervised cluster analysis heat map, difference between 
baseline and Week 26, 10 HCS patients and 10 placebo patients.   
Figure 5.38: Unsupervised cluster analysis heat map, difference between 
baseline and Week 26, post-hoc combined data, 17 HCS patients and 13 
placebo patients. 
Figure 5.39: Supervised cluster analysis heat map, difference between 
baseline and Week 26, post-hoc combined data, 17 HCS patients and 13 
placebo patients. Yellow box highlights HCS patients. 
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1 Introduction 
1.1 Systemic sclerosis 
1.1.1 Epidemiology and classification 
Systemic sclerosis (SSc) is a multisystem disease that is associated with 
inflammation, fibrosis and vasculopathy.  It is clinically heterogeneous although 
certain clinical and investigational features are common to the majority of cases. 
It is uncommon, affecting approximately 1 in 10,000 in the UK but has a very 
high morbidity and the highest case-specific mortality of any rheumatic disorder 
with 50% of patients dying or developing major internal organ complications 
within 3 years of diagnosis (1).   
 
Only a few studies on SSc prevalence and incidence have been reported due to 
the low frequency of disease, large variability in clinical manifestations and 
severity, large variability in study design and lack of uniform diagnostic criteria. 
A recent systematic literature review looked at all reported studies in a 55 year 
period (2). Huge differences in prevalence and incidence were found in different 
geographical locations. The USA and Australia had the highest prevalence 
rates compared with Japan and Europe. Europe also displayed a north-south 
gradient with the lowest prevalence in Northern Europe. The prevalence in the 
USA and Australia is in the region of 250 cases per million, while in Japan it is 
38 per million for definite SSc. Studies in Greece and France showed a 
prevalence of 154 and 158 cases per million respectively, while in Northern 
Europe, studies in the UK and Iceland showed a prevalence of 88 and 71 per 
million respectively.  
 
Incidence rates in the USA appeared to have substantially increased from 0.6 
cases per million per year in 1947 to 19 cases per million per year in 2001, and 
has remained stable since then. In Australia, the incidence increased from 12 
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cases per million per year in 1982 to 22 cases per million per year in 1999. In 
Europe the incidence rates have been stable at about 3.7 cases per million per 
year in the Northern countries, however a study in Greece revealed a much 
higher incidence rate at 11 cases per million per year and in Spain 23 cases per 
million per year (3) (2). 
 
Several studies have also found ethnic variability with a lower age of onset and 
worse disease in black and Hispanic patients compared to Caucasians. SSc is 
rare in childhood and increases with age to a peak incidence in the 5th decade. 
It is more frequent in women than men and has an earlier age of onset in 
women (2). A twin study has found low concordance of SSc in twins (4.7%, 
monozygotic and dizygotic twins were similar) but a high concordance of anti-
nuclear antibodies in monozygotic twins (4).  
 
Environmental factors, particularly organic solvents and silica exposure, appear 
to increase the risk of SSc, especially in men. There is no evidence of an 
increased risk with breast implants. There also appears to be an increased risk 
of malignancy in SSc patients, particularly in lung, skin, hepatocellular, 
oropharangeal and oesophageal cancers as well as hematopoietic 
malignancies (3). Recent studies have also shown a link with malignancy in SSc 
and the RNA polymerase III antibody with a close temporal relationship 
between the onset of SSc and the onset of cancer (5) (6) (7) (8).  
 
The first standardised classification criteria for SSc were published in 1980 (9). 
The classification criteria were developed to ensure that patients enrolled into 
research studies had definite disease. However classification criteria are not the 
same as diagnostic criteria, though they list many of the same features. 
Diagnostic criteria are often more inclusive as they are based on physician 
diagnosis. The 1980 classification criteria were developed using a population of 
long-standing SSc patients. Therefore, they do not perform well in patients with 
early SSc or in patients with the limited cutaneous form of the disease. Since 
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the publication of the 1980 criteria, recent advances in laboratory testing for 
autoantibodies and nailfold capillaroscopy have improved the ability to diagnose 
SSc early. Therefore a new set of classification criteria were published in the 
last year which have a higher sensitivity and specificity than the 1980 criteria 
(10). 
 
The 2013 classification criteria are presented as an 11 item list with weighting of 
items. If a patient has skin thickening of the fingers of both hands that extends 
proximal to the metacarpophalangeal joints, the classification system assigns 9 
points for this one item alone, which is sufficient to classify the patient as having 
SSc with no further application of the point system needed. Otherwise a points 
system applies. The maximum score is 19 and patients with a score of ≥9 are 
classified as having SSc. All cases that were classified as SSc by the 1980 
criteria were also classified as SSc by the new criteria as well as a few cases 
that were not classified as SSc by the 1980 criteria. The system also performs 
well in early disease (10).  
1.1.2 SSc Clinical Features 
Systemic sclerosis is clinically heterogeneous.  All cases manifest Raynaud’s 
phenomenon and most have features of gastro-oesophageal reflux. There are 
two major subsets based on extent of skin fibrosis, limited cutaneous SSc 
(lcSSc) and diffuse cutaneous SSc (dcSSc) (11). Approximately one fifth of 
cases of SSc also manifest features of another autoimmune rheumatic disease.  
These are designated as SSc overlap syndromes. The commonest overlap 
feature is myositis but other cases manifest Sjogrens, vasculitis or inflammatory 
arthritis.  Clinical or serological features of systemic lupus erythematosus (SLE) 
may also be present. This project involves patients with dcSSc only, without 
overlap features. 
 
In patients with lcSSc, Raynaud’s phenomenon usually precedes the onset of 
skin fibrosis by many years, whereas in contrast, dcSSc patients usually 
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develop Raynaud’s contemporaneously with their skin symptoms. Persistent 
vasospasm can lead to ischaemia, digital ulceration and infarction or gangrene.  
 
Gastrointestinal involvement is the commonest visceral involvement. Almost all 
patients have gastro-oesophageal reflux, ranging from mild to severe. Some 
have difficulty maintaining adequate nutrition and require naso-gastric or naso-
jejunal feeding. Gastric antral vascular ectasia may occur, requiring laser 
therapy and multiple blood transfusions. Other symptoms include bacterial 
overgrowth in the midgut causing malabsorption and diarrhoea, severe gut 
dysmotility causing constipation and anal incontinence.  
 
Scleroderma renal crisis (SRC) is one of the most important major organ 
complications. SRC most often develops in patients with early dcSSc in 
association with rapidly worsening skin disease. It is associated with anaemia, 
new cardiac events, anti-polymerase I and III antibodies and high dose 
preceding medications such as steroids and non-steroidal anti-inflammatory 
drugs. Apart from SRC, many patients have some degree of renal impairment. 
 
Interstitial lung disease (SSc-ILD) and pulmonary arterial hypertension (PAH) 
are now the two major causes of morbidity and mortality. For this reason, 
annual screening tests such as echocardiogram, ECG and lung function tests 
are performed on all patients as early treatment improves survival and 
morbidity. Early SSc-ILD is often asymptomatic but in later stages can present 
with dyspnoea, chest tightness, cough and fatigue. SSc-ILD is more commonly 
found in dcSSc patients. PAH can also be asymptomatic until late in its course 
and has similar symptoms to SSc-ILD, though cough is more suggestive of 
SSc-ILD (12). 
1.1.3 Diffuse cutaneous systemic sclerosis (dcSSc) 
DcSSc represents approximately one third of SSc cases. Common features of 
dcSSc include proximal skin thickening (i.e. skin thickening that extends to 
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upper arms, thighs, trunk and/or back), a maximum modified Rodnan skin score 
(MRSS) of >18 and a short history of Raynaud’s syndrome. It is usually 
associated with anti-topoisomerase or anti-RNA polymerase III antibodies. The 
various hallmark autoantibodies occurring in SSc are mutually exclusive and 
several studies have demonstrated that individuals carrying each of these 
autoantibodies are associated with different frequencies of internal organ 
complications (13) (14). This also allows patients who are at increased risk of 
pulmonary, cardiac or renal complications to be identified. Pulmonary fibrosis 
and renal crisis are more commonly associated with the dcSSc disease subset.  
 
DcSSc typically is most active in the first 3 years from onset (early stage 
disease) and this is the time during which major organ complications develop. 
The skin disease usually plateaus or improves over 1 to 2 years. Skin disease is 
the hallmark feature of SSc and can be associated with major disability. The 
severity and extent of skin involvement correlates to internal organ involvement 
(15). Skin inflammation causes oedema, pruritis, hypo-/hyper-pigmentation, and 
shiny inflamed skin resulting in skin thickening and fibrosis. Skin sclerosis can 
lead to joint contractures and loss of function. Although there is understandable 
focus on the high burden of severe skin and internal organ involvement in early 
stage diffuse SSc, with less than 3 years disease duration, there is also 
substantial burden at later stages and this has been highlighted in recent cohort 
studies (16).   
1.1.4 Pathogenesis and Pathobiology 
The pathogenesis of SSc is still poorly understood although it seems likely that 
there is interplay between inflammation, vascular and fibroblast dysfunction, 
lymphocyte activation, autoantibody production and connective tissue fibrosis. 
This leads ultimately to accumulation of the constituents of extracellular matrix, 
which replaces the normal tissue architecture in skin and internal organs, 
leading to organ failure (17) Figure 1.1.  
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Figure 1.1: The pathogenesis of SSc is a complex interplay between vasculopathy, 
inflammation and fibrosis. 
Genetic factors are thought to confer susceptibility to disease which is triggered 
by a combination of environmental factors such as solvents, toxins, infections 
and oxidative stress. Several genome wide association studies (GWAS) have 
identified single nucleotide polymorphisms (SNPs) in genes associated with 
SSc (18) (19) (20) (21) (22) (23) (24) (25). Other studies have identified 
changes in cytokine profiles and signalling pathways associated with SSc.  
 
Traditional models of pathogenesis have suggested that early vascular events 
associated with autoimmunity and inflammation lead to subsequent fibrosis.  
Although this is plausible and supported by preclinical mechanistic studies it is 
clear that a broad range of biological processes interact in SSc and that these 
include involvement of key pro-fibrotic cytokines such as transforming growth 
factor-β (TGF-β) and connective tissue growth factor (CTGF) as well as pro-
inflammatory cytokines such as IL-6 and TNFα. There is also increasing 
evidence of an imbalance in Th1/Th2/Th17/Treg system promoting inflammation 
and fibrosis and activation of B cells promoting production of autoantibodies 
(26).  
 
DcSSc is often categorised as early-stage or established/late-stage disease and 
it is possible that the pathogenic factors underlying the distinct phases of the 
disease are different.  In particular, pathogenic drivers of late-stage disease are 
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less clear, but there is emerging evidence that persistent perturbation of 
immune cell function is increasingly important (27).   
 
Vasculopathy is one of the hallmarks of the disease and peripheral 
vasculopathy or Raynaud’s phenomenon is one of the first symptoms and is 
present in almost all patients. As the disease progresses, loss of 
microvasculature occurs, causing tissue hypoxia and endothelial injury. This 
normally initiates vasculogenesis and angiogenesis. However, in SSc 
vasculopathy results from an inappropriate repair process after endothelial 
injury causing vasoconstriction, adventitial and intimal proliferation, 
inflammation and thrombosis. It involves all layers of the vessel wall and is 
characterised by fibrotic intimal hyperplasia. Endothelial dysfunction plays a key 
role and chronically impaired production of vasoactive mediators, such as nitric 
oxide and prostacyclin, combined with over-expression of vasoconstrictors such 
as endothelin-1 (ET-1) affect vascular tone and promote vascular remodelling 
(28). The expression of ET-1 is induced by TGF-β, and ET-1 is considered to be 
a downstream mediator of some profibrotic TGF-β responses (29). 
 
Vasculopathy in SSc displays a number of organ-specific features but also 
shares similarities in pathogenesis. Plexiform lesions develop in pulmonary 
arterial hypertension, which consist of endothelial cells and myofibroblasts. In 
renal crisis, the renal arteries display characteristic overgrowth of the 
epithelium, fibrinoid necrosis, onion-skin lesions and deposition of scar tissue in 
the blood vessels (17). In digital ulceration, vascular remodelling leads to 
progressive occlusion of the blood vessels and this, combined with reduced 
capillary density, results in hypoxia, necrosis and tissue loss (30). 
 
Vasculogenesis appears to be impaired in SSc. Endothelial progenitor cells 
(EPCs) and monocytic EPCs have a reduced ability to form new blood vessels 
in SSc. This is combined with impaired angiogenesis in SSc in spite of 
overexpression of angiogenic factors such as vascular endothelial growth factor 
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(VEGF), fibroblast growth factor (FGF) and interleukin-8 (IL-8).The dysregulated 
response to these angiogenic factors in SSc is a complex combination of 
multiple pathways. For instance, the angiogenic response to VEGF is affected 
by the downregulation of kallikrein 12 and the overexpression of Fra-2. 
Similarly, FGF is affected by pentraxin 3, urokinase plasminogen activator 
receptor and junctional adhesion molecule-A (31). 
 
Fibroblasts maintain the structural integrity of connective tissue, secreting 
fibrillar procollagens, fibronectin, and regulating the turnover and composition of 
the extracellular matrix (ECM). Following tissue injury, quiescent fibroblasts are 
activated during the wound healing and inflammation phase, producing 
granulation tissue and a provisional matrix, a process that is subsequently 
reversed to remodel the scar. In SSc, this scar is not properly remodelled and 
fibroblasts continue to promote a pro-fibrotic microenvironment rich in growth 
factors and ECM, resulting in excessive scar formation and fibrosis. 
 
In SSc, activated fibroblasts are responsible for the development of fibrosis and 
the accumulation of ECM molecules (17). Fibroblasts explanted from lesional 
skin in SSc synthesise increased collagen and fibronectin in vitro. Moreover, 
they show constitutive production of cytokines and chemokines and 
spontaneous myofibroblast transdifferentiation (32). Activated fibroblasts in SSc 
may be derived from a number of different origins. Mesenchymal precursor cells 
may be recruited from the bone marrow via the circulation or resident tissue-
specific percursors can be utilised from the surrounding tissues (33). Quiescent 
fibroblasts can be activated in a number of different ways including direct cell-
to-cell contact, stimulation by soluble mediators or by cell-matrix interaction 
(17). 
 
Hypoxia, TGF-β and Wnts promote the transition of precursor and non-
fibroblastic cell types towards an activated myofibroblast phenotype and PPAR-
γ (peroxisome proliferator-activated receptor gamma) promotes cellular 
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quiescence. TGF-β is the pre-eminent signal for connective tissue synthesis 
and is considered the core pathway in wound healing and pathological fibrosis. 
In normal fibroblasts, TGF-β induces a Smad-independant activation of c-Abl (c-
Abelson, a non-receptor tyrosine kinase). Endogenous c-Abl is required for 
profibrotic responses induced by TGF-β in vitro. An important downstream 
target of c-Abl is Egr-1. Fibroblasts lacking Egr-1 show loss of collagen 
stimulation in response to TGF-β and lesional skin biopsies from patients with 
SSc show increased Egr-1 expression and activity, making it a potent fibrogenic 
mediator in SSc (32). 
 
The Wnts constitute a large family of secreted signalling proteins important in 
embryonic organogenesis. While active in embryogenesis, the Wnts are 
normally tightly controlled in adults. Canonical Wnt signalling is initiated by 
ligand binding to Frizzled (FZD) and low density lipoprotein receptor-related 
protein (LRP) surface receptors, stabilising cytosolic β-catenin, blocking its 
degradation, which stimulates fibroblast activation. Abberant Wnt signalling is 
important in SSc (32). 
 
PPAR-γ modulates TGF-β signalling and mesenchymal cell plasticity. Studies 
show that PPAR-γ is a cell-intrinsic anti-fibrotic pathway and activation of 
PPAR-γ ligands resulted in abrogation of TGF-β induced collagen production 
and Smad-3 dependant transcriptional responses (34). PPAR-γ also blocks the 
activation function of Egr-1 (35). PPAR-γ plays a fundamental role in regulating 
mesenchymal cell lineage fate determination and can shift progenitor cell 
differentiation along fibrogenic or nonfibrogenic pathways. Animal studies have 
shown that reduction in PPAR-γ causes increased fibrosis and PPAR-γ 
expression and activity are impaired in lesional skin in SSc. PPAR-γ expression 
is also inversely correlated with TGF-β signalling (35). A schematic 
representation of the major players in the pathogenesis of SSc is presented in 
Figure 1.2. 
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Figure 1.2: Schematic representation of pathogenesis of SSc.. 
1.1.5 Immune abnormalities 
The immune system is also involved in the pathology of SSc. Cytokines play a 
major role in regulating the production of ECM by fibroblasts. Elevated levels of 
growth factors (TGF-β, connective tissue growth factor (CTGF), VEGF, FGF), 
interleukins (IL-2,4,6,8,10 and 13), chemokines (CCL-2, also called monocyte 
chemoattractant protein-1 (MCP-1)) and cytokines (tumour necrosis factor-
alpha (TNF-α), fractalkine and others) have been found in SSc patients (17). 
Interferon gamma (IFN-γ) inhibits, while IL-4 and IL-13 enhance collagen 
synthesis. 
 
Many recent studies have shown preferential accumulation of T cells producing 
high levels of IL-4 and IL-13 belonging to a Th2-like subset in SSc. Th2 
cytokines favour collagen production, are pro-fibrotic and pro-angiogenic, 
whereas Th1 cells are anti-fibrotic and anti-angiogenic but it is unknown what 
drives Th2 differentiation in SSc. MCP-1 is produced in large amounts by SSc 
skin fibroblasts and has a direct role on collagen and matrix metalloproteinase-1 
(MMP-1) production. It is produced by both Th1 and Th2 cells and is present at 
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sites of ongoing fibrosis (36). Other studies suggest a Th1 response especially 
in early inflammatory SSc, which seems to decrease in later disease whereas 
Th2 responses appear to actively promote fibrosis throughout (37). 
 
Th17, as well as IL-17, appears to be increased in SSc patients. TGF-β, IL-1 
and IL-6 have a role in Th17 priming and are all increased in SSc patients. Th17 
appears to be anti-fibrotic and pro-inflammatory but several studies suggest that 
SSc fibroblasts may be resistant to the effects of IL-17. Regulatory T cells 
(Tregs) are reciprocally linked to Th17 cells and data are conflicting in SSc. 
Tregs are reported to be reduced in number and defective in function in 
SSc.Th22 cells (producing IL-22) also appear to be increased in SSc, though 
little is known about these cells in SSc. There was a positive correlation 
between Th22 cells and CCR6 and SSc-ILD was strongly associated with an 
increased number of Th22 cells (37).  
 
B cell activation is enhanced by a Th2 environment and Th2 cytokines enhance 
immunoglobulin production by B cells. B cells, in turn, promote Th2 cell 
production with their antigen presenting capacity. B cells can also affect 
dendritic cells as IL-10 produced by activated B cells inhibits IL-12 production 
by dendritic cells, promoting Th2 differentiation. Activated B cells also produce 
IL-6, and several studies have found increased IL-6 in skin and serum of SSc 
patients (38) (39). In addition to autoantibody production, 
hypergammaglobulinema and polyclonal B cell hyperactivity, other B cell 
abnormalities are detected in SSc. Total B cells are increased, with naive B 
cells increased and memory B cells and plasmablasts reduced. There is also 
over-expression of CD19 (40). 
 
Autoantibodies are detectable in the vast majority of SSc patients. Currently 
there are 5 major autoantibodies associated with SSc, being mutually exclusive 
and associated with different patterns of internal organ involvement. These are 
anti-topoisomerase antibody (anti-Scl70), anti-centromere antibody, anti-RNA 
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polymerase III antibody, anti-U1 and U3 (anti-fibrillarin) RNP antibodies. There 
is also anti-PMScl antibody, which is associated with overlap SSc and 
polymyositis, and a number of other antibodies under investigation such as 
antibodies against MMP1 and 3, heat shock protein 47 (HSP47), anti-fibrillin 1, 
anti-fibroblast antibody (36), and anti-endothelial cell antibodies (which may 
also have a pathogenic role) (41). Ahmed et al showed that SSc sera from both 
dcSSc patients (with anti-topoisomerase antibodies) and lcSSc patients (with 
anti-centromere antibodies) contain anti-endothelial cell antibodies, which can 
trigger apoptosis and are associated with increased caspase-3 activity as well 
as the re-expression of endothelial cell fibrillin 1.  
 
Another recent study (42) shows higher levels of anti-angiotensin II type 1 
receptor antibodies and anti-endothelin-1 type A receptor antibodies in SSc 
sera compared to healthy controls and other autoimmune diseases.  A strong 
correlation between the 2 autoantibodies was found. Furthermore, the authors 
show that the autoantibodies induce ERK 1/2 and induced gene expression of 
TGF-β, blocked by their respective blocking agents. Patients with high levels of 
the two autoantibodies had a higher risk of developing dcSSc, late onset PAH, 
ILD and digital ulcers and a higher risk of dying from SSc-related causes. 
Lastly, the 2 autoantibodies have similarities to anti-endothelial cell antibodies 
since endothelial cells express both receptors. In another study by the same 
group (43), the authors found that these 2 autoantibodies induce activation of 
fibroblasts, increased expression of IL-8 and increased neutrophil migration into 
target tissues. Animal studies with passive transfer of the antibodies showed 
marked structural alteration of the lungs with increased interstitial cellular 
density and wound migration studies showed reduced wound repair correlating 
to the two autoantibodies. The authors also show increased type 1 collagen 
expression in response to the autoantibodies, attenuated somewhat by their 
respective blockers. 
 
Different antibodies are also associated with different organ complications. Anti-
topoisomerase antibodies are associated with interstitial lung disease, while 
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anti-RNA polymerase III is associated with scleroderma renal crisis and a 
predisposition to malignancy. Anti-U3 RNP is most often seen in males and 
African Americans and is associated with cardiac and skeletal muscle disease, 
Table 1.1 (44). 
 
Table 1.1: Auto-antibodies in SSc and their clinical associations 
 
Autoantibody Clinical associations Frequency Specificity 
for SSc 
Anti-
topoisomerase 
dcSSc>lcSSc, SSc-ILD, 
severe digital vasculopathy 
9-39% 97-100% 
Anti-centromere lcSSc, isolated PAH, Primary 
biliary cirrhosis, protective for 
SSc-ILD  and SRC 
16-39% 99.8-100% 
Anti-RNA 
polymerase III 
dcSSc, SRC, malignancy 4-25% 98-100% 
Ant-U3 RNP dcSSc>lcSSc, severe 
disease, muscle involvement, 
PAH 
1-6% - 
Anti-PMScl Polymyositis/dermatomyositis 
overlap, arthritis overlap, ILD 
0-6% 45% 
Anti-Th/To lcSSc, PAH, SSc-ILD 1-7% - 
Anti-U1 RNP Overlap syndromes 5-35% - 
Anti-Ku Myositis, arthritis 1-3% - 
Anti-U11/U12 
RNP 
ILD 1.6-5% - 
Abbreviations: dcSSc; diffuse cutaneous systemic sclerosis, lcSSc; limited cutaneous systemic 
sclerosis, SSc-ILD; systemic sclerosis associated interstitial lung disease, PAH; pulmonary 
arterial hypertension, SRC; scleroderma renal crisis 
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Over the past few years, through research we have a better understanding of 
the role of the innate immune system in autoimmune disorders such as SSc, 
particularly the link between inflammation and fibrosis. The innate immune 
system provides immediate defence against a variety of pathogens and 
endogenous danger signals based on recognition of a variety of microbial 
patterns and acts to trigger inflammation and promote development of specific 
adaptive immune responses to pathogens. The innate immune system 
responds rapidly to the presence of certain patterns that microbes possess 
more commonly than mammalian hosts and these patterns trigger pattern 
recognition receptors (PRRs) which are widely expressed on cells of the 
immune system, epithelial and mesenchymal cells (such as fibroblasts). 
Toll-like receptors (TLRs) are important PRRs. All TLRs except TLR-3 signal 
through the adaptor molecule MyD-88. TLRs are divided into 2 groups; one 
group based on the cell surface and recognise bacterial, fungal, mycobacterial 
and parasitic patterns (these include TLR-1, -2, -4, -5, -6 and -10) and the 
second group is found intracellularly in endosomes and recognise bacterial and 
viral patterns (these include TLR-3, -7, -8, and -9). Of the first group, TLR-2 and 
-4 are most relevant to SSc and bleomycin has been recently found to be a 
TLR-2 ligand. The second group have also been implicated in SSc as well as 
SLE. In SLE, anti-DNA antibodies bind to the Fc receptor on plasmacytoid 
dendritic cells (pDCs) and this leads to internalisation and delivery of the 
nucleic-acid containing immune complex to an endosomal compartment where 
TLR-9 is activated by a pattern on the ssDNA. Similar activation with immune 
complexes containing RNA has been identified and these have been shown to 
activate TLRs -7 and -8, which also reside in the endosome. There have been 
several recent advances in SSc research that show a similar mechanism may 
be occurring in SSc (45). 
 
 After activation of the endosomal TLRs, the pDC produces a burst of type I 
interferon (IFN). An “interferon gene signature” has been found in both SLE and 
SSc and in SLE correlates with disease activity, though a correlation has not 
been found in SSc. Type I IFN includes IFNα and β, and their production is 
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initiated early in the innate immune response. IFNα and β also increase type II 
IFN (IFNγ) by T cells and dendritic cells (DC). Polymorphisms associated with 
SSc (both anti-topoisomerase and anti-centromere positive) have been found in 
the genes for IRF-5 (IFN regulatory factor-5), which regulates IFN genes. IRF-5 
polymorphisms have also been associated with SSc-ILD (45). 
 
TLR-3 stimulation increased fibrosis and endothelin-1 production in fibroblasts 
and endothelial cells. Type I IFN also increases TLR-3 expression on healthy 
and SSc fibroblasts, potentially extending the inflammatory and fibrotic 
response. Human microvascular endothelial cells also express TLR-3 on the 
cell surface as well as in endosomes. The association between endothelial cell 
apoptosis and autoimmunity has been strengthened by the finding that 
apoptotic endothelial cells localize the centromere protein, CENP-B, to 
apoptotic blebs. CENP-B is the protein target of anti-centromere antibodies 
commonly found in patients with limited SSc (45). A recent study also 
demonstrated that IFN genes are up-regulated in skin from SSc patients (as 
opposed to PBMCs) and incubation with the synthetic TLR-3 agonist poly (I:C) 
induces both the IFN signature and TGF-β responsive genes (46).  
 
A role for TLR-4 has been demonstrated in SSc patients in which monocytes 
derived from SSc patients with interstitial lung disease have an enhanced pro-
fibrotic phenotype and can differentiate into fibrocytes (CD45+ CD34+) and 
secrete higher collagen after exposure to the TLR-4 agonist LPS, implying that 
TLR-4 is inducing a pro-fibrotic situation in the monocytes. In a recent study it 
was demonstrated that TLR-4 is elevated in SSc biopsies from both skin and 
lung and in vitro stimulation with dermal fibrosis with LPS produced global gene 
changes related to wound healing. It was also shown that in vitro stimulation of 
dermal fibroblasts with LPS and TGFβ leads to synergy in the production of 
collagen and that this is abrogated with knockdown of TLR-4, the LPS receptor. 
It is unlikely that in SSc LPS is the agonist responsible for TLR-4-mediated 
fibrosis but more likely that endogenous signals derived from damaged or redox 
‘stressed’ cells are responsible for the fibrosis. One ‘danger signal’ released 
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from damaged cells that binds TLR-4 is HMGB-1 and this is elevated in tissue 
and serum from SSc patients and correlates with the skin score (46).  
 
The inflammasome is an intracellular association of proteins, which act as a 
receptor for multiple ‘danger signals’ and results in triggering of the caspase 
system and release of IL-1β. The NLR (NOD (nucleotide-binding and 
oligomerization domain)-like receptor) family are part of the PRR system that 
are localized to the cytoplasm. Here these receptors recognize intracellular 
motifs. Upon ligation they lead to the activation and initiation of NF-κB (nuclear 
factor κB) and MAPK (mitogen-activated protein kinase) ultimately leading to 
the expression of pro-inflammatory cytokines. NALPs, when activated, create a 
complex that recruits pro-caspase-1, which is activated, resulting in recruitment 
of the adaptor protein ASC (apoptosis associated speck-like protein containing 
a CARD (caspase recruitment domain)) and activation of the ‘inflammasome’, a 
molecular platform, resulting in the activation and secretion of IL-1β and IL-18 
via caspase-1. Environmental/occupational exposure to silica has been 
associated with SSc as mentioned above. The mechanism by which silica 
causes inflammation was recently described to involve activation of the NALP3 
inflammasome. The NALP3 inflammasome is also activated in other 
inflammatory disorders such as gout and pseudogout and autoinflammatory 
disorders such as Muckle-Wells (46). 
 
Polymorphisms in NLRP1 (nucleotide-binding domain, leucine-rich-containing 
family, pyrin domain-containing 1) are associated with SSc-related pulmonary 
fibrosis and anti-topoisomerase-positive SSc patients. Furthermore, in SSc 
dermal fibroblasts, elevated levels of NOD2, NLRP3 and AIM2 (absent in 
melanoma 2) were observed. AIM2 is an intracellular bacterial and a viral DNA 
sensor. A recent study demonstrated that the inflammasome is necessary to 
mediate fibrosis induced by bleomycin. Using the bleomycin model of fibrosis 
they showed that NALP3-knockout mice had significantly reduced fibrosis 
compared with wild-type mice receiving bleomycin. Furthermore, they 
demonstrated that uric acid is the trigger for the activation of the inflammasome 
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as treatment of the mice with allopurinol reduced fibrosis in the wild-type mice 
given bleomycin. It is known that IL-1 is essential for pulmonary fibrosis in the 
bleomycin model of lung fibrosis (46). Furthermore, Artlett et al (47) inhibited 
caspase 1 using small molecule inhibitors or siRNA which showed that IL-1β, 
IL-18 and collagen secretion were attenuated in the SSc fibroblasts and also the 
hydroxyproline levels were lower. Also, their knockout mice were resistant to 
bleomycin induced fibrosis. Interestingly, in the formation of α-smooth muscle 
actin, the myofibroblast marker was also attenuated.  
 
Most cells can perform functions of the innate immune system, however mast 
cells, macrophages, dendritic cells and natural killer (NK) cells are noteworthy. 
In addition to histamine, mast cells secrete several cytokines and other 
mediators associated with fibrosis such as TGF-β, IL-4, IL-13, platelet-activating 
factor, PDGF, MCP-1, IFN-α and endothelin-1. Mast cells have recently been 
identified as an important source of TGF-β in the skin of SSc patients. In SSc, 
mast cells are found in increased numbers in clinically uninvolved skin from 
early SSc patients, and these mast cells already express markers of activation 
and are degranulated. Later in the disease course, when the skin is atrophic, 
the density of mast cells appears to be decreased. Monocytes and 
macrophages have long been recognised as one of the predominant 
inflammatory cells present in the dermis of SSc patients. The macrophages are 
activated and produce CCL-2, TGF-β and PDGF. Natural killer cells are 
cytotoxic lymphocytes that can be rapidly activated and proliferate upon 
stimulation with type I IFN. Like mast cells and macrophages, NK cells can 
secrete several factors implicated in the pathogenesis of fibrosis such as IL-13, 
IL-10 and TGF-β. Circulating NK cells are increased in SSc and have an 
activated phenotype, though their function is controversial (45).   
 
Dendritic cells are the ‘professional antigen-presenting cells’ of the immune 
system. The two main types of DCs in humans are the pDC and the 
conventional or myeloid DC that express TLR-2 and TLR-4 and secrete IL-12 
on activation. pDCs express CD123 and were recently found to be increased in 
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SSc dermis by Fleming et al (48) as part of a translational analysis from the SSc 
Cyclophosphamide or Transplantation (SCOT) clinical trial. Following 
autologous stem cell transplantation treatment, the patients had dramatic clini-
cal improvement and repeat skin biopsy showed decreased pDC density and 
less IFN-α mRNA. Langerhans cells (LCs) are a type of DC that circulate 
between the epidermis, dermis and lymphoid tissue. Several studies have 
shown a relative paucity of LC in SSc compared with healthy controls, although 
the differences were more pronounced in lesional skin. LC were found to 
promote regulatory T cells and IL-10 production (45). 
 
IL-6 is a classic proinflammatory cytokine that is often dysregulated in 
autoimmune diseases. IL-6 is also associated with the wound healing pathway 
and deserves particular mention. It can be synthesised by a wide variety of cells 
and can have effects on many different cell types including B cells. The IL-6 
receptor (IL-6R) can bind IL-6 in low affinity binding; however signal 
transduction requires a signalling molecule gp130, which is expressed on 
virtually all cells. IL-6 signalling is complex; classic signalling involves 
dimerisation of IL-6R with gp130, leading to activation of Janus kinases (JAKs), 
signal transducers and activators of transcription (STATs) and ERK and is 
restricted to hepatocytes and lymphocytes expressing membrane bound IL-6R. 
However there is a second signalling pathway called trans signalling which can 
occur in all cells expressing gp130 via soluble IL-6R. Soluble gp130 is the 
natural inhibitor of trans signalling but does not affect the classic pathway. IL-6 
can upregulate αSMA and in vitro blockade of IL-6 reduced fibroblast production 
and secretion of collagen. Tissue inhibitors of metalloproteinases (TIMPs) are 
specific inhibitors of matrix metalloproteinases (MMPs) which break down ECM. 
TIMP-1 is elevated in SSc and IL-6 enhances TIMP-1 production in a STAT-3 
dependant manner (49). Recently it has been shown that IL-6 trans signalling is 
mediated through a TGF-β signalling and downstream Smad3 (50). 
 
Khan et al report that high levels of IL-6 correlate with thrombocytosis in dcSSc 
patients and serum IL-6 levels positively correlate with CRP and platelet count. 
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When IL-6 and IL-6R are added to cultured fibroblasts, there was an increase in 
collagen expression and also in αSMA and CTGF. This group confirmed a 
correlation between skin score and IL-6 levels but there was also a moderate 
correlation between peak skin score and IL-6 at time of presentation. In a 
subgroup of dcSSc patients, serum IL-6 at presentation correlated with MRSS 
at 36 month follow-up and furthermore, high IL-6 levels at presentation 
predicted higher mortality with 15 year survival 30% in these patients compared 
to 93% in the group with low IL-6 at presentation (39). Serum IL-6 has also 
been shown to be an independent predictor of DLCO decline in SSc-ILD with a 
threshold level of 7.67pg/ml. In a larger cohort IL-6 levels >7.67pg/ml was 
predictive of FVC and DLCO decline within the first year and predictive of death 
within the first 30 months. When stratified according to ILD severity (FVC<70), 
serum IL-6 was predictive of functional decline or death in the first year in 
patients with mild disease only (38). 
1.1.6 Immunomodulatory treatment 
The cornerstone of management of early stage diffuse SSc is broad spectrum 
immunosuppression. Currently, no treatment is proven to be effective in 
preventing progression of disease, reversing fibrosis or improving long-term 
outcome. Several studies have reported effectiveness of immune modulating 
drugs in the treatment of this disease, although these have mostly been in 
open, uncontrolled trials. These drugs include azathioprine, cyclosporin, 
methotrexate, mycophenolate mofetil and cyclophosphamide (51). However, an 
observational study looking at outcomes of 5 different treatment protocols in 
early dcSSc found no significant difference between the treatment protocols 
(52). 
 
Emerging data support the benefit of immunosuppression for skin and lung 
fibrosis in SSc, especially when given at the early stages of disease The 
EULAR Scleroderma Trials and Research group (EUSTAR) recently published 
a set of core recommendations for treatment of SSc. Cyclophosphamide (2-3 
mg/kg), in combination with low-dose prednisone is recommended for skin 
disease in dcSSc and for lung fibrosis. Methotrexate can be used in skin 
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disease or in patients with features of overlap inflammatory arthritis. 
Mycophenolate mofetil is increasingly being used in skin and lung disease with 
azathioprine as an alternative option (53). The main currently used treatment 
approaches are discussed below. 
1.1.6.1 Cyclophosphamide 
Two open label trials of cyclophosphamide have shown possible benefit in 
scleroderma lung disease (54) (55). A further open label trial in 18 patients 
showed stabilisation of lung function for up to 3 years after 1 year treatment 
(56). Two retrospective case series also show stabilisation in lung function with 
cyclophosphamide (57) (58). Two landmark randomised, double-blind, placebo 
controlled trials for cyclophosphamide in SSc-ILD, the Scleroderma Lung Study 
(oral) (59) and the FAST trial (intravenous) (60), showed beneficial effects on 
lung function. The 2 year data from the Scleroderma Lung Study showed a 
sustained benefit in dyspnoea index and difference in FVC of 6.8% predicted in 
the cyclophosphamide treated group at 18 months but this benefit was no 
longer significant at 2 years, suggesting that longer term immunosuppression 
may be warranted to maintain benefit (61). There were also beneficial effects on 
skin and this has also been seen other open-label uncontrolled trials (62) (63). 
 
Berezne et al report stabilisation or improvement in 70% and 51.8% of their 
patients after 6 months and 2 years, respectively with intravenous 
cyclophosphamide followed by oral maintenance immunosuppression in a 
multicentre retrospective cohort (64). However, a meta-analysis by Nannini et al 
concluded that while previous trials with cyclophosphamide show a statistically 
significant improvement in lung function, they do not show a clinically significant 
improvement  (>10% change in lung function) (65). A further recent long term 
observational study found that 5 of 13 patients relapsed after 1 year and 
concluded that long term immunosuppression maintenance will be necessary to 
maintain remission (66) and an open label study found improvement or 
stabilisation in 31 of 36 patients (67). 
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1.1.6.2 Methotrexate 
Methotrexate has been reported to be effective in a case-report (68), three open 
studies (69) (70) (71) and two placebo-controlled double-blind trials (72) (73). In 
these studies improvement was observed in approximately 70% of patients, 
either in skin involvement or arrest of progression of internal organ involvement.  
 
The largest of these trials was considered to be underpowered (72). Although 
there was statistically significant improvement, it was not considered clinically 
significant. In this study, the dose of methotrexate was modest at 15mg and 
was not increased in cases of inefficacy. There is a lack of data about 
progression or stabilisation of lung fibrosis with methotrexate, although this 
study shows minor non-significant improvements. Using the data from the Pope 
study for reanalysis using Bayesian methods, a recent article by Johnson et al 
suggest that, in fact, methotrexate has a high probability of beneficial effects in 
SSc for skin disease and global assessment (74).   
 
Currently, methotrexate is the treatment of choice in patients with SSc/myositis 
or SSc/inflammatory arthritis overlap syndromes. A rare but severe side effect 
of methotrexate is pneumonitis. Methotrexate should therefore be used 
cautiously in scleroderma patients with advanced pulmonary fibrosis who have 
diminished respiratory reserve. 
1.1.6.3 Mycophenolate Mofetil 
Mycophenolate mofetil (MMF) has been used in various autoimmune diseases 
particularly systemic lupus erythematosus with good results. In a small case 
series, benefit in skin scores was reported with MMF when given as 
maintenance treatment after anti-thymocyte globulin (ATG) induction treatment 
(75). A further report from a large retrospective study showed similar efficacy in 
skin improvement and reduced progression to severe lung disease in SSc when 
compared to other immunosuppressive drugs, with a good safety profile (76).  
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A small retrospective analysis found an improvement in SSc-ILD with MMF, in 
keeping with similar findings in other small case series (77). One retrospective 
case control study comparing cyclophosphamide and mycophenolate found no 
change in PFTs in either group but a radiological decline in the MMF group (78). 
A further recent retrospective observational study on 98 patients also showed 
an improvement in MRSS compared to historical controls taken from other 
studies (79). 
 
Two recent prospective observational trials in 25 (80) and 15 (81) early dcSSc 
patients reported significant improvement in skin score and though not powered 
for lung, showed stable/slight improvement in lung function tests. Two 
prospective open label trials in connective tissue disease-associated lung 
fibrosis including 9 patients (82) and 14 patients (83) with SSc-ILD suggest 
benefit or stabilisation with MMF. The Scleroderma Lung Study 2 (SLS2) is 
currently underway with a study protocol assessing efficacy of 
cyclophosphamide versus mycophenolate mofetil. 
1.1.6.4 Azathioprine 
Most of the published data regarding azathioprine in SSc refers to maintenance 
immunosuppression using azathioprine after cyclophosphamide induction 
therapy (60) (64) (84). One study reported stabilisation of skin score and lung 
parameters with azathioprine maintenance treatment, but there was no control 
group in this study (84). One unblinded study reported better efficacy of 
cyclophosphamide compared to azathioprine (85) and two retrospective studies 
reported stabilisation of lung function with azathioprine treatment (86) (87). 
1.1.6.5 Tolerance to human Type I Collagen 
Several studies have identified a variety of autoantigens in SSc patients. One of 
these autoantigens is type I collagen (CI). A previous open-label study using 
bovine CI to induce immune tolerance to human CI showed very promising 
results, with a reduction in skin score of 23% (88). Patients with diffuse 
cutaneous SSc did better than the limited subset. Recently, a larger placebo 
controlled trial in diffuse cutaneous SSc showed no significant differences in 
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skin score in the total number of patients treated. However, a subgroup of 
patients with late stage diffuse cutaneous SSc had a significant reduction in skin 
scores. The authors concluded that it may be beneficial in selected patients and 
that further study of this interesting treatment is warranted (27). The results of 
this study were important for generating a hypothesis and the planning and 
setup of this trial. 
1.1.6.6 Intravenous Immunoglobulin 
Human pooled immunoglobulin contains polyclonal IgG antibodies against 
pathogens, foreign antigens and autoantigens. It is used in low doses as 
replacement therapy in immunodeficiency syndromes and in high doses as 
immunomodulatory therapy for autoimmune conditions such as dermatomyositis 
and idiopathic thrombocytopenia purpura. A number of open-label trials have 
shown an improvement in skin score with intravenous immunoglobulin (IVIG) 
(89) (90) (91) (92). A recent retrospective single centre observational study of 
30 patients with refractive dcSSc (with and without immunosuppressants) 
showed significant reduction in MRSS at 24 months, indicating that it may be an 
effective adjunctive treatment (93). To date, only one randomised double blind 
trial has been completed. In this trial, a single 5-day course of IVIG did not show 
significant improvement but a retreatment with a second course showed an 
improvement in skin score. The authors suggest further trials with repeated 
courses of IVIG should be considered (94).  
1.1.6.7 Haematopoietic Stem Cell Transplant (HSCT) 
Cases have been reported of patients with autoimmune diseases and coexisting 
haematological conditions, treated with HSCT and also experienced 
improvement in their autoimmune diseases. The first reports from the European 
Blood and Marrow Transplantation/European League against Rheumatism 
(EBMT/EULAR) Registry of HSCT in SSc showed a significant improvement in 
skin score, however, transplant related mortality was 17% (95). Transplant-
related mortality dropped to 8.7% on analysis of a second cohort, 3 years later 
and skin score improvements continued to be significant (96). A long-term 
follow-up study of 27 patients in the US, using a regime which included total 
body irradiation showed a skin score reduction of 39% at 12 months and a 
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continuing trend after this. Estimated progression-free survival was 64% at 5 
years (97). 
 
The long-term follow-up of two trials from the Netherlands and France with a 
median follow-up was 5 years showed 81% patients demonstrated a clinically 
beneficial response. 73% patients had a >25% reduction in skin score in the 
first year and 5 and 7 year survival was 96.2% and 84.8%, respectively (98). 
Another single centre study of 26 patients in Germany showed treatment related 
mortality 11% and progression free survival at 74% (99). 
 
The ASSIST trial (open-label) reported a much better outcome for skin and lung 
function in the HSCT arm compared to the cyclophosphamide arm. 19 patients 
were enrolled, 10 in the HSCT arm and 9 on cyclophosphamide alone. In the 
cyclophosphamide arm, 8 of 9 patients progressed and 7 of these were treated 
with HSCT after 1 year. Mean MRSS was higher in HSCT group at baseline and 
improved after 1 year, but worsened in the cyclophosphamide group after 1 
year. The MRSS in the patients who crossed over to HSCT also improved. 
There were no deaths during the study period, possibly due to relatively mild 
disease at entry and a small sample size (100). Burt et al also report a 
retrospective analysis of 90 patients who receive HSCT as part of a study or on 
compassionate basis in the US. Five of 90 patients died from treatment related 
causes (6%), 4 of these from cardiac causes. HSCT improved MRSS and FVC 
in treated patients. 5 year relapse free survival was 70% (101). 
 
The results of two further trials (ASTIS and SCOT) have been reported at 
international conferences. The Autologous Stem cell Transplantation 
International Scleroderma (ASTIS) trial was the first phase 3 trial enrolling 156 
patients over 8 years (2001-2009) in 29 centres. Patients were randomised to 
HSCT or 12 monthly pulses of IV cyclophosphamide. Patients randomised to 
HSCT experienced more events and higher mortality in the first year compared 
to controls but had a significantly better long-term event free and overall 
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survival. Treatment related mortality was 10% in the HSCT group. There were 
no treatment related deaths in the control group, but most deaths occurred due 
to disease progression. 8 patients in the cyclophosphamide group received 
rescue HSCT and 2 in the HSCT group received rescue IV pulsed 
cyclophosphamide (102) (103). Mean change in baseline to 2 years follow-up 
for MRSS showed significant benefit for the treatment group compared to the 
control group (MRSS improvement by 19.9 in treatment group vs 8.8 in control 
group, p<0.001). There was also significant improvement in FVC, TLC, HAQ-DI, 
physical component of SF-36 and the EQ5D, whereas creatinine clearance was 
significantly worse in the treatment group. Sensitivity analysis showed loss of 
significance for FVC, TLC, HAQ-DI and SF-36 due to missing data and smaller 
patient numbers when data was missing because of death. 7 of the 8 patients 
who died due to treatment in the HSCT group were current or former smokers 
(103). 
 
The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial is a 
randomised controlled phase 3 trial still ongoing in North America enrolling 
patients from 2005-2011, with similar endpoints and control treatment to ASTIS 
but a different protocol for HSCT which includes total body irradiation and 
equine anti-thymocyte globulin (instead of the rabbit form in ASTIS) as part of 
conditioning. Renal toxicity was observed in 12% HSCT patients and so 
bilateral lung and kidney shielding was employed as a modified protocol. The 
results of this trial are still awaited (102). 
1.1.6.8 Biological Agents  
A retrospective study of etanercept in SSc-associated inflammatory joint 
disease showed a good response of joint disease with a trend towards 
improvement in skin score (104). A more recent prospective open-label pilot 
study of infliximab showed a stabilisation of skin score and a fall in two 
laboratory markers of collagen synthesis, but no clear benefit was seen (105). A 
further observational study on 10 patients with SSc and inflammatory arthritis 
concluded that etanercept was effective in inflammatory arthritis associated with 
SSc, but there was no change in MRSS in this study (106). 
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Rituximab, a monoclonal antibody against CD20 present on mature B cells, is a 
B cell depleting agent. Four small open label trials have been reported in SSc 
with conflicting results. Three report benefit in skin (107) (108) and lung function 
(109) while another found no improvement is skin disease in SSc (110). 
However one of these trials, the patients remained on other treatments and the 
Rituximab and conventional treatment groups were not matched (109).  
 
Two further open label trials, each with 8 patients and for 2 years, again report 
significant improvement in skin and lung disease (111) (112). A recent nested 
case-control study from the EUSTAR group has reported improvement in skin 
and stabilisation in lung disease, providing further encouraging results (113). 
Further double blind randomised trials are needed to confirm efficacy. 
 
The first case report on 2 patients treated with Tocilizumab, an IL-6 receptor 
antibody, showed improvement of MRSS in these patients (114). The same 
author reported another case of dcSSc that improved with both skin score and 
joint range of motion with Tocilizumab (115). This is particularly interesting in 
view of the data above on IL-6 associated with the pathogenesis of SSc and IL-
6 being a predictor of worse disease and mortality in SSc patients. Abatacept is 
cytotoxic T lymphocyte antigen 4 immunoglobulin (CTLA4Ig). EUSTAR have 
reported finding from an observational study showing significant improvement in 
joint counts in patients treated with tocilizumab and abatacept, but no change in 
skin or lung parameters and no improvement in SSc-related myositis (116). 
 
A randomised double-blind clinical trial of Tocilizumab in SSc is currently 
underway and full results are eagerly awaited. Interim 24 week data were 
presented at the American College of Rheumatology annual meeting 2014. 87 
patients were enrolled, 43 tocilizumab and 44 placebo. There was a trend to 
improvement in MRSS (p=0.09) and numerically more patients in the 
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tocilizumab group achieved a clinically important improvement in MRSS (>4.7 
units improvement), though the primary endpoint was not met. More patients in 
the placebo group had worsening of lung function compared to the tocilizumab 
group. The frequency of AEs and SAEs were similar, though there were more 
infectious complications in the tocilizumab group (117).  
 
1.1.6.9 Other Treatments 
Two open-label trials for imatinib have been reported, the first showing some 
efficacy in SSc-related lung disease, but with a note of caution regarding the 
large number of adverse events from the medication (118). The second open-
label trial also showed improvement in skin and lung function (119) and an 
extension phase recently published showed continued improvement in skin 
score with most adverse events that were attributed to the medication being 
graded mild to moderate (120). Two randomised double-blind trials have also 
been reported, showing efficacy in skin disease in one, though the cohort 
enrolment criteria were not uniform with regard to skin disease and 
classification of SSc (121) and in the second study, imatinib was very poorly 
tolerated so efficacy could not be assessed properly, though skin score did not 
change between those who completed 6 months of treatment and those who 
did not (122).  
 
Two further studies were reported at 2010 and 2011 American College of 
Rheumatology conferences. The first trial in 7 patients showed improvement in 
skin score (123). The second trial showed no efficacy at 24 weeks and trend to 
improvement of skin score at 48 weeks, but when compared to a historic cohort, 
the trend to skin improvement was not significant (124) (125) (126). 2 other 
recent reports, the first a case series of 6 patients (127) and the second a trial in 
30 patients with SSc-ILD, suggest that low dose imatinib (127) may be tolerated 
better and may improve SSc symptoms. 
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A recent randomised single blind pilot trial comparing rapamicin with 
methotrexate in SSc reported improvement in skin score in both groups, 
however further follow-up studies will need to confirm efficacy (128). 
 
Other novel approaches include rilonacept (anti-IL-1), pomalidomide, 
ambrisentan, tadalafil, LPA receptor antagonists, PPARγ agonists, and anti-IL-
13 monoclonal antibody which are all potential treatments affecting different 
targets and are currently in trials or trials are being planned (129). 
 
1.1.7 SSc general management approaches 
As SSc is a clinically heterogeneous disease, management is tailored to the 
individual patient, depending on stage, severity and organ complications. A 
general approach to management is outlined in Figure 1.3. Once a patient has 
a potential diagnosis of SSc, full clinical history and examination including 
MRSS, serological profile, chest radiograph, pulmonary function tests, 
echocardiogram and ECG should be performed to investigate for organ based 
complications and overlap features (12). After diagnosis, the benefit of regular 
screening tests should not be underestimated. A report by Nihtyanova et al 
demonstrated that regular screening has led to better ascertainment of organ-
based complications, with earlier diagnosis and treatment of these 
complications, leading to better survival in these patients. Therefore, it is 
recommended to perform non-invasive screening tests on an annual basis in 
stable patients, and more frequently if the patient becomes progressively 
symptomatic. These tests should include an ECG, routine blood tests, 
echocardiogram and pulmonary function tests. If these indicate possible organ 
complications, then further tests such as right heart catheter, high resolution CT 
chest scan or cardiac MRI may be ordered (16). 
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Figure 1.3: General management of SSc 
Immunosuppressants remain the cornerstone of management of skin disease 
and organ complications in SSc. Treatment of skin disease is usually indicated 
in the first few years of disease in those who have active dcSSc and can be 
discontinued in most patients after a few years, once the disease becomes less 
active. The choice of immunosuppressant, as discussed above, depends on 
other organ complications and whether there are any overlap features. If there 
are no organ complications or overlap features, MMF or MTX are the most 
appropriate choices. In very severe cases, cyclophosphamide or HSCT may be 
considered. If there is evidence of SSc-ILD, where FVC >70 on lung function 
tests, MMF is normally used, while in more extensive lung disease IV 
cyclophosphamide is more appropriate. In patients unresponsive to treatment, 
Rituximab is considered. Patients with myocarditis are treated with IV 
cyclophosphamide or MMF and if immunosuppression is required in renal crisis, 
low dose MMF is considered. In patients with overlap, immunosuppression 
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appropriate to the overlap syndrome is considered. For example, if there are 
features of joint synovitis or myositis, MTX is more appropriate (130). 
 
Apart from immunosuppression, it is important to consider symptomatic 
treatment of skin inflammation and other symptoms. Pruritis is treated with 
topical measures, antihistamines, and if severe, low dose glucocorticoids and/or 
leukotriene receptor antagonists.  Telangiectases can be treated with laser. 
Minocycline can be considered for calcinosis but, unless severe, surgery is not 
usually indicated as calcinosis tends to recur. Calcinotic deposits may become 
infected and ulcerated so may require courses of antibiotics. 
 
Raynaud’s syndrome is often very debilitating and treatment includes lifestyle 
changes such as stopping smoking, avoiding cold and wearing layers of warm 
clothing and gloves. Calcium channel blockers, angiotensin II receptor blockers 
and selective serotonin reuptake inhibitors may be helpful. Iloprost IV, 
phosphodiesterase 5 (PDE5) inhibitors and endothelin receptor antagonists 
(ERAs) are considered for severe Raynaud’s especially if associated with digital 
ulceration or critical digital ischaemia. Sympathectomy may also be considered 
in severe cases. 
 
Gastrointestinal symptoms are extremely common and most patients have 
some element of gastroesophageal reflux which is treated with proton pump 
inhibitors. Many patients have severe symptoms requiring higher doses to 
control symptoms or the addition of histamine 2 receptor antagonists. 
Prokinetics may be prescribed for dysphagia and rotating courses of antibiotics 
for small bowel overgrowth causing diarrhoea. Constipation may be treated with 
regular laxatives and anal incontinence may require a sacral nerve stimulator.  
 
In addition to immunosuppression discussed above, N-acetylcysteine may be 
beneficial in SSc-ILD. Low dose glucocorticoids and alternative 
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immunosuppression with azathioprine may be considered. In severe cases, 
lung transplantation may be appropriate. Treatment of PAH includes, diuretics, 
anticoagulation, oxygen and digoxin. Monotherapy with advanced therapies 
such as prostanoids, PDE5 inhibitors and ERAs is considered first and 
combination therapy is appropriate if monotherapy fails. Riociguat, a guanylate 
cyclise agonist, is a new class of drug, which has recently reported benefit in 
PAH. Renal crisis is treated by removing any known trigger, angiotensin 
converting enzyme inhibitors and supportive care including dialysis. Renal 
function can improve up to 18 months after SRC, therefore renal transplantation 
should not be considered for at least 2 years (130) (12). 
1.2 Hyperimmune Caprine Serum 
1.2.1 Hyperimmune caprine serum manufacture and 
composition 
Hyperimmune caprine serum (HCS) is a goat serum extract derivative supplied 
frozen and thawed to a liquid for immediate injection. It is produced in goats 
raised and housed at a licensed facility in Tasmania, Australia.  The animals are 
vaccinated using detergent- inactivated HIV viral lysate.  The caprine model is 
an ideal vehicle for this as it cannot propagate the HIV virus in vivo. Serum is 
shipped frozen to the manufacturing facility in Victoria, Australia where the sera 
are pooled, fractionated and diafiltered to preserve various macromolecules, 
immunoglobulin species and low molecular weight components prior to further 
processing nanofiltration and vialing. 
 
The final product contains principally caprine immunoglobulins but also various 
small molecular weight species including cytokines. ELISA characterisation of 
the serum has revealed the presence of a range of components including the 
cytokines IL-4 and IL-10, proopiomelanocortin (POMC), arginine vasopressin, -
endorphin and corticotrophin-releasing hormone (CRH). Previous studies have 
shown that when peripheral blood mononuclear cells (PBMCs) are isolated and 
incubated with serial dilutions of HCS, raw hyperimmune serum and heat-
inactivated sera induced the release of IL-10 in vitro {Investigator Brochure, 
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Daval International, personal communication}. The following sections describe 
mechanism of action and previous animal and human studies with HCS. Most of 
the data are unpublished, apart from abstracts presented at international 
meetings, as indicated below. 
1.2.2 Anti-Inflammatory action 
The therapeutic efficacy of HCS is based on the presence of a novel stable multi-
protein complex, whose key components include; CRH, α-2 macroglobulin (α-2M) 
and lipoprotein-related peptide-1 (LRP-1). α-2M, a well-known protease inhibitor, 
protects CRH from normal proteolytic degradation. The stabilisation of the CRH 
peptide allows it to have a longer half-life (t1⁄2) in the body (14-16 hours vs. 2.5 
to 4.5mins), leading to its sustained-release within homeostatic boundaries.  
 
HCS’s reparative qualities are thought to be as a result of the stabilised 
complex’s targeting of the proximal hypothalamic-pituitary-adrenal (HPA) axis 
and extra-hypothalamic sites where the CRH-receptor-1 is expressed centrally. 
HCS’s subcutaneous delivery results in sustained release of CRH which is the 
principal neuroregulator of the basal and stress-induced production of 
adrenocorticotropin releasing hormone (ACTH), β-endorphin and several other 
POMC related peptides. HCS’s ability to re-establish the HPA axis’s normal 
responsiveness to biologic and environmental stressors is the hallmark of a 
drug {Investigator Brochure, Daval International, personal communication}. 
 
The stabilised protein-peptide complex that incorporates CRH and LRP-1 is 
made possible by the structure created by the α-2 macroglobulin. The degree of 
penetration of activities associated with different domains on α-2 macroglobulin, 
may be regulated asynchronously by conformational change in α-2 macroglobulin 
and by other regulatory proteins in the cellular microenvironment, allowing a novel 
complex to be formed in a caprine vehicle exposed to a specific attenuated 
inoculate as seen with the medicinal product. The ability of α-2 macroglobulin to 
“trap” caprine CRH affords the neuropeptide “protection” from rapid proteolytic 
degradation (131). 
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Analysis and characterisation of the composition of the medicinal product has 
been carried out using Size Exclusion Chromatography (SEC), which shows that 
approximately 95% is in the caprine IgG size while the remainder is composed of 
higher molecular weight components. The molecular and proteomic analysis of 
the medicinal product has been carried out in collaboration with the Public Health 
England (PHE) using SELDI-TOF mass spectrometry and 1-D and 2-D gel 
electrophoresis with proteomic analysis. Peptide-capture from the medicinal 
product using immobilised monoclonal or polyclonal antibodies (where 
appropriate) was used to detect peaks that matched the predicted molecular 
mass for specific molecular species. Specificity was demonstrated and confirmed 
with the use of a number of irrelevant control antibodies. 
1.2.3 Sodium channel effect 
Previous exploration of the potential applications of HCS has focused on its 
neurological properties. Some 400 patients with multiple sclerosis (MS) have 
taken the medication for periods of up to five years. In excess of 50,000 doses 
have been given over this period, without significant side-effects (Daval 
International Ltd., personal communication). Uncontrolled (open-label) 
observations suggest that many such MS patients experience an improvement 
in motor function, fatigue and bladder control, and there have been reported 
instances of marked improvement in colour vision and balance. Findings on 
threshold tracking / electrotonus testing on a patient with Chronic Inflammatory 
Demyelinating Polyradiculoneuropathy (CIDP) before and within two hours of 
her first treatment with HCS, showed a reduction in triggering voltages of 
sodium channels in peripheral nerves and a prolongation of their opening, thus 
favouring conduction in damaged or demyelinated axons (132) (Abstract 549, 
XVIIIth World Congress of Neurology 2005) (133). 
 
A trial in optic neuritis showed a non-significant trend for improvement of 
automated visual field measurements in MS patients with chronic visual 
symptomatology, under double-blind conditions (134) (Abstract 71, Proceedings 
of the Association of British Neurologists 2005). In another study, reversal of 
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conduction block within optic nerve fibres was demonstrated in one of six 
patients, using visual evoked potential studies, with a significant and sustained 
improvement in colour vision within the group as a whole (135) (Abstract 77, 
Joint Sino-British Neurology meeting, Beijing 2004). These rapid improvements 
in neurological function seem also to occur in patients with muscular dystrophy 
(136) (Abstract 272, XVIIIth World Congress of Neurology 2005) and 
myasthenia gravis (137) (Abstract 306, XVIIIth World Congress of Neurology 
2005) consistent with a unifying sodium channel effect. 
1.2.4 Animal studies 
1.2.4.1 Murine and Equine lipopolysaccharide (LPS) model 
In a murine and equine lipopolysaccharide (LPS) model of 
inflammation/endotoxaemia, HCS significantly decreased production of several 
pro-inflammatory cytokines including TNF-α and led to improved clinical outcome 
when compared to controls. HCS increased survival in the murine LPS model. In 
addition, Dr. Simon Bailey, a Veterinary Pharmacologist at the University of 
Melbourne, Australia, administered either HCS, placebo, or a registered 
intravenous anti-inflammatory comparator (Flunixin®) to standard bred horses at 
the University of Melbourne, following injection of according to a double- blind 
“low dose” protocol. He found that HCS and Flunixin significantly reduced peak 
body temperature compared with placebo and that HCS, in particular, lead to an 
earlier recovery of blood leukocyte counts post-acute margination, although there 
was also an effect seen in HCS treated animals only, where peak TNF-α levels 
were significantly reduced (abstract in 3rd AVA/NZVA Pan Pacific Veterinary 
Conference, Equine stream, June 2010). 
1.2.4.2 Bleomycin Lung Model 
For this study, there were 5 groups; a NAIVE SERUM group that received no 
bleomycin (BLM) challenge and no treatment, and a second control that 
received no BLM challenge and no treatment with NAIVE SERUM (i.e. saline 
only). The remaining study animals were treated with either saline (negative 
control), NAIVE SERUM (negative control for compound activity), or HCS along 
with BLM.  All mice used in this project were C57BL/6 females, 8 to 10 weeks 
old, obtained from Charles River Laboratories, Hollister, CA. After 3 days of 
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acclimation, animals were treated with of saline, NAIVE SERUM (100 μg) or 
HCS (100 μg) via subcutaneous injection delivered under the skin on the back 
of the mice beginning on day 1, administered QD for 28 days (28 injections total 
per mouse). Mice also received either BLM (0.045 units/50 μl) or saline control 
(50 μl) via intratracheal instillation on day 1 following saline, NAIVE SERUM or 
HCS delivery. On Day 28, animals were anaesthetized and bled via retro-orbital 
sinus and followed by tissue and broncheal-alveolar lavage (BAL) fluid 
collection. 
 
No statistical changes were observed in any experimental group when 
compared to any control group when analysing lung homogenates for α-MSH, 
CRH, CRH2, CRHBP, MC1R, MC4R, IL17F, LRP1, hydroxyproline or PIIIINP. 
Serum samples were assayed for circulating cytokine levels by ELISA; no 
statistical changes were observed in any experimental group when compared to 
any control group when analysing for CRHBP. An increase in α-MSH was 
observed though not significant in the BLM/HCS group. Serum MMP-1 and 
MMP-13 showed a trend to decrease in the BLM/HCS group but this was not 
found to be significant. 
 
Serum MMP-9, BAL fluid IL-12p70, MCP-1 and TNFα analysis revealed that 
there were significant differences between groups; a statistically significant 
decrease was noted in the BLM/HCS group compared to the BLM/NAIVE 
SERUM and BLM/Saline groups. The difference was more significant 
comparing BLM/HCS and BLM/saline. Under the conditions of this study, injury 
to the lung and the consequent fibrosis were focal to multifocal and of generally 
minimal or mild severity.  The two control groups (saline and NAIVE SERUM) 
had no increase in pulmonary fibrosis.  Among the groups with increased 
pulmonary fibrosis, the lowest mean group severity scores for fibrosis was 
present in the BLM/HCS group.  The lowest mean group severity scores for all 
findings were present were also present in the BLM/HCS treatment group 
(unpublished data, Daval international, personal communication). 
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1.2.4.3 Bleomycin Lung Function Model (Buxco) 
Lung function, including respiratory volume changes and rate of volume 
change, was assessed in conscious unrestrained mice by use of the BUXCO 
plethysmograph system. Baseline functional data was collected while mice were 
breathing air, while stressed in a 5% CO2 atmosphere and then during recovery 
in air. This study was separate from the above assays, and used mice treated 
with BLM/HCS (n=9), BLM/NAIVE SERUM (n=9), and untreated control mice 
(n=3), with functional analysis at 10 and 28 days after study initiation. No 
significant changes were observed between the BLM/NAIVE SERUM and 
BLM/HCS groups at any time point or during CO2 stress or recovery. The 
BLM/HCS group exhibited a significantly lower tidal volume and minute volume 
following a 5% CO2 stress challenge at 28 days versus the BLM/NAIVE 
SERUM treatment group. The profile of change in the BLM/HCS group was in 
the same direction as the normal controls, that is, with an associated decrease 
in residual and minute volumes post-CO2 exposure. Interestingly, the changes 
were paradoxical within the BLM/NAIVE SERUM treatment group at 28 days. 
The animals recovered to near the control group when returned to air 
(unpublished data, Daval international, personal communication). 
1.2.4.4 Bleomycin Skin Model 
After 3 days of acclimation, animals were treated with of saline, NAIVE SERUM 
(100 μg) or HCS (100 μg) in 100 μl volume via subcutaneous injection 
beginning on day 1, administered QD (daily) for 52 days (52 injections total per 
mouse). Mice also received either BLM (0.09 units/50 μl) or saline control (50 
μl) via subcutaneous injection QD for 45 days, beginning on day 1 until day 45 
of the study. On Day 52, animals were anaesthetised with inhaled isoflurane, 
and bled via retro-orbital sinus and tissues collected. Blood was processed into 
serum and kept frozen at -80ºC until analysed. Skin, lung, brain, adrenal, heart, 
and retroperitoneal adipose tissues were collected from a subset of the animals 
in each study group, and serum samples were collected from all mice.  
 
CRH levels in skin homogenates were significantly lower in the BLM/HCS group 
versus the BLM/NAIVE SERUM group and BLM/Saline group (p=0.014). Tissue 
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CRH2 analysis showed that no statistically significant difference between the 
BLM/NAIVE SERUM and BLM/HCS treatment groups (p=0.432).  However, a 
strong trend was observed with an increase in CRH2 in the BLM/Saline group 
(p=0.067). CRH-binding protein as measured in the skin homogenate exhibited 
no significant difference in any of the treatment groups. These data likely point 
to a net rise in the “free” active fraction of CRH1/2 in situ. 
 
A potential downstream mechanism of action of HCS was observed, as 
evidenced by the maintenance of protein levels of α-MSH, likely due to 
increased proteolytic cleavage of POMC by regional cells. Skin exposed to BLM 
has been shown to reduce intrinsic α-MSH expression, which may have a 
negative impact on cell survival. 
 
α-MSH levels were significantly increased and/or maintained in the BLM /HCS 
(171±17pg/mL) treatment group versus BLM/Saline (87±10 pg/mL) or 
BLM/NAIVE SERUM (129±9 pg/mL) treatment groups (p=0.013 and p=0.003) 
respectively. MC4R expression was significantly lower in the BLM/HCS group 
(4392.7±1645 pg/mL) when compared to the BLM/saline and BLM/NAIVE 
SERUM groups (p=0.017). In contrast, there were no significant differences in 
the levels of MC1R expression between any of the BLM treatment groups. The 
changes in MC4R may have been due to a compensatory response that 
reflected the greater fall in α-MSH levels in both the BLM/NAIVE SERUM and 
BLM/Saline treatment groups. 
 
Of the three markers of skin fibrosis that were assayed in the skin 
homogenates, interesting observations were made with both intrinsic (local) 
LRP-1 expression and total hydroxyproline content. Both showed significant 
changes that favoured a reduced local fibrotic response. In contrast, analysis of 
skin tissue homogenate levels of PIIINP expression showed no significant 
differences between the various BLM-treatment arms. The hydroxyproline 
content was significantly lower in the BLM/HCS group (2351.7±348.2 μg per mg 
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of protein) compared to the positive control (BLM/Saline, 5958.7±1226.5 μg per 
mg of protein, p=0.012) or the BLM/NAIVE SERUM (4526.4±669.3 μg per mg of 
protein, p=0.0133) groups respectively. 
 
Cytokine levels in serum showed analysis of CRH-1 BP revealed that there 
were no significant differences between the treatment groups. However when a 
Mann-Whitney test was performed significant differences were seen between 
the BLM/saline and the saline group (p=0.0080), between the BLM/NAIVE 
SERUM and the NAIVE SERUM groups (p=0.0095) and between the BLM/HCS 
and the NAIVE SERUM groups (p=0.0077).  No differences were seen between 
the BLM/HCS, BLM/Saline and the BLM/NAIVE SERUM groups (p=0.2987). 
 
Cytokine analysis in serum showed that there was a strong trend but not 
significant increase in α-MSH in the BLM/HCS group versus BLM/Saline 
positive control (p=0.054). Analysis of TGF-β showed no statistically significant 
differences between the treatment groups. Factors regulating the extracellular 
matrix remodelling such as MMP-1, MMP-9, MMP-13 and TIMP-1 were all 
assayed in serum with several mediators providing strong evidence of an anti-
fibrotic signal in response to HCS post-BLM in skin. TIMP-1 analysis revealed a 
strong trend in reduction in expression in the BLM/HCS group compared to the 
BLM/NAIVE SERUM group (p=0.058) and BLM/Saline (p=0.054), however as 
can be seen this did not achieve statistical significance. The ulcerating lesion is 
more florid and larger in the BLM/Saline and BLM/NAIVE SERUM groups as 
compared with the BLM/HCS treatment arm at day 50 of the experimentation. 
 
In rodents, bleomycin administration induces an inflammatory response 
characterised by leukocyte infiltration, fibroblast proliferation, and increase in 
collagen content that can culminate in the development of pulmonary lesions 
similar to those observed in human idiopathic pulmonary fibrosis. Previous 
studies have demonstrated a genetic susceptibility to bleomycin-induced 
pulmonary toxicity based on the close association between mouse strain and 
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the fibrotic outcome. C57Bl/6 mice are considered to be fibrosis prone. HCS 
attenuates both the histological and biochemical features associated with the 
Bleomycin-induced cutaneous fibrotic model (unpublished data, Daval 
International, personal communication). 
1.2.4.5 Superoxide Dismutase (SOD1) G93A Transgenic (TG) Mouse 
Model of ALS 
Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder 
primarily involving motor neurons. A subset of individuals with familial 
autosomal dominant forms of the disease have mutations of the copper/zinc 
superoxide dismutase (Cu/Zn SOD, SOD-1) gene, which encodes a 
ubiquitously expressed enzyme that plays a key role in oxygen free radical 
scavenging. The G93A SOD-1 mouse introduces a mutation into the mouse 
SOD-1 gene that corresponds to one of the changes found in the human gene 
in familial amyotrophic lateral sclerosis. The original article describing the 
generation of these mice reported early onset of the disease (~100 days) and 
rapid decline with the affected mice reaching the end stage on average within 
40 days after disease onset (typical survival 130-160 days) (138). 
 
The objective of the study was to determine whether targeting of the HPA axis 
at a specific site using HCS could elicit measurable efficacy in the G93A SOD1 
murine model (Abstract 48.08, Society for Neuroscience 2013, Abstract P221 
ALS/MND International Symposium 2013). Age-matched G93A male/female 
mice n=20 per treatment group (NAIVE SERUM/WT, NAIVE SERUM/TG and 
HCS/TG animals were injected once daily (100μg subcutaneously) using a 
double-blind experimental protocol from day 60 days to 150 days and analysed 
using open-field testing, survival rate, clinical standard methods of assessment 
as well as utilising a 1H-MRS brainstem study. Significant maintenance was 
observed in rotarod latency, grip strength and concomitant changes were 
observed in several key cellular metabolites, using 1H-MRS at 90 and 110 
days. Delayed onset of disease and prolonged survival were also observed 
though not significant. 
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Onset of disease for each mouse were recorded when they reached a disease 
stage 4. The mice were carefully examined using clinical scoring three times a 
week. The clinical scoring system was on a scale of 1 to 5; with 1 as the 
endpoint for euthanasia, and 5 as healthy with little or no signs of onset of 
disease. The disease onset was delayed by 6 days in the HCS versus NAIVE 
SERUM treatment in the TG groups though this was not statistically significant. 
The survival (%) was not statistically different between the intervention groups 
with a mean survival time of 105 days. 
 
The data show that at 90 days there was a significant difference noted between 
the TG/HCS and TG/NAIVE SERUM treated groups where grip strength did not 
deteriorate in TG/HCS group to such an extent as the TG/NAIVE SERUM 
treated group and the rotarod latency superseded both that seen in WT and 
TG/NAIVE SERUM treated groups. 
1.2.4.6 Alzheimer’s Mouse Model 
The objective of the study was to determine whether using novel stabilized HCS 
could elicit measurable efficacy and if so, by what mechanism in the Tg2576 
transgenic mouse model of Alzheimer’s disease (AD), which overexpresses a 
mutant form of amyloid precursor protein (APP), APPK670/671L, linked to early 
onset familial AD (Abstract 753.18, Society for Neuroscience meeting 2013). 
Age-matched Tg2576 (Tg) male and female mice, n=15 per treatment group (wild 
type/NAIVE SERUM, Treatment group/NAIVE SERUM and Tg/HCS), were 
injected twice weekly with 100 µg HCS s.c. using a double-blind experimental 
protocol starting from 3-months of age and continued to 5-months of age. Mice 
were analysed for contextual fear conditioning testing and disease progression 
at 5-months of age. Levels of hippocampal metabolites were analysed pre- and 
post-dose using non-invasive in vivo 1H-MRS at 3 and 5 months. 
 
The major protein component of amyloid deposits associated with Alzheimer's 
disease is a 39-42-amino acid, self-assembling peptide, known as the amyloid 
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Aβ peptide. Biochemical analysis of the amyloid peptides isolated from 
Alzheimer’s disease brain indicates that Aβ1-42 is the principal species 
associated with senile plaque amyloids. Significant reduction in soluble amyloid 
Aβ1-41 and Aβ1-42 was noted in the hippocampus, ventral cortex, CSF and 
serum of the Tg/HCS treated group vs. Tg/NAIVE SERUM as measured by 
ELISA. Insulin degradation enzyme activity in the hippocampus by 
immunocapture activity assay was unchanged. Significant maintenance was 
observed with open-field testing and with preservation of contextual fear 
conditioning outcome.  
 
There was significant increase in neurogenesis as evidenced by increased BrdU+ 
and CD34+ in the hippocampus determined by immunohistochemistry following 
introduction of HCS. Significant changes in the cellular hippocampal metabolite 
choline using 1H-MRS at 5-months, indicated increased cellular mitosis. 
1.2.4.7 Inflammatory Airways Disease in Horses 
The purpose of this study was to determine whether HCS is able to reduce or 
abolish clinical signs and inflammatory changes associated with inflammatory 
airway disease (IAD) in horses. The horses recruited for this trial showed the 
characteristic clinical signs of inflammatory airway disease, and were typical of 
the large numbers of young horses in early training all over the world which show 
signs of IAD. These signs included coughing and nasal discharge, either at 
exercise or at rest, and excessive mucus in their airways and markedly increased 
numbers of neutrophils in their bronchial fluid. These signs caused interruption to 
their training program. 
 
HCS treatment produced significant beneficial effects compared with saline 
between days 0 and 16, assessed by coughing and mucus viscosity, with the 
amount of mucus accumulation also tending to decrease. Furthermore, the 
objective data provided by the differential cell counts in the tracheal wash fluid 
showed that HCS significantly reduced the numbers of neutrophils. 
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Horses receiving HCS from days 16 to 32, after not responding very well to 
conventional antibiotic therapy only (from the original saline control group) did not 
respond as favourably as those horses treated initially with HCS. The injections 
were generally well tolerated and in the majority of cases, the 10 ml of HCS 
deposited subcutaneously disappeared within a few hours, as observed in 
previous studies involving standard bred horses. Unfortunately however, fluid 
swellings were observed in two of the sixteen fine-skinned thoroughbred. 
Although these gradually disappeared over 24-72 hours, and no systemic 
adverse effects were noted, these reactions were unsightly (in the skin) and in 
one case painful (pectoral muscle). The reason for these reactions is unclear. In 
the two cases where they did occur, they tended to be more pronounced following 
repeated administrations, suggesting that they may be immune-mediated, after 
prior sensitisation. However, the skin swellings were fluid in nature and there was 
no external evidence of any tissue thickening or cellular tissue reaction either 
within or beneath the skin (unpublished data, Dr. Bryan Youl, personal 
communication). 
1.2.4.8 Twitcher Mouse Model (Krabbe’s Leucodystrophy) 
Krabbe’s Leucodystrophy disease is a fatal genetic neurodegenerative disorder, 
predominantly affecting infants, caused by a mutation in the gene encoding for 
the lysosomal enzyme galactocerebrosidase. An immune and inflammatory 
involvement has been associated in the pathogenesis of this disease.  Treatment 
options available for this disorder to date are limited. Anti-inflammatory therapies 
have been shown to reduce excessive activation of inflammatory molecules, 
which contribute to disease progression in various neurological disorders 
including potentially in Krabbe’s 
 
A study was conducted by the University of Sydney using HCS, to test the safety 
and efficacy, as well as the clinical and pathological effects of HCS using a 
Twitcher mice murine model of Krabbe’s disease. The Twitcher mouse 
(C57BL/6J-GALCtwi; twi/twi), an enzymatically authentic model of human Krabbe 
disease (Kobayashi et al., 1980), was used in the studies. The model involved 
sacrificing c. 30 mice at 30-35 days (Twitchers twi/twi) and 45 days (normal) that 
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had been injected with HCS or placebo every second day for 3 days a week, 
commencing at 10 days to 35 days . Following sacrifice, blood was extracted and 
analysed, as well as brain, spinal cord and sciatic nerve samples. Luxol Fast Blue 
(LFB), with Periodic Acid Schiff (PAS) as counterstain, was performed under 
standard staining procedures to assess the level of myelination of the samples. 
In addition, glial fibrillary acidic protein (GFAP) immunohistochemical staining 
was performed to define levels of astrocytosis. 
 
Drug safety was shown, as no adverse effects were recorded in the normal mice 
that were administered with HCS. Furthermore, no significant difference in 
measured parameters was noted between HCS and placebo treated normal 
mice. LFB staining of the medial corpus callosum was more severe for both 
placebo-treated, and HCS-treated Twitchers, compared to normal mice 
(p<0.001). Importantly LFB staining was more significantly intense in the HCS-
treated Twitchers compared to placebo-treated Twitchers (p=0.043). Normal 
mice had fewer, shorter, lightly stained GFAP-positive processes, while an 
increase in staining was evident in both placebo- and HCS-treated Twitcher mice. 
Upon visual examination, astrocytes appeared to be more densely packed, and 
intensely stained with thicker cellular processes in Twitcher mice that received 
placebo treatment, than those of HCS-treated Twitcher mice. This observation 
was supported by statistical evidence to indicate a significant difference in GFAP 
stained area between placebo-treated and HCS-treated Twitcher mice (p=0.029). 
Less astrocytosis was observed in the HCS versus placebo-treated Twitcher 
mice. Exaggerated astrocytosis has been shown to be causative in pathological 
demyelination. 
 
Box testing was also performed in the form of an open field during which 
exploratory activity is assessed through a series of qualitative and quantitative 
measures. Twitcher mice in both groups were considerably less mobile than 
normal mice and were observed to generally tend to stay on the corner of the 
enclosure and remain there for the duration of the test compared to the normal 
inquisitive behaviour of mice. Dragging of limbs was observed in both HCS and 
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placebo treated Twitcher mice thus exhibiting less exploratory activity levels than 
normal mice.  
 
Although on gross observations, the two Twitcher groups cannot be 
differentiated, the values recorded for each of the clinical parameters consistently 
showed HCS-treated Twitcher mice to have the milder clinical condition. Box 
testing and body weight in the HCS versus placebo treated groups showed either 
significant, or near significant differences, respectively (Box test: p=0.039, one-
tailed t-test, Body weight: p=0.068, one-tailed t-test) (unpublished data, Daval 
International, personal communication) . 
1.2.5 Human studies 
1.2.5.1 Case reports 
A number of case studies have been reported in patients with MS, ALS (139) 
(140), CIDP (141) (Abstract, British Society for Clinical Neurophysiology, 
London 2004), optic neuritis (135) (Abstract 77, Joint Sino-British Neurology 
meeting, Beijing 2004) and Krabbe’s leukodystrophy (142) (Abstract 38, XVIIIth 
World Congress of Neurology 2005). HCS is being prescribed in patients with 
non-inflammatory central nervous diseases such as Krabbe’s leukodystrophy 
(for which an Orphan Status designation has been awarded by the Therapeutic 
Goods Administration (TGA) in Australia) and demyelinating peripheral nervous 
system disorders such as Charcot-Marie-Tooth disease, Type I and CIDP. HCS 
also has FDA Orphan drug approval for ALS in MND based on the case report 
and study below (Section 1.2.5.5). 
1.2.5.2 UK DDX pre-2004 Multiple Sclerosis Trials 
In total, two previous clinical studies received MHRA and ethics approval under 
the UK DDX system, pre-2004. The first, the Oxford optic neuritis study with 11 
patients (134), was completed. The patients had chronic stable visual loss due 
to multiple sclerosis, and a total of three, weekly doses of either HCS or a 
human albumin placebo were followed by a wash out period of approximately 6 
weeks and then the crossover regimen.  A trend towards an improvement in 
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HCS treated patients in automated visual field scores did not reach statistical 
significance.  No adverse effects of medication or placebo were recorded. 
 
The second, a double blind placebo controlled study in secondary progressive 
MS, due to run for 2 years, was halted after 6 months due to hospital pharmacy 
failure to apply correct standards of preservation in handling the study material 
(HCS must remain deeply frozen until immediately prior to injection). Six month 
safety data were collected from all 47 patients and there were no adverse 
events attributable to HCS or the placebo. 
1.2.5.3 Phase II Double Blind Multiple Sclerosis Trial 
This trial was conducted at the same time as the trial reported in the thesis, but 
was not completed until later and the data has not yet been published. The data 
presented here are from Daval International and are being prepared for 
publication. The primary objective of this Phase II trial was to explore safety and 
tolerability and measure the effect of regular HCS injections on the symptoms of 
overactive bladder and several pre-defined non-bladder secondary and tertiary 
outcome measures in Secondary Progressive Multiple Sclerosis (SPMS). 
Secondary objectives were to seek signals indicative of efficacy and biological 
activity. 
 
20 SPMS patients were randomised to receive either HCS (n=10) or placebo 
(n=10) by subcutaneous injection. One mL, containing 4.5 mg protein per mL, 
was injected twice weekly for four weeks, followed by a six week wash-out 
period, and then a crossover to the other treatment for four weeks. Patients 
were entered into the trial based on a confirmed diagnosis of SPMS together 
with having no relapses in the preceding year six months prior to enrolment. 
Patients were ambulatory, at least 18 years old, passed urine at least 8 times 
per 24 hours and had urinary urgency. Patients had no more than one relapse 
in the previous 12 months and no relapse in the last six months with respect to 
their MS. Following completion of the cross over period all patients were then 
offered open-label use of HCS for an additional 38 weeks. 
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Safety was assessed by summarising incidence and type of adverse events 
through to Week 14 and in the case of continued treatment through to Week 56. 
All patients were included in the safety assessment. Efficacy endpoints included 
bladder function (a selected primary endpoint), measured by change in average 
voided volume of urine and percentage improvement was measured using the 
MSFC (MS functional composite), which produces scores for each of the three 
individual measures (25 foot walk, 9 Hole Peg Test and Paced Auditory Serial 
Addition Test – PASAT3) as well as a composite score. Visual acuity and colour 
vision were also tested. A 12 item multiple sclerosis walking scale (MSWS-12, 
version 1), Incontinence on Quality of Life (I-QOL) Patient Questionnaire score, 
a Multiple Sclerosis Impact Scale (MSIS) questionnaire on physical ability and 
the Expanded Disability Status Scale (EDSS) (which measures for visual, 
pyramidal, sensory, brain stem, cerebellar, bowel and bladder, and cerebral 
function) were also performed. Specific biomarker analyses on cytokines, growth 
factors and miRNA was conducted as part of one of the secondary outcome 
measures.  
 
HCS was defined as a safe and well-tolerated treatment up to 12 months of 
analysis. No treatment related severe adverse events were recorded. The mean 
urinary frequency (voids / day) by visit for the open-label phase showed that 
HCS significantly decreased the mean frequency from baseline (8.41) to 52 
weeks (7.18) (adjusted mean change -1.6; p<0.0001). In addition, improved 
bladder function was observed by the fall in mean urinary incontinence 
(episodes / day) by visit during the open-label phase, evidenced by HCS 
significantly decreasing the mean frequency from baseline (2.12±2.94) to Week 
26 (1.14±1.51) (adjusted mean change -0.84; p=0.0009). HCS did not show a 
significant difference in bladder function between four weeks of treatment with 
HCS and four weeks of treatment with placebo in the double blind phase. 
 
An analysis of the mean total MSFC score with treatment difference for the double 
blind phase showed that HCS significantly increased the total MSFC score from 
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-0.259±1.771 to 0.177±1.361 (adjusted mean change 0.694; p=0.0215). This 
compares to the placebo group where a significant increase was not observed in 
the DBPC phase (from - 0.773±2.695 to 0.116±1.735; p=0.297). The mean total 
MSFC score by visit for the open-label phase also suggested that a longer period 
of treatment with HCS significantly increased the total MSFC score from -
0.45±1.85 at baseline to -0.127±1.95 at week 52 (adjusted mean change 0.661; 
p=0.021). The individual components that make up the MSFC were analysed and 
all 3 components showed significant improvements with HCS in the double blind 
phase and further improvements in the open label phase suggesting that longer 
treatment led to improved efficacy.  
 
The visual acuity (LogMar for both eyes combined) showed significant 
improvement with HCS versus placebo during the blinded phase (p=0.026). The 
Visual Evoked Potential (VEP) studies, using HCS on P100 latency, provided 
additional confirmatory evidence on demyelination and inflammation of the optic 
nerve. The visual acuity (LogMar for individual eyes) showed that HCS 
significantly improved right eye visual acuity LogMar versus placebo during the 
open label phase (p=0.005). The mean colour vision score, by treatment period 
and overall, showed that HCS nearly significantly decreased the mean colour 
vision score (that is tending to normalisation) during the double blind phase from 
baseline 138.9±125.2 to end of period 106.1±106.4 (adjusted mean change -
18.4; p=0.06). 
 
HCS treatment showed trends to improvement in mean MSWS during the open-
label phase and statistically significant improvement in the overall I-QOL during 
the open-label phase. Improved quality of life was observed when using HCS as 
evidenced by the patient’s Question 2 responses from the beginning of the 
treatment period for the open-label phase to 26 weeks as shown by a 53.3% 
improvement in the cohort group; 26.7% showed no change and only 20.0% of 
patients worsened (reflecting attenuation of the natural course of SPMS where 
up to 79% of patients worsen by 6 months). A further analysis showed that HCS 
at 52 weeks saw 42.9% of patients stating an observed improvement, and 42.9% 
no change and only 14.3% feeling that they were worse. Further functional 
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improvement, with respect to the mean MSIS, for the double blind and open- label 
phases was also seen. 
 
This trial was a proof of concept and safety trial, as part of the development of 
HCS. The medication was found to be well tolerated with minor injection site 
reactions being the main side effect recorded. Although the trial did not show a 
difference in bladder function between four weeks of treatment with HCS and four 
weeks of treatment with placebo, implying that short-term administration of HCS 
may not be effective for the SPMS indication, during the open- label phase of the 
study results of bladder and non-bladder assessments showed a number of 
functional areas of significant improvement, suggesting the need for longer term 
administration of HCS during future clinical studies {Investigator Brochure, Daval 
International ,personal communication}.  
1.2.5.4 Open Label Multiple Sclerosis Trial 
The study was conducted in multiple centres across the United Kingdom with 
registered clinicians (consisting of neurologists and general practitioners), 
commencing 2004 (Abstract SC23, CMSC-ACTRIMS meeting May 2013). The 
objective of the open label study was to retrospectively analyse the safety, 
tolerability and efficacy of HCS in progressive MS. The open label format of the 
study allowed the safety and efficacy of HCS to be assessed in MS patients 
over an extended time period. 154 patients were treated with 1 mL of 4.5 
mg/mL. HCS 1-3 times weekly, via subcutaneous injection, on an open-label 
basis for 2 weeks to 3 years (3 to 150 doses).  
 
Of the 154 patients treated on a named patient basis 140 had adequately 
documented follow-up and assessment available for review. The patients were 
ambulant, aged at least 18 years, with progressive MS (the majority with SPMS) 
for duration of 3 months to 40 years. Adverse events were limited to skin irritation 
at the injection site. 19 patients reported mild self-limiting reactions: some 
needing topical antihistamines; 8 reported more persistent reactions needing oral 
antihistamines; 1 patient withdrew from treatment due to persistent skin irritation. 
No treatment-related severe adverse events were noted. Of all the EDSS scores 
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recorded, 117 patients (over 80%) reported clinical benefit in 1 or more areas 
while 16 patients reported no overall benefit and 9 patients showed overall 
worsening by 1 point in 1 area. 96 patients had improvement in 2 or more areas 
and as such were likely to have a change of at least -0.5 in their EDSS score, 35 
of these had changes in 4 or more areas indicating a probable EDSS change of 
-1.0. Clinical benefit was reported largely in the following areas of the EDSS: 
motor (97 patients), energy (56 patients), bladder (37 patients) and sensory / pain 
(33 patients). Bladder efficacy was demonstrated in the open label study on 
longer-term use of HCS. The implications of this are important as they 
corroborate with the data readout from the open label phase of the SPMS Phase 
II clinical trial (above). 
 
A second open label study was performed with a total of 14 patients. The mean 
age was recorded at 53.1±3.76 years with a male-female ratio of 1:4. The 
average duration of treatment was 12.3±2.35 months. While patients showed a 
pre-treatment average EDSS score of 30.5±2.73, HCS significantly improved the 
EDSS score with an mean of -12.79±2.18 resulting in a post-HCS EDSS score of 
17.71 ±1.94, (p<0.0001) {Investigator Brochure, Daval International, personal 
communication}. 
1.2.5.5 Open Label Amyotrophic Lateral Sclerosis Trial 
This is an open label study in amyotrophic lateral sclerosis (ALS), also known 
as Motor Neuron Disease (MND). ALS was investigated following the 
identification of a significant efficacy signal from a single long-term ALS patient 
case study mentioned above in section 1.2.5.1 (139) (140). The primary 
objective of the study was to prospectively analyse the longer term safety, 
tolerability and efficacy of HCS in patients diagnosed with ALS. 1 mL of 4.5 
mg/mL HCS was administered daily, via subcutaneous injection. Patients were 
assessed intermittently against a number of standardised criteria over the 
course of the open-label study (Abstract P320, ALS/MND International 
Symposium 2013). Patients in the study had been monitored between 4 to 18 
months at time of reporting. Mean patient treatment duration was 181 days at 
time of IB publication. Patients were both ambulant and non-ambulant, aged at 
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least 18 years, with independently confirmed ALS (based on EI Escorial 
Criteria) and disease duration of more than 24 months from the time of 
diagnosis. In total 20 patients have taken part in the study at time of reporting. 
 
Adverse events were recorded and collated as change from baseline (prior to 
therapy) and post dose during the entire treatment period. The ALSFRS-R 
(revised ALS Functional Rating Scale), the ALS Assessment Questionnaire 
(ALSAQ-40), ALS score of Hillel and the ALS score of Jablecki were assessed 
at visits. Pulmonary function testing incorporating standard spirometry, full blood 
profiles, electrocardiography (ECG) and clinical examination by several 
clinicians at each study site were performed.  
 
There have been no serious adverse events recorded during the clinical study to 
date and non-serious adverse events have been limited to a reversible and mild 
skin irritation at the injection site which was resolved spontaneously after 24hrs. 
No biochemical or haematological adverse issues were observed. Twenty 
patients have been enrolled to date. The mean age of the study group was 48.45-
yrs, with a disease duration of >2.5-yrs (from the time of diagnosis) and a M: F 
ratio of 4:1. The patients had been monitored from between 4 to 18 months 
depending on the time of enrolment by their treating clinician (mean 0.95±0.36 
yrs).  
 
In summary, patients showed a significant improvement in ALSFRS-R 
(p<0.0001), FVC (p<0.011) and stabilisation in ALS scores of Jablecki and Hillel 
during the study period. ALS-QOL was also stable. Muscle power (increase of 
6.5% from baseline in the dominant hand) using a hand held digital dynameter 
testing grip strength (dominant and non-dominant hand assessment). This 
correlated with no deterioration in mid-thigh circumference - a measure of 
muscle wasting. The study also showed a distinct stabilisation post treatment in 
BMI with a 1.57% improvement (p=0.002). 
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This study also showed that patients either improved or stabilized irrespective of 
their stage of ALS. No deterioration was observed in respiratory function testing. 
Patients showed early improvement in pseudobulbar/bulbar and spasticity 
within 4-6 weeks of starting treatment. Patients did not develop any tolerance to 
the medicinal product. Despite a trend of benefit, larger, blinded, studies of the 
effect of HCS in ALS patients will need to be performed to truly prove efficacy 
{Investigator Brochure, Daval International, personal communication}. 
1.3 Caprine Serum in other contexts 
The caprine serum fraction-immunomodulator (CSF-I) mentioned below is a 
completely different immunomodulatory agent than HCS. It is produced in a 
different way and has a different mode of action. HCS is produced by injecting 
goats with an inactivated HIV virus to produce an immune response and serum 
is then collected, pooled and nanofiltered. HCS is then frozen and thawed just 
prior to injection. In contrast, CSF-I is produced by collecting serum from goats 
and is fractionated by collecting material flowing through a dialysis membrane 
with a cut-off of 6-8kDa, then lyophilised to a powder. The powder is 
reconstituted with water before injection. It is interesting to note that both induce 
changes in the cytokine balance and innate immunity in humans and animals 
and that both have been investigated for therapeutic use.  
 
Caprine serum fraction-immunomodulator has a limited license for veterinary 
use since 1993. Field trials have shown efficacy of CSF-I against bacterial, viral, 
and environmental stress challenges as found in bovine shipping fever and 
respiratory disease, canine parvovirus and lymphoma, and ovine footrot 
according to the patent application (143). 
 
Willeford and colleagues (144) reported a study on CSF-I in 2000, which they 
described as a nonadjuvanted immunostimulant derived from goat serum. Their 
study in chickens was the first to show that material derived from goats had the 
potential to retard the progression of bacterial infection (pasteurella multocida) 
in a non-mammal. This infection results in high rates of mortality in chickens, 
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but their data shows that CSF-I retards pathogenesis and reduces mortality. 
The higher dose regimen with 2 doses instead of one had the best prognosis. 
 
Hamm et al (145) reported 2 blinded studies and field studies in horses with 
lower respiratory disease (LRD) using CSF-I in combination with standard 
antibiotics which was usual standard of care for LRD. Their data show that in 
study 1 (dose finding study, placebo, 15mg, 30mg and 60mg) all CSF-I treated 
horses improved but only the highest dose of 60mg produced a statistically 
significant improvement both at day 7 and day 14. Eight of 10 non-responsive 
control horses were treated with CSF-I at day 14 and these subsequently 
improved so the difference between groups was insignificant by day 28. Study 2 
(placebo, 60mg, 120mg) showed a significant improvement in all CSF-I treated 
horses by day 7, but no difference between 60mg and 120mg groups. Again 
control horses treated at day 14 improved and there was no statistically 
significant difference by day 21. The field studies in 4 centres confirmed the 
previous findings and 75% CSF-I treated horses had improved by day 14. This 
increased to 83% at day 21 compared to 10% in the control population. 
 
Parker et al (146) studied mice injected a tripeptidic immunostimulant (TPI) 
isolate of CSF-I prior to infection with salmonella. Their data shows no benefit of 
injection 4 days prior to infection but a benefit was observed if mice were 
injected at day -2, -1 or day 0. By day 8, the mortality in the control population 
reached 80%, while groups that received TPI on day -2, -1 and day 0 had 
mortality rates of 60, 32 and 54%, respectively. The day -1 treatment group had 
significantly lower mortality than the day 0 and day -2 TPI treatment groups, 
(p=0.0193 and p=0.0014, respectively). The prophylactic benefit occurred in a 
dose-dependent manner, with a maximal effect seen when approximately 15 
mg of TPI (a total of 5.6 mg of protein) was administered. The benefit appeared 
to derive from TPI’s proteinaceous components, in light of the observation that 
all benefit was lost after proteolytic digestion with bromelain and proteinase K or 
incubation at 85°C, procedures known to denature protein. 
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Parker et al subsequently reported another study using the same mouse model 
as 2002 and depleting NK cells prior to treatment with TPI (now called innate 
immune regulatory factor, IIRF). While 85% of control mice and NK depleted 
treatment mice died, only 30% of the treated NK cell intact mice died showing 
that NK cells were involved in IIRF-induced protection. In a NK sensitive mouse 
model of melanoma the authors also showed that IIRF suppresses cancer 
metastases twofold and that IIRF is not directly toxic to cancer cells (147). 
 
In a further study in mice, Parker et al (148) showed induction of IL-6 and IL-10 
after intraperitoneal injection of IIRF. IL-6 peaked at 3 hours and was back at 
baseline by 8 hours. IL-10 peaked at 8 hours and returned to baseline by 36 
hours. There were no changes in any of the other cytokines measured. Serum 
levels of haptoglobin and serum amyloid A were also elevated after IIRF 
administration. IIRF also stimulated production of IL-6 in human monocytes in a 
dose dependant manner. In a separate experiment on mouse whole blood, NK 
cells were found to be at least partly responsible for inducing IL-6 production 
after IIRF treatment but it is unsure whether it is a direct or indirect effect. 
 
Thacker et al (149) reported the chemical structure of the active component of 
CSF-I, present only in serum and not in plasma. The compound is described as 
1-peptidyl-2- arachidonoyl-3-stearoyl glyceride (1p2a3sg). To determine the 
bioequivalence between the natural product 1p2a3sg and a synthetic version, 
normal human fibroblasts were exposed to 1p2a3sg and synthetic 1p2a3sg, 
and IL-6, IL-8, MCP-1, and MIP-1R expression was measured. IL-6 mRNA was 
elevated 20% in response to synthetic 1p2a3sg and 40% with natural 1p2a3sg 
relative to a β-actin control (p < 0.05). It was found that 5 ng/mL of synthetic 
1p2a3sg was approximately equivalent to the natural product diluted 1:100. 
Compound 1p2a3sg induced IL-8 expression by about 5-fold compared to 
untreated fibroblasts, in dose-response studies. Both synthetic 1p2a3sg (3 
ng/mL) and the natural product (1:100 dilution) induced a 3-fold increase in 
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MCP-1 mRNA relative to the β-actin control and increased MIP-1R mRNA 
expression relative to β-actin by 15%.   
 
The peptide showed identical sequence homology to amino acids 558-574 in 
the transient receptor potential channel-related protein 1 (TRPC-1). The data 
also suggest that the role of the diacylglycerol moiety is to facilitate 
transportation of the peptide across the cell membrane. The 
cytokine/chemokine expression that is mediated by 1p2a3sg arises from the 
peptide alone and that the intracellular peptide signalling from 1p2a3sg is 
mediated through the inflammasome and IL-6 and IL-8 production may arise as 
a downstream event from IL-1β secretion and feedback signalling through the 
IL-1β receptor. 
 
The authors conclude that this is a new immunomodulatory compound originally 
isolated from caprine serum, 1p2a3sg, the peptide portion from which was 
found to be 100% homologous to a unique region of TRPC-1. The in vitro data 
suggest that the peptide in 1p2a3sg may activate the host innate immune 
response against pathogen infection or other cellular injury and may induce 
Th17 cell differentiation in vivo. The data suggest a role for 1p2a3sg and the 
peptide moiety of 1p2a3sg as damage-associated molecular patterns in the 
host response to pathogen infection or other cell injury. 
 
Thacker et al further reported on 1p2a3sg mechanism of action (150). They 
reported a significant reduction in white cell count in cows with mastitis treated 
with 1p2a3sg and a significant reduction in mortality in mice infected with 
salmonella (from 100% in control population to 20% in treated mice). In vitro 
experiments with human monocytes infected with Chlamydia pneumonia 
showed a reduction of infection from 90% in untreated cells to 12% in cells 
treated with 1p2a3sg at 100ng/ml, 35% at 50ng/ml and 40% at 25ng/ml. Using 
a caspase-1 inhibitor, the authors show that 1p2a3sg induced a caspase-1-
dependent secretion of inflammatory cytokines (IL-1β, IL-18, and IL-33) from 
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primary human fibroblasts, suggesting that the effects of 1p2a3sg are mediated 
through the inflammasome complex and using knockout mice, they confirmed 
that this was mediated, at least partially, by the NLRP3 inflammasome. Looking 
at gene signatures in human fibroblasts, 1p2a3sg had maximal effect at 48 
hours and was down regulated at 72 hours. Using a mouse model infected with 
cutaneous MRSA, the authors show a significant reduction in skin infection in 
treated mice, combined with elevation of IL-33, IL-8, IL-6 and CCL-2. Their data 
also show that the compound enhances recruitment monocytes, which then 
differentiate into macrophages. 
In conclusion, CSF-I or 1p2a3sg, as the active component is now known, has 
been identified as a lipopeptide and is anti-infective with a mechanism of action 
mediated through the innate immune system and the NLRP3 inflammasome. It 
is possible that HCS may also have some effect via the lipopeptide mechanism. 
However, the majority of HCS action is likely through its effect on the HPA axis 
via the CRH complex and also possibly due to an IVIg effect, though the dose of 
IVIg is small. It is interesting to note that both induce changes in the cytokine 
balance in humans and animals and that both have been investigated for 
therapeutic use. 
1.4 Clinical trial design and endpoints 
1.4.1 Clinical trial design 
Conducting clinical trials in SSc is challenging due to the heterogeneous nature 
of the disease, lack of validated or highly sensitive outcome measures and SSc 
is a rare disorder, making recruitment difficult.  Recruitment of an adequate 
number of subjects to trials remains a challenge often necessitating multicentre 
involvement or extended periods of recruitment. Most clinical trials in SSc focus 
on either skin or lung fibrosis as the primary outcome, with other organ systems 
being evaluated as secondary outcomes. For skin disease, efficacy is measured 
by improvement of skin fibrosis using MRSS and for lung disease a scoring 
system on HRCT chest and/or lung function tests are used. Composite indices 
are being developed and could be more responsive and clinically meaningful 
than current measures (151). 
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In the past, proof-of-concept studies have often been open label uncontrolled 
trials. These are of limited usefulness regarding efficacy, but can be used in 
safety evaluations of therapeutic agents. The general consensus is that clinical 
trials should have a comparator group and randomised controlled studies are 
optimal for assessment of therapeutic efficacy. All clinical trials should involve 
collection and storage of serum and plasma samples for biomarker analysis. 
Proof-of-concept studies can, at best, provide possible efficacy signals. 
However, a fully powered randomised double-blind controlled trial is necessary 
to confirm efficacy. Rarer manifestations of SSc, such as joint disease, 
myopathy, gastrointestinal disease, cardiac and renal disease, are often 
neglected in clinical trials and should be included as secondary endpoints in 
larger controlled trials (151). 
 
Over the past number of years a number of innovative alternative trial designs 
have been developed, which may improve efficiency and allow smaller numbers 
to be recruited for trials. Some of these designs have already been used 
successfully in SSc and other rare diseases, such as the Add-on design, the 
Early escape design and randomised withdrawal though all have some 
limitations (152). Recently a group of international experts in SSc have 
published guidelines on conducting trials in SSc, including many of the points 
mentioned above and expanding on further issues such as trial duration, 
selection criteria for subjects (uniformity versus generalisability), outcome 
measures, statistical analysis and power calculations (153). 
1.4.2 Modified Rodnan Skin Score (MRSS) 
In 1960, Farmer et al first published the observation that extensive skin change 
correlated to internal organ involvement in SSc (154). This was a pivotal 
observation as skin change could then be used as a prognostic factor and a 
biomarker for severe disease. Rodnan et al published the first standardised 
semi-quantitative skin score in 1979 (155) by weighing skin biopsies and 
measuring collagen content. This was a 26 site assessment, graded 0-4. 
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Subsequently there were 3 further modifications; a 22 site assessment (156), a 
10 site assessment (157) and a 17 site assessment (158), all graded 0-3. The 
final modification, the 17 site modified Rodnan skin score (MRSS), is currently 
used in clinical trials and clinical practise. There is good correlation between 
histological appearance on skin biopsy and grade at assessment on skin 
scoring. The interobserver variability was found to be 25% and intraobserver 
variability 12% in one study (158). However, with training, the variability can be 
reduced significantly (159). The gold standard is to have a single assessor for 
MRSS assessments in clinical trials to reduce variability, but this is rarely 
feasible. 
 
Subsequent studies have shown that baseline skin score is predictive of 
outcome and high baseline skin score correlates with increased mortality (157) 
(160). Studies also show that changes in skin score are prognostic, with 
improvement in skin score correlating with improved survival (161). Rapid 
worsening in skin score in the first 2 years after diagnosis is associated with 
reduced short term survival and renal crisis (162). Skin thickening usually peaks 
within the first 2 years of disease (163). In a recent analysis of clinical trials that 
a negative outcome, overall MRSS tended to improve over the course of a 
clinical trial, however, those with a worse baseline skin score (more severe 
disease) at study entry tend to improve while those with less severe disease at 
entry tend to worsen (164). Another study confirmed decline in skin score 
overall, but found that patients enrolled with a disease duration <6 months had 
a small but significant increase in skin score before a subsequent decline and 
patients with a disease duration >2 years had a greater rate of skin score 
decline than the other groups (165).  
 
Shand et al showed that patients could be grouped into 3 categories according 
to change in skin score in the first 3 years after diagnosis; a group with low 
baseline skin score who improve over time, a group with high baseline skin 
score who improve and a group with high baseline skin score who don’t 
improve. The group with high baseline skin score who didn’t improve over time 
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were found to have a significantly higher mortality than the other 2 groups and 
there were fewer organ based complications in the low baseline skin score 
group (15). Maurer et al recently published a report looking at predicting 
patients who will progress with worsening skin scores. They found that a low 
baseline skin score (<22/51) and shorter disease duration (<15 months) and 
joint synovitis at baseline predicted worsening skin fibrosis at 1 year. This was 
validated in a second cohort and resulted in a 4.5 fold increased prediction rate 
(166). 
1.4.3 Key points 
SSc is a multisystem rheumatic disease with high morbidity and the highest 
case specific mortality of any rheumatic disorder. As no treatment is proven to 
be effective in preventing progression of disease, reversing fibrosis or improving 
long-term outcome, there is a huge unmet medical need to explore novel 
therapies for this disease. Late-stage dcSSc has very high morbidity and few 
studies are specifically designed to look at this stage of disease.  
 
The pathogenesis of early dcSSc is very complex and involves interaction 
between inflammation, vasculopathy and fibrosis. Key drivers of SSc 
pathogenesis are immune system dysfunction (pro-fibrotic and pro-inflammatory 
cytokine activation, such as TGF-β and IL-6 and innate immune system 
activation), endothelial dysfunction, fibroblast activation and dysregulated 
collagen turnover. However, pathogenic drivers of late-stage disease are less 
clear, but there is emerging evidence that persistent perturbation of immune cell 
function is increasingly important. Therefore, ongoing research into 
pathogenesis of disease and potential biomarkers is important. Multiplex serum 
analysis is increasingly being used to identify potential new biomarkers. 
 
Treatment of skin disease with immunosuppressants is usually indicated in the 
first few years of disease in those who have active dcSSc and can be 
discontinued in most patients after a few years, once the disease becomes less 
active. However, some patients may require ongoing immunosuppression and 
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the balance between benefit and side-effects must be considered. In previous 
studies, HCS has shown some efficacy in inflammatory diseases such as optic 
neuritis and multiple sclerosis. Its novel mechanism of action on the HPA axis 
makes it a useful medication to consider in inflammatory rheumatic diseases, 
especially as drug-related side effects are infrequent. However, as HCS has not 
previously been administered to SSc patients, safety was the primary objective, 
followed by assessment of potential efficacy. The clinical trial design was 
important as SSc is a rare disease and recruitment of potential patients is 
challenging. The inclusion of a placebo arm is vital as it enables assessment of 
potential efficacy signals, which would not be possible with an open label 
design. The inclusion of cytokine and potential biomarker assessment is also an 
important part of modern trial design, to further understanding of pathogenesis 
and improving future treatment of disease. 
1.4.4 Study Objectives 
The primary objective of the study was to assess safety of using HCS in late-
stage dcSSc. The secondary objectives were assessment of possible treatment 
effect (using clinical outcomes such as modified Rodnan Skin Score (MRSS), 
SSc Health Assessment Questionnaire Disability Index (SSc HAQ-DI) and Short 
Form 36 (SF-36) quality of life questionnaire) and the exploration of candidate 
biomarkers (including vWF, sIL-2R, PIIINP, as well as multiplex analysis of 
serum and plasma). The study was approved by the NHS NRES Hampstead 
Local Ethics Committee.  
1.5 Hypothesis 
The hypothesis addressed in this project is that hyperimmune caprine serum 
improves skin and other measures of disease severity in established dcSSc by 
modulating immunological function that determines persistence of clinical 
disease. Established dcSSc has a high morbidity, and as such, provides a 
“safety platform” to assess this novel immunomodulatory agent. This is a unique 
strength of this study. This hypothesis is explored through 1) a prospective 
clinical trial, 2) long-term clinical use and 3) detailed assessment of serum 
growth factors and cytokines, as well as established and exploratory markers of 
disease. 
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2 Methodology 
2.1 Clinical Trial Methodology 
2.1.1 Patients and Methods 
This is a single centre, placebo controlled, double blind, parallel group pilot 
randomised controlled trial (167). Eligible patients were identified and recruited 
from outpatient clinics and chart reviews. The major eligibility criteria are 
included in sections 2.1.2 and 2.1.3 below. All patients fulfilled eligibility criteria. 
Case report forms (CRF) were used to collect data and the trial was conducted 
to Good Clinical Practise (GCP) standards with standard verbal and written 
informed consent procedures. The trial was approved by the local ethics 
committee. We treated 10 subjects with established dcSSc using HCS and 
compared outcome over 6 months with 10 control subjects receiving placebo.  
Patients were randomised to receive 1ml study drug or placebo subcutaneously 
twice weekly for 6 months. The first two doses of medication were administered 
in the study centre under supervision at week 0, day 0 and week 0, day 3. 
2.1.2 Inclusion criteria 
Full inclusion criteria are included in Table 2.1. In brief, patients recruited to the 
study were required to be >18 years, have dcSSc by LeRoy criteria (11) of at 
least 3 years duration and fulfil the 1980 preliminary classification criteria for 
systemic sclerosis of the American Rheumatism Association (American College 
for Rheumatology) (9). Screening laboratory and radiology tests did not reveal 
malignancy or infections and were in the range specified by the protocol. 
Patients adhered to the visit and protocol requirements including contraceptive 
advice. 
 
2.1.3 Exclusion criteria 
Full exclusion criteria are provided in Table 2.2. In brief, patients included in the 
study were not permitted to take immunosuppressant agents and did not have 
evidence of pregnancy, severe organ disease, infections or malignancy at 
screening. 
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Inclusion Criteria 
Men and women ≥18 years of age.  
Patients must fulfil the 1980 Preliminary Classification Criteria for systemic sclerosis of 
the American Rheumatism Association (American College for Rheumatology) (9) 
Clinical classification must be diffuse cutaneous SSc, as evidenced by skin sclerosis 
proximal to the elbows or knees and absence of the anti-centromere autoantibody.  
At least three years must have elapsed since the first non-Raynaud’s manifestation of 
scleroderma. 
Men and women of childbearing potential must use adequate birth control measures 
(e.g., abstinence, oral contraceptives, intrauterine device, barrier method with 
spermicide, or surgical sterilization) for the duration of the study and should continue 
such precautions for six months after receiving the last injection of HCS. 
The screening laboratory test results must meet the following criteria: Haemoglobin 
≥8.5 g/dL, WBC   ≥3.5 x 109/L, Neutrophils ≥1.5 x 109/L, Platelets ≥100 x 109/L, SGOT 
(AST) and alkaline phosphatase levels must be within twice the upper limit of normal 
range for the laboratory conducting the test.  
The patient must be able to adhere to the study visit schedule and other protocol 
requirements.  
The patient must be capable of giving informed consent and the consent must be 
obtained prior to any screening procedures.  
There must be no radiological evidence of malignancy, infection or (previous) 
tuberculosis in a chest radiograph performed within three months prior to the first 
injection of study drug.  
 
Table 2.1: Inclusion criteria 
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Exclusion Criteria 
Women who were pregnant, nursing, or planning pregnancy within one and a half years after 
screening (i.e., approximately six months following last injection of study drug) 
Patients using any investigational drug within one month prior to screening or within five half-lives of 
the investigational agent. 
Patients taking a putative disease modifying drug (such as D-penicillamine, methotrexate, 
azathioprine, mycophenolate mofetil etc.) within one month of screening. 
Treatment with any therapeutic agent targeted at reducing TNF (e.g., infliximab, pentoxifylline, 
thalidomide, etanercept, etc.) within three months of screening. 
Immunosuppressive therapy within one month of screening.  
Previous administration of HCS or history of known allergy to animal proteins. 
History of serious infections (such as pneumonia or pyelonephritis) in the previous three months.  
Less serious infections (such as acute upper respiratory tract infection [colds] or simple urinary tract 
infection) were monitored to their conclusion or treated, as appropriate, prior to inclusion.  
Active hepatitis B or hepatitis C or active tuberculosis. 
Opportunistic infections, including but not limited to evidence of active cytomegalovirus, active 
Pneumocystis carinii, Aspergillosis, histoplasmosis or atypical mycobacterium infection, etc., within 
the previous six months.  
History of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of 
possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (such as 
nodes in the posterior triangle of the neck, infra-clavicular, epitrochlear, or periaortic areas), or 
splenomegaly or patients with malignancy within the past five years. 
Known recent substance abuse (drug or alcohol).  
Poor tolerability of venepuncture or lack of adequate venous access for required blood sampling 
during the study period.  
Presence of a transplanted organ (with the exception of a corneal transplant > three months prior to 
screening). 
Signs or symptoms of severe, progressive or uncontrolled renal, hepatic, haematologic, 
gastrointestinal, endocrine, pulmonary, cardiac or neurological disease (including demyelinating 
diseases such as multiple sclerosis).  
Patients who, within the previous three months, had either a myocardial infarction, uncontrolled 
congestive cardiac failure, unstable angina, uncontrolled systemic hypotension or uncontrolled 
systemic hypertension. 
Screening laboratory values which deviated 20% or more from the upper or lower limits of normal or 
which were considered to be clinically significant to the investigator. 
 
Table 2.2: Exclusion criteria 
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2.1.4 Concomitant medications 
An attempt was made to keep all medications stable for the duration of the trial. 
Medications contraindicated during the treatment phase included other 
investigational drugs, drugs targeting TNF or any immunosuppressive agents. 
Sodium channel blocking agents such as anti-convulsant medications (e.g. 
lamotrigine, gabapentin, pregabalin) were also contra-indicated. Medications 
that were allowed during treatment phase included low dose steroid up to 
10mg/day, simple analgesics and other medications as required for treatment of 
Raynaud’s and other disease related conditions including intravenous 
prostacyclin. 
2.1.5 Randomisation 
Randomisation was achieved by a computer program assigning random 
numbers, performed by the statistician, Dr. Sockler of Datapharm. The 
sequence of numbers was transmitted to the company who packaged the 
medication (Biotec Services International, Bridgend, Wales). The medication 
was labelled with patient numbers and a specific code to which the site, 
investigators and patients were blinded and only the packaging company and 
the statistician had access to. Code break envelopes were produced and kept in 
the site file in case of emergency.  
2.1.6 Double-blind Phase 
2.1.6.1 Study Visit Schedule 
Figure 2.1 shows the study visit schedule. The visit flow chart is provided in 
Figure 2.2 and these visits are discussed in more detail below. 
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Screening/Baseline
Week 0, Day 0
Week 0, Day 3 or 4
Week 2
Week 6
Week 14 Week 20
Double-blind Treatment Phase Compassionate Treatment Phase
Week 26 Week 52
 
 
Figure 2.1: Study visit schedule.  
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Screening/ 
Baseline 
Week 0 
Day 0 
Week 0 Day 
3 or 4 Week 2 Week 6 Week 14 Week 20 Week 26 Week 52 
Consent X                 
Demographics X                 
Disease History X                 
Medical History X                 
Pregnancy Test X             X X 
Physical Examination and Vital signs X X X X X X X X X 
Concomitant Medications X X X X X X X X X 
Eligibility Criteria X                
Chest X-ray X                
HRCT (if applicable) X            X   
ECG X      X     X X 
Echocardiogram X      X     X   
Pulmonary function tests (PFTs) X      X     X   
Haematology, Biochemistry, Coagulation X X   X X X X X X 
Cytokine samples X  X *   X X X X X X 
Serology X            X   
Thyroid function tests X      X     X X 
Study defined biomarkers X      X     X X 
R-R interval variation    X *           X   
MRC Sum Score    X *     X     X   
MRSS   X     X     X X 
Questionnaires (HAQ, SF-36, UK-FS, Neuropathic 
pain VAS)   X     X     X   
Physician Global VAS   X     X     X   
Adverse Events reporting   X X X X X X X X 
Figure 2.2: Study visit flow chart. * denotes that the test is done before and 2 hours after the first administration of the study drug. 
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2.1.6.2 Screening and Baseline 
Screening and baseline visits were performed on the same day. Informal 
consent was obtained prior to the visit and signed informed consent was 
obtained at the screening visit. Demographic data, medical history, concomitant 
medications and a physical examination including vital signs and MRSS was 
obtained and a pregnancy test was performed for women of child bearing 
potential. The patient had a comprehensive assessment including 
electrocardiogram (ECG), echocardiogram, pulmonary function tests, routine 
and study specific bloods, urinalysis and chest radiograph. The patient also 
completed the study specific questionnaires (see section 2.2.3). Eligibility 
criteria were confirmed and the patient was randomised to placebo or active 
medication. 
2.1.6.3 Week 0; Day 0 and Day 3 or 4 
On Day 0 and Day 3 or 4, a history and physical examination were performed 
and any changes to medications noted. An injection of placebo or active 
medication was administered under instruction on both days. Vital signs were 
performed pre-injection and every 30 minutes thereafter for three hours. On Day 
0, serum samples, R-R interval and MRC sum score were performed before 
and 2 hours after the injection. Follow-up and delivery plans for the medication 
and home freezer for the storage of medication were arranged. 
2.1.6.4 Week 2, 14 and 20 
At these visits, a history and physical examination was performed with 
assessment for adverse events and change in medications. Routine and study 
specific bloods, vital signs and urinalysis were also obtained. 
2.1.6.5 Week 6 and 26 
At these visits, a history and physical examination was performed with 
assessment for adverse events and change in medications. Routine and study 
specific bloods, vital signs, MRSS and urinalysis were also performed. A 
comprehensive assessment with echocardiogram, pulmonary function tests, 
ECG, MRC sum score and study specific questionnaires were completed. A 
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repeat R-R interval and sample for repeat serology were completed on week 
26. 
2.1.7 Safety phase and follow-up 
At week 52 (26 weeks after trial completion) a safety visit was performed to 
collect data on new medications and adverse events since trial completion. A 
full history and clinical examination was performed including routine and 
exploratory blood tests, ECG and MRSS.  
 
Most of the patients opted to receive a trial of HCS on a compassionate basis 
after the 6 month double blind phase. Some patients did not receive HCS due to 
early trial termination or other medical or personal reasons. Between trial 
termination and the safety visit, patients were seen as per routine practice, 
depending on severity of disease and symptoms and these visits were 
documented in the patients hospital notes as per routine practice. 
2.1.8 Adverse events 
Patients were monitored for the occurrence of adverse events for three hours 
after the initial and second injections. At each of the study visits, the patient was 
questioned about the occurrence of new adverse events and changes in 
concomitant medications since the last visit, or the outcome of any adverse 
events reported at previous visits. Any pre-existing conditions were recorded in 
the medical history and pre-existing conditions that worsened in severity or 
frequency during the study were also recorded as adverse events.  
 
Serious adverse events occurring after the first injection and up to 6 months 
after the last injection were documented and reported to the sponsor within 24 
hours. A serious adverse event was defined as any adverse event occurring at 
any dose that results in death, life-threatening adverse event, inpatient 
hospitalization or prolongation of existing hospitalisation, persistent or 
significant disability/incapacity, congenital anomaly/birth defect, or deemed by 
the principle investigator to be serious. 
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2.1.9 Compliance 
Compliance was assessed by a self-reported patient diary and was calculated 
as the amount of study medication the patient received according to the diary as 
a percentage of the amount the patient should have received. If a patient 
withdrew from the study prematurely, the dose the patient should have received 
was calculated based on the time the patient was in the study. Exposure to 
study treatments was calculated as the number of injections received and the 
total volume of study medication injected. 
2.1.10 Statistics 
2.1.10.1 General statistical methodology 
As this is a parallel group study design, no ‘overall’ data is presented. 
Continuous measures are summarised and tabulated using the number of 
observations (n), mean standard deviation, minimum, median and maximum. 
Categorical measures are summarised and tabulated using the count and 
percentage of patients within the group (n (%)). The denominator used to 
calculate percentages is the number of patients in the group for measures of 
efficacy. For measures of safety and tolerability, the number of patients in each 
group at each visit serves as the denominator. 
 
With any patients inadvertently receiving the incorrect treatment, safety 
population tables are tabulated by the study treatment actually received, 
whereas ITT population tables are tabulated by the treatment to which the 
patient was randomised. 
 
Baseline measurements are defined as the last measurement taken prior to the 
first dose of study medication. Where repeated measurements are taken for the 
same visit, the latest measure for the visit is summarised and tabulated for pre-
treatment measures, while the first measure for the visit is used in post-
treatment measures. As the primary outcome of this study is the safety and 
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tolerability of HCS compared to placebo, no imputation of missing data has 
been performed. 
2.1.10.2 Power calculations 
This study represents the first administration of HCS to patients with systemic 
sclerosis and the primary objective was assessment of safety.  Since this was a 
pilot study to inform potential future larger evaluation, formal power calculation 
was not considered appropriate.  However to provide confidence that we could 
address our objectives we undertook a limited determination of likely statistical 
power of the study based upon the number of subjects and known changes in 
efficacy measurement of MRSS.  The main concern was not to miss a potential 
positive clinical outcome and so, for the purpose of power estimation, a 
relatively low level of statistical significance was selected of 0.20.  Assuming 
standard deviation of 4.0 units for MRSS and a target effect size of 4.0 units 
MRSS between treatment arms the sample size was calculated to be n=20, 1:1 
randomization, consistent with the executed study design for this trial. 
2.1.10.3 Primary efficacy analysis 
Key measures of efficacy in this study are the change in SSc Health 
Assessment Questionnaire (HAQ) overall disability index (DI) from baseline to 
Week 26, the change in Modified Rodnan Skin Score (MRSS) from baseline to 
Week 26, the change in the SSc Functional Score (SSc-FS) from baseline to 
Week 26 and the change in Short Form-36 questionnaire (SF-36) scales from 
baseline to Week 26. These four measures will be considered as signals for 
efficacy of HCS in systemic sclerosis. Change in HAQ-DI and MRSS analysed 
as a continuous variable were the pre-specified efficacy end points.  Responder 
frequency analysis for MRSS was also included post-hoc to capture clinically 
meaningful change in MRSS.   
 
Inferential testing has been performed to compare groups in the change from 
baseline to each post-treatment visit. Two-sided p-values <0.05 were 
considered statistically significant. A mixed models repeated measures 
(MMRM) analysis was performed on the data in the first instance. In some 
cases the mixed models algorithm could not converge, so a standard repeated 
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measures analysis of variance (RMANOVA) was performed. The use of the 
MMRM also allowed the calculation of probabilities for the adjusted mean 
change value tested against a standard value of zero, whereas the RMANOVA 
does not calculate those probabilities, but does provide the 95% confidence 
interval. Other analysis included a responder frequency analysis to capture 
individual patient data within the more variable cohort changes in mean MRSS.  
The unconditional z-pooled test was used to analyse responder frequency 
analysis, as recommended by Lydersen et al (168). 
 
The baseline values of both the assessment under analysis and the HAQ-DI 
score and baseline (of assessment) by visit interaction terms have been used 
as covariates in the analysis. Primary inferences have been made for the 
change from baseline to Week 26, although the model also provides analysis of 
all preceding visits as supportive information. 
2.1.10.4 Secondary efficacy analysis 
Secondary efficacy measures include change from baseline to Week 26 in each 
of the eight scales of the SSc HAQ, MRC Sum Score, chemokines, cytokines, 
Scleroderma Physician Global Visual Analogue Scale (VAS) and the 
Scleroderma Neuropathic Pain Scale VAS. Chemokines and cytokines have 
been analysed by blinded independent laboratories. The statistical methods 
used for the multiplex analysis are described in Chapter 5, Section 5.3. 
2.2 Clinical assessments 
2.2.1 Demographics 
Demographic data were recorded at the screening visit. These included age, 
sex, race, smoking habits, height, weight, BMI, time since diagnosis of dcSSc, 
time since onset of first Raynaud’s symptoms, time since onset of first non-
Raynaud’s symptoms and family history of SSc. SSc functional class was also 
recorded (169). 
2.2.2 Clinical history and examination 
Each patient had a comprehensive clinical history taken at the screening visit 
including current symptoms, SSc diagnosis and symptoms, past medical and 
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surgical history and family history. This was followed by a full clinical 
examination. This formed the baseline for comparison at future visits, for the 
identification of new or worsening symptoms. At each subsequent visit, each 
patient had a current history taken and a full clinical examination.  
 
Modified Rodnan skin score (MRSS) (158) is a standard method of defining skin 
involvement in SSc. 17 sites are assessed, and a score of 0 (normal skin), 1 
(slight thickening), 2 (moderate thickening) or 3 (hidebound skin sclerosis) is 
assigned at each of these sites (face, chest and abdomen – a single score each 
– and bilaterally from upper arm, forearm, hand, fingers, thigh, leg and foot).  
The score ranges, therefore, from 0 to 51, Figure 2.3. MRSS was performed at 
each study visit by the same investigator throughout the study. 
 
Face
Upper arm
Chest
Forearm
Hand
Fingers
Thigh
Leg
Foot
Upper arm
Abdomen
Forearm
Hand
Fingers
Thigh
Leg
Foot
Total ______ / 51
1 320
1 320
1 320
1 320
1 320
1 320
1 320
1 320
1 320
1 320
1 320
1 320
1 320
1 320
1 320
1 320
1
3
2
0
1 320
Uninvolved
Mild thickening
Moderate thickening
Severe thickening
Date
ID
Modified Rodnan Skin Score
 
Figure 2.3: An example of the MRSS scoring sheet. 
 
MRC sum score (170) is a global score of muscle strength, measuring 6 muscle 
groups on each side with a score from 0-5, as described in the boxes below, 
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Figure 2.4. The global score ranges from 0-60. MRC sum score was performed 
at 3 intervals during the study. 
 
 
0 No visible contraction
1 Visible contraction without limb movement
2 Movement of limb, but not against gravity
3 Movement of limb against gravity over (almost) full range
4 Movement against gravity and resistance
5 Normal  
Figure 2.4: MRC sum score 
2.2.3 Questionnaires/Quality of Life Assessments 
2.2.3.1 Scleroderma Health Assessment Questionnaire (SSc-HAQ) 
The Health Assessment Questionnaire (HAQ) is a patient self-administered 
questionnaire commonly used to assess quality of life in rheumatological 
conditions, most notably rheumatoid arthritis. It was developed in 1978 by J. 
Fries, published in 1980 and modified subsequently (171) (172) (173). It is 
composed of 20 items in eight domains, scored 0-3. The HAQ disability index 
(HAQ-DI) is calculated by calculating the highest score in each domain and 
adding these together and dividing by the number of domains; this gives a score 
between 0 and 3, a lower score is better quality of life. The patient has to 
answer at least 6 of the 8 domains for the HAQ-DI calculation. 
 
The HAQ has been modified to include a number of visual analogue scales to 
measure symptoms specific to scleroderma (SSc-HAQ, SHAQ) and this has 
been validated in a number of studies (174) (175). SSc-HAQ is now routinely 
used in scleroderma studies as an outcome measure for quality of life (QoL) 
Muscle Groups (Right and Left)
Abduction of the arm
Flexion of the forearm
Extension of the wrist
Flexion of the leg
Extension of the knee
Dorsiflexion of the foot
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and improvement in disease status (176) (177). An example of the SSc-HAQ is 
given in the Appendix, Section 8.1.1. 
2.2.3.2 Short-Form 36 (SF-36) Questionnaire 
The short-form 36 (SF-36) questionnaire is a 36 item questionnaire in 8 
domains with weighted scoring used to measure quality of life in many different 
diseases (178) (179)  (180). The original SF-36 was designed for the Medical 
Outcomes Study and subsequently modified to the SF-36v2, now in use in 
many rheumatological trials including scleroderma (181) (182). The health 
transition index is a question asking the patient to compare their health now with 
the same time last year and answer one of 5 options: much better, somewhat 
better, about the same, somewhat worse or much worse. This index is often 
used as a summary measure in studies for comparison. An example of the SF-
36 is given in the Appendix, Section 8.1.2. 
 
2.2.3.3 Systemic Sclerosis Functional Score (SSc-FS) 
The SSc-FS is an 11 item 4 grade questionnaire, developed specifically to 
assess functional capacity in scleroderma patients (183) (184). An example of 
the SSc-FS is given in the Appendix, Section 8.1.3. 
2.2.3.4 Patient Global and Physician Global Visual Analogue Scales 
(VAS) 
Patient global VAS score is incorporated into the SSc-HAQ. Physician global 
VAS is usually a separate VAS 10cm scale asking the physician to rate the 
patients’ global condition from very good to very poor in their medical opinion. 
 
Neuropathic pain VAS was also included as the mechanism of action of HCS 
included sodium channel opening effect, which could, in theory, improve 
neuropathic pain. It is a 10cm scale rating neuropathic pain from none to very 
severe. 
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2.2.3.5 Outcome measures 
SSc-HAQ, SF-36, SSc-FS and global VAS scales are all used in current clinical 
trials. While each alone can be used, each has a distinct validity and 
combination can give more useful information (185) and correlate to certain 
aspects of disease and functionality (186).  
2.2.4 Physiological assessments 
2.2.4.1 Cardiological assessments 
ECG and echocardiogram were performed at 3 time periods as described 
above during the study to monitor for worsening cardiac disease. ECG was 
performed on the same machine and interpreted by the same investigator 
throughout the study. The echocardiogram was performed in the cardiology 
department by a qualified technician and interpreted by a cardiologist. 
2.2.4.2 Pulmonary function tests 
Pulmonary function tests (PFTs) were performed and interpreted in the 
pulmonary function laboratory by a qualified technician dedicated to clinical 
trials at 3 time periods as described above throughout the study. 
2.2.4.3 Chest radiograph and High resolution Computer Tomography 
(HRCT) 
Chest radiograph was performed on the screening visit to rule out chest 
infection, evidence of tuberculosis, severe lung fibrosis and neoplastic disease. 
HRCT chest is used to define lung fibrosis more completely. During this study, 
HRCT was only performed in patients who had worsening PFTs or a clinical 
suspicion of worsening lung symptoms. If HRCT showed worsening fibrosis, 
further treatment options were discussed with the patient. 
2.2.5 Exploratory physiological studies 
2.2.5.1 Sniff nasal inspiratory pressure (SNIP) 
Inspiratory muscle weakness is a recognised cause of unexplained dyspnoea. 
Many patients with SSc have dyspnoea and in some, a cause is not found. It is 
possible that patients with SSc can have respiratory muscle weakness due to 
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myositis associated with their disease. As HCS has a potential sodium channel 
opening effect, it was hypothesised that if a patient had inspiratory muscle 
weakness, it would improve with HCS treatment. Sniff nasal inspiratory 
pressure (SNIP) is a pulmonary function test that measures inspiratory muscle 
function. This assessment has been validated in a number of studies (187) 
(188). 
 
SNIP is performed in a seated position by inserting a catheter tip into one nostril 
and occluding the other nostril. The catheter is attached to a computer. The 
patient is asked to take a short, sharp sniff. The test is repeated 10 times with 
30 second rest periods (as there is an element of learning) and the maximal 
SNIP from the 10 tests is recorded as the test value (189), Figure 2.5. 
Computer
Transducer
Tubing
Nasal 
catheter
 
Figure 2.5: Equipment used for SNIP measurement. 
2.2.5.2 R-R interval 
Heart rate variability (HRV) is governed by vagal tone which is controlled by the 
autonomic nervous system. Therefore, HRV can be a surrogate marker or 
biomarker of autonomic dysfunction. Autonomic dysfunction is a well-
recognised association with SSc (190) (191) (192). HRV to assess autonomic 
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dysfunction in SSc was first reported in the mid 1990’s (193) (194) (195). HRV 
is non-invasive and relatively easy to perform and, as an adjunct to other 
cardiological tests, may provide important diagnostic and prognostic information 
(196) (197). As HCS has a potential sodium channel opening effect, it was 
hypothesised that it may improve autonomic dysfunction, and therefore 
normalise HRV.  
 
HRV is measured in time and frequency domains. Time domain analysis refers 
to statistics that are derived directly from the measurement of the normal-to 
normal (N-N) intervals (i.e. intervals between consecutive QRS complexes 
resulting from sino-atrial discharge) and statistics calculated from the 
differences between successive N-N intervals. N-N interval is also called R-R 
interval (R wave to R wave), which is the term used in this study.  Premature 
ectopic beats are ignored in these analyses. R-R interval-based measures are 
influenced both by short-term factors (e.g. respiratory) and long-term factors 
(e.g. circadian). The simplest variable to calculate is the standard deviation (SD) 
of the R-R intervals (SDRR, also called SDNN). SDRR reflects all the cyclic 
components (i.e., short-term and long-term) that are responsible for variability in 
the period of recording. The RMSSD, another variable often reported, is the 
square root of the mean squared differences in successive R-Rs (198) (199). 
The Valsalva ratio (VR) is calculated as the longest R-R interval within the 30 
seconds after the manoeuvre divided by the shortest R-R interval during or 
within the first 5 seconds after the manoeuvre (max/min). In this study, time 
domain variables alone were analysed. 
 
The patient was asked to lie on a couch semi-prone at an angle of 45 degrees. 
3 electrodes are applied to the skin, one below right clavicle, one in left upper 
quadrant of abdomen and one on right hand (earth) ensuring the electrodes 
were picking up good signal and the R waves were upright (electrodes plugged 
in properly). The electrodes were attached to a computer. The test was 
performed in 3 separate modes, normal breathing, deep breathing and Valsalva 
manoeuvre. Each was recorded for one minute. Deep breathing was performed 
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with the aid of a visual prompt on the computer screen with timed inhalation and 
exhalation, 6 cycles in a one minute period. Verbal prompts from the 
investigator were used in tandem with the visual cues. The Valsalva test was 
performed with the aid of an animation/cartoon. The patient is instructed to 
breathe normally for the first 10 seconds and then the cartoon will prompt to 
blow out, whereby the patient is instructed to take a breath in and blow out 
against the cheeks with the mouth closed. This is demonstrated for the patient, 
with a trial run until the patient felt comfortable with the instructions. Each set of 
3 tests was done a second time to verify results. Variables recorded were 
SDRR, RMSSD and max-min/mean for normal and deep breathing and VR for 
the Valsalva manoeuvre. 
2.3 Laboratory studies 
2.3.1 Routine laboratory assessments 
Routine laboratory assessments for safety were performed at every visit apart 
from Week 0, Day 3 or 4. These included blood samples taken for full blood 
count, biochemistry, erythrocyte sedimentation rate (ESR), C-reactive protein 
(CRP), thyroid function (on 4 occasions, including week 52 safety visit), 
coagulation screen (if the patient was on warfarin), pregnancy test 
(screening/baseline), SSc serology sample (screening/baseline and end of 
double-blind period) and a urine sample for urinalysis. Blood samples were sent 
to the main hospital laboratory and urine samples were tested in the clinical 
trials department with a standard urine dipstick test. Urine samples were sent to 
the hospital laboratory for further testing if there were any abnormal results with 
dipstick testing. 
2.3.2 Exploratory laboratory assessments 
Exploratory blood samples were obtained at baseline, week 0 day 0 (pre- and 
post-injection of medication), week 26 (end of study) and week 52 (end of safety 
period). These followed the template of recent expert consensus regarding 
exploratory biomarker studies in SSc trials (151). A 10ml serum sample, a 10ml 
plasma sample with EDTA and a 4ml plasma sample with trisodium citrate were 
obtained. The EDTA and citrate samples were centrifuged immediately at 3000 
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rpm for 10 minutes. After centrifuging, the plasma was aliquoted into 1ml 
sample bottles, labelled and stored in a -80°C freezer. The serum sample was 
allowed to clot for 30 minutes at room temperature and then centrifuged at 3000 
rpm for 10 minutes. The serum fraction was then aliquoted into 1ml sample 
bottles, labelled and stored in a -80°C freezer. All samples were stored until the 
end of the safety period. 
 
Samples were separated into 2 groups. The first group contained 2ml serum 
and 1ml EDTA plasma samples and was sent frozen to Quest Diagnostics 
(Valencia, CA 91355 USA) for analysis of procollagen III N-terminal propeptide 
(PIIINP), soluble IL-2R (sIL-2R), cartilage oligomeric matrix protein (COMP), 
TGF-β1 and von Willebrand factor (vWF). The second group contained 1ml 
serum samples sent frozen to Quansys Biosciences (Utah 84321, USA) for 
analysis of αMSH, ACTH, ANG2, HGF, PDGF-bb, TIMP-1, TIMP-2, VEGF, FGF 
basic, Eotaxin, GRO-α, MCP-1, MCP-2, RANTES, I-309, TARC, IP-10, IL-1α, 
IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-15, IL-17, IL-23, IFN-γ, 
TNF-α, TNF-β, IFN-α, IFN-β, Fractalkine and PARC by multiplex analysis. The 
remaining stored samples were transferred to Daval International for storage. 
2.3.2.1 Quest Diagnostics samples 
vWF samples were plasma samples and an enzyme linked immunosorbent 
assay (ELISA) Aushon Biosystems, Inc. (Cat. #84793) and a Searchlight 
analyser was used. Samples were thawed on ice, centrifuged at 20,000 x g for 
5 minutes to remove any residual precipitate and appropriately diluted before 
placement onto Searchlight plates in duplicate. Samples and standards were 
incubated at room temperature for 1 hour while shaking. Plates were washed 
three times using a plate washer, biotinylated secondary antibody added, and 
incubated for an additional 30 minutes. After three more washes, streptavidin- 
HRP was added to the plates, incubated for 30 minutes, washed again, and 
substrate added. Images of the plates were taken within 10 minutes, followed 
by image analysis using Searchlight array analysis software. 
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COMP samples were serum samples and an ELISA BioVendor, Inc. (Cat. 
#RD194080200) and a Tecan Genios Pro analyser were used. Standards, 
quality controls and diluted samples were incubated in microplate wells pre-
coated with monoclonal anti-human COMP antibody. After 60 minutes 
incubation and washing, biotin-labelled second monoclonal anti-human COMP 
antibody was added and incubated with captured COMP for 60 minutes. After 
another washing, streptavidin-HRP conjugate was added. After 30 minutes 
incubation and the last washing step, the remaining conjugate was allowed to 
react with the substrate solution (TMB). The reaction was stopped by addition of 
acidic solution and absorbance of the resulting yellow product was measured. 
The absorbance is proportional to the concentration of COMP. A standard curve 
was constructed by plotting absorbance values against concentrations of 
standards, and concentrations of unknown samples were determined using this 
standard curve. 
 
Soluble IL-2R samples were serum samples and an ELISA Thermo Scientific 
(Cat. #EH2IL2R) and a Tecan Genios Pro analyser were used. An anti-IL-2R 
monoclonal antibody was pre-coated onto polystyrene microtiter wells.  
Standards, controls, or patient samples were introduced to the wells followed 
immediately by the addition of an enzyme conjugated anti-IL-2R monoclonal 
antibody.  The soluble IL-2R present in the standards, controls, or samples was 
bound to the coated antibody while the conjugated antibody was bound to a 
second, distinct epitope on the IL-2R molecule completing the sandwich.  
Unreacted components were removed by washing.  A chromogen solution was 
added to the wells forming a coloured end product that is proportional to the 
amount of IL-2R present in the sample.  The reaction was terminated by the 
addition of stop solution, and the absorbance at 450nm, or 450 minus 550 nm, 
was measured.  A standard curve was prepared from six IL-2R standards.  
Unknown values were determined from the standard curve. 
 
TGF-β1 samples were serum samples and an ELISA R&D Systems, Inc. (Cat. 
#DB100B) and a Tecan Genios Pro analyser were used. This assay employs 
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the quantitative sandwich enzyme immunoassay technique. TGF­β soluble 
receptor Type II, which binds TGF­β1, was pre­coated onto a microplate. 
Standards and samples were pipetted into the wells and any TGF­β1 present 
was bound by the immobilized receptor. After washing away any unbound 
substances, an enzyme­linked polyclonal antibody specific for TGF­β1 was 
added to the wells to sandwich the TGF­β1 immobilized during the first 
incubation. Following a wash to remove any unbound antibody-enzyme reagent, 
a substrate solution was added to the wells and colour developed in proportion 
to the amount of TGF­β1 bound in the initial step. The colour development was 
stopped and the intensity of the colour was measured. 
 
PIIINP samples were serum samples and a radioimmunoassay Orion 
Diagnostica (Cat. #06098) was used, with a Cobra-II Auto Gamma Counter to 
analyse data. The Orion Diagnostica UniQ PIIINP RIA kit is based on the 
competitive radioimmunoassay technique. A known amount of labelled PIIINP 
and an unknown amount of unlabelled PIIINP in the sample compete for the 
limited number of high affinity binding sites of the antibody. After separating the 
free antigen, the amount of labelled PIIINP in the sample tube is inversely 
proportional to the amount of PIIINP in the sample. The concentrations in 
unknown samples are obtained from a calibration curve.  
 
All reagents and samples were brought to room temperature before testing and 
test tubes labelled appropriately and in duplicate. 200 μL of calibrator, control or 
patient samples were added to the appropriate tubes and 200μL tracer was 
added. 200 μL of antiserum was added to all tubes except non-specific binding 
(NSB) and total and 200 μL of distilled water was added to the NSB tubes. All 
tubes were mixed on a vortex mixer, then covered with paraffin film and 
incubated for 2 hours at 37°C. The separation reagent thoroughly by gentle 
inversion and 500 μL was added to all tubes except totals. The tubes were 
mixed on a vortex mixer and incubated for 30 minutes at room temperature. All 
tubes were centrifuged (except totals) for 15 minutes at 2000 g at 4 °C. The 
supernatants were decanted and the head of each tube, except the totals, was 
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tapped firmly against absorbent paper. Each tube was counted using a gamma 
counter for at least 1 minute or until 10,000 counts per tube were accumulated 
{Quest Diagnostics, personal communication}. 
2.3.2.2 Quansys Biosciences samples 
Quansys samples were tested on Quansys Biosciences’ (Logan, UT, USA) Q-
Plex Array™ kits for Human Angiogenesis (#150251HU), Human Chemokine 
(#120251HU), and Human Cytokine (#110951HU).  Both Fractalkine and PARC 
were custom developed from match pair antibodies available from R&D 
Systems (Minneapolis, MN, USA).  Samples were received, counted, and 
stored under appropriate storage conditions. 
 
Q-Plex™ technology involves the micro-spotting of individual groups of capture 
antibody in either a cartesian or polar coordinate system on the bottom of a 96 
well plate, each spot being its own micro ELISA. Each well was identically 
spotted. Standard ELISA incubation steps apply such as initial sample 
incubation, washing, secondary antibody incubation, washing, incubation with 
the label and measurement are involved. The label and reporting system used 
in a Q-Plex Array™ is chemiluminescent. 
 
The Q-Plex™ kits used in the sample testing have undergone extensive 
validation. Ranges for each assay were determined by dilutions determining 
upper ranges where high end hook effect and apparent antibody saturation are 
avoided and lower ranges that are above detection limits (200). Lower limits of 
detection (LLD) were calculated based off 2x the standard deviation of the 
background of 20 negative wells. Intra assay precision was measured with 
acceptance criteria of a coefficient of variation (%CV) of less than 15. Inter 
assay variability across plates was also determined to be less than 15% CV. 
Samples from human serum, plasma, or other biological fluid anticipated to 
have lower concentrations of expressed protein (i.e. cytokines) were tested 
using a modified, high sensitivity protocol. Antigen standard curves were 
performed in duplicate diluting the antigen standard 1:3 for 11 points with a 
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single negative point. The sample and antigen standard incubation was 
extended from one hour to two hours and the detection or secondary antibody 
incubation was extended from one hour to two hours. Lower limits of 
quantification (LLOQ) were determined to be the lowest point of the 10 point 
positive standard curve where the back-fit regression values are within 20% of 
the known value.   
 
Samples were thawed on ice and diluted into Quansys Human Sample Dilution 
Buffer or Mouse Sample Dilution Buffer. The sample buffers were formulated to 
reduce effects from heterophilic antibodies and other interferants (201). 
Samples were diluted at ratios of 1 to 2 (sample to buffer) (50%), 1 to 20 (5%) 
and 1 to 200 (.5%). Each dilution is loaded into three wells and measured in 
triplicate, a total of 9 wells per sample. The optimal dilution was selected by 
finding the dilution where the pixel intensity values fall on the most linear portion 
of the standard curve. Preparatory polypropylene low-binding 96-wellplates 
were used to prepare the samples and standards prior to loading the Q-Plex™ 
plate with a multichannel pipettor in order to reduce pipetting error.  
 
A composite or stacked image composed of individual exposures of 30, 60, and 
180s with camera noise background subtraction was performed using the Q-
View Imager™ and Q-View Software™. Levels of luminescent units or pixel 
intensity units were measured by the Q-View Software™. The duplicate 
standard curves are fit by the Q-View Software™ which allows for the selection 
of multiple non-linear and linear equations to fit the standard curve. Optimal 
curve fits are determined by visual graph evaluation and comparison of Aikake’s 
information criteria (AIC) values.  Measured pixel intensity values are regressed 
using the selected equation to interpolate concentrations in appropriate units. 
These concentrations are used in reporting on the sample testing report form 
{Quansys Biosciences, personal communication}. 
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3 Clinical Trial – Primary endpoints and key 
secondary endpoints 
3.1 Demographics and patient characteristics 
Twenty two subjects were screened and there were two screen failures. Twenty 
subjects were enrolled into the study, all of whom received at least one dose of 
study medication. Of these, 17 completed the study and there were 3 
withdrawals. None were lost to follow-up, Figure 3.1.   
 
 
 
Figure 3.1: Screening, HCS vs Placebo. 
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Demographic characteristics of the cohort are summarised in Table 3.1 and 
disease characteristics at baseline are outlined in Table 3.2.  These features 
were as expected for a cohort of subjects with established diffuse SSc. 
Table 3.1: Demographics of the study cohort 
Characteristic  HCS Placebo 
Age (years)  n 10 10 
  Mean (SD) 53.3 (12.66) 53.6 (13.23) 
  Min, Max 35 , 75 29 , 77 
  Median 55.7 57.2 
Weight (Kg)  n 10 10 
  Mean (SD) 75.80 (20.531) 70.00 (14.765) 
  Min, Max 51 , 123 52 , 98 
  Median 75.50 70.00 
Height (m)  n 10 10 
  Mean (SD) 1.64 (0.089) 1.63 (0.083) 
  Min, Max 1.5 , 1.8 1.5 , 1.8 
  Median 1.64 1.62 
BMI (kg/m2)  n 10 10 
  Mean (SD) 27.93 (5.484) 26.47 (4.976) 
  Min, Max 21.8 , 36.7 20.1 , 32.5 
  Median 27.66 26.75 
Gender Male n (%) 1 (10.0) 1 (10.0) 
 Female n (%) 9 (90.0) 9 (90.0) 
Race Caucasian n (%) 8 (80.0) 9 (90.0) 
 Asian n (%) 2 (20.0) 0 (0.0) 
 Other n (%) 0 (0.0) 1 (10.0) 
Smoking Status Non-Smoker n (%) 5 (50.0) 7 (70.0) 
 Ex-Smoker n (%) 4 (40.0) 3 (30.0) 
 Current Smoker n (%) 1 (10.0) 0 (0.0) 
Number of Pack Years Current Smoker n 1 0 (0.0) 
  Mean (SD) 5.3 0 (0.0) 
  Min, Max 5 , 5 0 (0.0) 
  Median 5.3 0 (0.0) 
 Ex-Smoker n 4 3 
  Mean (SD) 14.0 (15.39) 14.5 (20.02) 
  Min, Max 1 , 31 1 , 38 
  Median 10.0 5.0 
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Table 3.2: Baseline characteristics of the study cohort 
 
Parameter 
 
Placebo 
(n=10) 
HCS 
(n=10) 
Disease duration, 
years 
  
   Mean (SD) 10.95 (5.5) 10.21 (8.5) 
   Median 10.9 7.99 
   Min, Max 3.7, 20 3, 33 
MRSS   
   Mean (SD) 13.2 (4.7) 16.9 (9.1) 
   Median 12.5 12.0 
   Min, Max 7, 22 6, 31 
Autoantibodies, no. 
(%) 
  
   Anti-Topoisomerase 4 (40) 2 (20) 
   RNA Polymerase III 3 (30) 5 (50) 
   Other 3 (30) 3 (30) 
MRSS= modified Rodnan Skin Score 
9 of 10 patients in each group were female (reflecting the disease predominance 
in females). The median patient age was similar in each group (55.7 and 57.2 
years for the HCS and placebo groups, respectively). In the HCS group, the 
youngest patient was 35 and the eldest 75 years, while in the placebo group; the 
youngest was 29 and the eldest 77 years. BMI was also similar in each group 
with a median of 27.66 and 26.75 in the HCS and placebo groups, respectively. 
Table 3.3 summarises disease history of the cohort. The median time since 
diagnosis of diffuse SSc was higher in the HCS group (10.50 years) than in the 
placebo group (7.54 years). The median time since diagnosis of first Raynaud’s 
symptoms was again higher in the HCS group, being 12.93 years and 10.14 years 
in the HCS and placebo groups, respectively. All patients in both groups had 
visceral involvement, indicating severe morbidity secondary to SSc. 
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Table 3.3: Disease history 
 
 HCS Placebo 
Time since diagnosis of diffuse 
cutaneous SSc (years) 
 n 10 10 
  Mean 10.35 9.19 
  SD 5.484 7.051 
  Min 2.9 2.3 
  Median 10.50 7.54 
  Max 19 27 
Time since diagnosis of first Raynaud’s 
Symptoms (years) 
 n 10 10 
  Mean 12.84 17.31 
  SD 6.100 20.856 
  Min 3.5 4.4 
  Median 12.93 10.14 
  Max 22 72 
Time since diagnosis of first non-
Raynaud’s Symptoms (years) 
 n 10 10 
  Mean 10.95 10.21 
  SD 5.513 8.527 
  Min 3.7 3.0 
  Median 10.90 7.99 
  Max 20 33 
Family History of SSc Yes n (%) 0 (0.0) 1 (10.0) 
 No n (%) 10 
(100.0) 
8 (80.0) 
 Unknown n (%) 0 (0.0) 1 (10.0) 
 
Figure 3.2 shows a schematic of patient progression through the study. 
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Figure 3.2: Patient progression through the study. There were 3 withdrawals in the 
double blind phase. At week 26, 3 patients from the whole cohort opted not to receive 
HCS and the 14 remaining patients received HCS for a further 26 weeks 
3.2 Safety assessments 
All subjects in both groups had at least one adverse event (AE) and AEs were 
frequent in both groups in keeping with the high morbidity of the disease. An AE 
was defined as any untoward medical occurrence in a clinical study participant 
administered an investigational product, including any clinical or laboratory test 
value abnormality which occurred during the course of the study, whether 
considered related to treatment or not. A serious adverse event was defined as 
any experience which was fatal or life-threatening, was permanently disabling, 
required hospitalisation or prolongation of hospitalisation, was a congenital 
anomaly, or was an important medical event that could jeopardise the patient or 
require intervention to prevent one of those outcomes. There were numerically 
more AEs in the placebo group compared to the treatment group (though it did 
not reach statistical significance), 154 in the placebo group and 139 in the 
treatment group. This supports a conclusion that the study drug was safe and 
well tolerated. Details of AEs are provided in Table 3.4.  
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Table 3.4: Summary of adverse events 
 
Parameter Placebo HCS 
Total no. of AEs 154 139 
Possibly/Probably related to study medication 18 12 
No. of patients reporting Grade 3/4 AEs (severe) 5 4 
No. of mild AEs 59 59 
No. of moderate AEs 84 76 
No. of severe AEs 11 4 
 
The most commonly reported AEs were injection site reactions, cutaneous or 
musculoskeletal-related issues (such as skin itching, joint pains and ischaemic 
digital ulcers) and infections. Transient injection site reactions (redness and 
swelling at the injection site) occurred in both groups, but were more common in 
the HCS treatment group, occurring in 9 out of 10 patients in this group. Three 
were graded mild, 5 moderate and 1 severe. An injection site haematoma and 
chills occurred in one patient, graded moderate, and injection site pain graded 
mild in one other patient in the placebo group. The frequency of other AEs was 
similar in both groups. There were no statistically significant differences in the 
safety laboratory values throughout the study and no differences were noted 
between the groups in vital signs, physical examination, electrocardiography or 
echocardiography. One patient had re-emergence of thyroid abnormalities due 
to known but undertreated hypothyroidism and one patient developed low 
calcium and magnesium secondary to an increase in proton pump inhibitor 
given for worsening reflux symptoms. 
 
There were 6 serious adverse events (SAE) in 3 patients in the placebo group 
and 4 SAEs in 3 patients in the treatment group in the blinded phase. Two 
patients in placebo group and one in the treatment group withdrew due to AEs 
or SAEs. None of the SAEs were considered due to HCS treatment. There were 
no deaths during the course of the study. Details of SAEs are provided in Table 
3.5. 
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Table 3.5: Summary of serious adverse events from baseline to week 26. 
 
Parameter Placebo HCS 
No. of subjects reporting SAEs 3 3 
Total no. of SAEs 6 4 
Withdrawal due to AEs and 
SAEs 
2 1 
   
SAE by organ system Intestinal Obstruction x 
2 
Cerebral infarct 
 Panenteric dysmotility Pulmonary 
embolus 
 Viral meningitis Atrial Fibrillation 
 Pyelonephritis Respiratory 
Tract Infection 
 Ischaemic digital ulcer  
 
The only treatment related AEs during extension were reported by patients from 
the placebo group who commenced HCS treatment after the blinded phase (six 
(85.7%) of 7 patients) and 5 of these were related to injection site reactions. 
One patient, placebo to HCS group, discontinued permanently (withdrew) due 
to an AE (severe injection site reaction). One patient in each of the continuing 
HCS and placebo follow-up only groups reported a serious adverse event, one 
was a respiratory tract infection in a patient receiving HCS who continued on 
HCS and one was an acute episode of digital ischaemia and ulceration in a 
patient who was on placebo and who chose not to receive HCS and was follow-
up only. The respiratory tract infection was not considered to be related to study 
medication. Both patients were hospitalised and recovered and so these were 
classified as SAE. 
 
A period of one month off immunosuppression was required for entry into the 
study. A total of 10 out of the 20 patients enrolled stopped immunosuppression 
prior to enrolment, 3 in the HCS arm and 7 in the placebo arm. Only 4 patients 
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started immunosuppression after 26 weeks, all in the placebo arm and 3 of 4 of 
these had been on immunosuppression prior to the study. Of these 4, 2 patients 
had worsening lung disease; 1 patient restarted immunosuppression and 1 
started immunosuppression after being off it for a number of years. Of the 
remainder, one had rapidly progressive skin disease and one had worsening GI 
and cardiac scleroderma. 
3.3 Efficacy assessments 
3.3.1 Modified Rodnan Skin Score 
The difference from baseline score to 26 weeks was analysed first as outcome 
variable using Student’s t-test and corresponding confidence intervals.  Using 
this approach, analysis for the primary data shows mean MRSS fell by 1.4±4.7 
units with active treatment but worsened by 2.1±6.4 units on placebo (p=0.181, 
unpaired t-test) when baseline values were compared to 26 weeks, Figure 3.3.  
 
 
Figure 3.3: Change in MRSS from baseline to 26 weeks, blinded cohort. 
 
Because some patients had demonstrated clinically significant improvement in 
MRSS, a post hoc analysis of responder frequency in active and placebo 
treated patients was performed.  In the active treatment group one (10%) 
patient had at least 20% improvement from baseline in MRSS at week 6, and 
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the number had increased to five (50.0%) at Week 26. In contrast the placebo 
group had a greater proportion of patients (four patients; 40.0%) with response 
at week 6, and fewer patients (one patient; 10.0%) at Week 26. The difference 
between groups at week 26 by the unconditional z-pooled test showed a strong 
trend towards statistical significance (p=0.067) Figure 3.4. 
 
 
 
Figure 3.4: Change in modified Rodnan Skin Score (MRSS) from baseline to week 
26. Horizontal bars show mean values. There was an increase in mean MRSS in the 
placebo treated subjects and improvement in those receiving active therapy.  This did 
not reach statistical significance but changes were driven by the larger number of 
cases on active treatment that showed clinically meaningful improvement in MRSS 
during the trial (> 4 skin score units and 20% of baseline MRSS). The lines marked in 
bold show cases with significant improvement on active treatment or placebo. 
Responder frequency analysis showed a strong trend in favour of active treatment 
(p=0.067). 
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As the assessor was blinded to treatment, and remained blinded until after all 
patients has finished the follow-up phase, there was some degree of blinding in 
the extension phase. All patients were given a new batch of medication and all 
patients had the first dose in hospital under supervision. To extend these skin 
score data and provide greater clarity further analysis from an extended dataset 
was performed, that is, from patients enrolled in the study but receiving HCS on 
a compassionate basis for 26 weeks after completion of the double-blind phase 
of the study. In this extended dataset, the 26 week score for the placebo 
patients was used as the baseline score and the 52 week score as the 26 week 
score. All patients had MRSS completed at 52 weeks, whether receiving HCS 
or not for the safety phase. Whilst these data were not completely blinded they 
are generally supportive of the trend for improvement seen in the analysis of the 
26 week blinded phase.  Thus, there is skin score data for 7 additional cases 
treated for 26 weeks with HCS, and from 3 cases that chose not to take HCS 
but that were observed for 26 weeks. For this larger patient group the change in 
MRSS between baseline and 26 weeks was -2.00±1.03 for those treated with 
HCS (n=17) and +2.39±1.64 in those not receiving active therapy (n=13).  Using 
Student’s t-test and corresponding confidence intervals, this difference reached 
statistical significance (p=0.025), although the limitations of open label data and 
a post hoc analysis must be considered, Figure 3.5.  
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Figure 3.5, A&B: Change in MRSS, baseline compared to 26 weeks of treatment, 
combined cohort (blinded results combined with compassionate use 26 weeks-52 
weeks results). Horizontal bars show mean values. 
 
Furthermore, looking at the 4 groups separately, though the results are not 
statistically significant, the patients who continued on HCS for a further 6 
months and the patients who had HCS in the first 6 months but chose not to 
continue treatment appear to have stabilisation or slight improvement of MRSS. 
The patients who had no treatment overall (placebo to no treatment) seemed to 
have a slight worsening of MRSS, while the patients who were on placebo and 
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changed to HCS overall seemed to have a slight improvement in MRSS, Figure 
3.6 A-D. 
 
 
 
 
Figure 3.6: Graphic representation of MRSS at baseline, week 26 and week 52; A) 
HCS continuing on compassionate HCS for a further 6 months, B) HCS treatment 
discontinued after 6 month double-blind period, C) Placebo patients who decided not to 
go on compassionate HCS, D) Placebo patients who started compassionate HCS for 6 
months. 
3.3.2 HAQ and HAQ-DI 
The HAQ-DI is calculated from patient responses to the HAQ questionnaire. The 
questionnaire assesses the performance of 20 daily activities (items) which are 
grouped into eight categories that represent functional activity. Responses to at 
least six of the eight categories are required to calculate the HAQ-DI and the 
highest sub-category score determines the value for each category. The category 
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scores are averaged into an overall single index of disability (HAQ-DI) ranging 
from zero to one (representing mild to moderate functional difficulty), one to two 
(representing moderate to severe functional disability) and two to three 
(representing severe to very severe functional disability). There was no significant 
difference between the groups, though the placebo group was slightly worse. 
Mean ±SD for HAQ-DI at baseline was 1.2±0.07 for the HCS group and 1.6 ± 
0.63 for placebo group and at 26 weeks was 1.2±0.98 for HCS and 1.6 ± 0.55 for 
placebo (p=0.47), Table 3.6. 
 
126 
 
Table 3.6: Summary statistics for HAQ-DI, baseline to week 26. Adjusted mean change 
for patient number. Higher scores indicate worse disability. 
 
Treatment 
group 
Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 1.2 0.7 0 1.3 2   
  Week 6 Visit value 9 1.1 0.89 0 1.3 2   
    
Change from 
baseline 
9 0 0.28 -1 0 0   
    
Adjusted 
mean change 
  0 (-0.3, 0.3)     0.9455 
  
Week 
26 
Visit value 9 1.2 0.98 0 1.3 3   
    
Change from 
baseline 
9 0.1 0.35 0 0.1 1   
    
Adjusted 
mean change 
  0.1 (-0.1, 0.4)     0.3759 
Placebo Baseline Visit value 10 1.6 0.63 1 1.5 3   
  Week 6 Visit value 10 1.3 0.51 1 1.3 2   
    
Change from 
baseline 
10 -0.3 0.51 -1 -0.1 1   
    
Adjusted 
mean change 
  -0.2 (-0.5, 0.0)     0.0875 
  
Week 
26 
Visit value 9 1.6 0.55 1 1.4 2   
    
Change from 
baseline 
9 0 0.31 -1 0 1   
    
Adjusted 
mean change 
  0 (-0.3, 0.2)     0.8833 
Difference 
between 
groups 
Week 6 
Adjusted 
mean change 
  0.3 (-0.2, 0.7)     0.2194 
Week 
26 
Adjusted 
mean change 
  0.1 (-0.2, 0.5)     0.473 
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There are eight functional activity category scores in the HAQ; groom and dress, 
arise, eating, walking, hygiene, reach, grip and activity. At 26 weeks, no changes 
were seen in median values for any of these categories for patients in both 
groups. Statistically there was no overall significant difference between the 
groups in any of the eight categories: groom and dress, arise, eating, walking, 
hygiene, reach, grip and activity (p=0.6139, p=0.6560, p=0.3927, p=0.8015, 
p=0.2506, p=0.5363, p=0.5628, p=0.8133 respectively). See Appendix Section 
8.2 for details. 
 
The SSc-HAQ also has disease-specific VAS items of bodily pain, intestinal 
symptoms, breathing problems, Raynaud’s syndrome and finger ulcers and the 
results showed no significant differences between HCS and placebo for 4 of 5 
scales. The only significant difference found was in the scale for finger ulcers with 
the HCS group showing an improvement with treatment in percentage change 
(p=0.0466). However there was no difference in absolute change. There was a 
large variability in a small sample size. Variability may be explained by the time 
of year the patients were seen as finger ulcers tend to be worse in colder months, 
Table 3.7. 
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Table 3.7: Summary statistics of the change in VAS scales of SSc-HAQ, baseline to week 26. Negative mean scores indicate increasing disease 
burden. 
 
VAS item Group n Mean SD Min Median Max 
95% Confidence 
interval of mean 
Prob (t) 
Intestinal 
problems 
HCS 8 8.9 29.73 -12 -4 79     
Placebo 7 -0.1 35.43 -57 7 46     
  Difference   11.7         (-17.4, 40.7) 0.4062 
Breathing 
problems 
HCS 8 4.3 14.92 -8 0.0 41     
Placebo 5 -9.8 23.71 -66 -3.0 12     
  Difference   14.3         (-3.3, 31.8) 0.1036 
Raynaud’s 
symptoms 
HCS 8 -0.9 19.81 -33 -2 44     
Placebo 7 3.8 41.72 -53 0.0 68     
  Difference   -0.9         (-27.6, 25.8) 0.9438 
Finger ulcers 
HCS 6 -1.3 4.7 -7 0.0 9     
Placebo 3 -3.9 32.4 -50 0.0 60     
  Difference   4.8         (-18.3, 27.9) 0.6654 
Pain 
HCS 9 -5.6 4.04 1 -15 6     
Placebo 9 17.29 6.25 8 20 -19     
  Difference   22.89         
(-28.98, 30.9) 
0.4844 
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3.3.3 SF-36 
The SF-36 is split into 8 domains, 4 for physical health (Physical functioning, 
Role Physical, Bodily pain and General Health) and 4 for mental health (Vitality, 
Social Functioning, Role Emotional and Mental Health). In the 8 domains of SF-
36, the only domain to show some change was Role Physical, which showed a 
worsening in the placebo group and maintenance or stabilisation in the 
treatment group between baseline and week 26, with trend to significance 
between the groups (p=0.0685), Table 3.8. 
 
For the SF-36 domain scales that mostly contribute to the scoring of the 
physical health summary outcome, patients in the HCS group reported 
improvement between baseline and Week 6 in role-physical and general health, 
however this was not maintained at Week 26 as results indicate that there had 
been no change from baseline median in role-physical and a worsening in 
general health. For the two other domain scales, physical functioning and bodily 
pain in this category there were no changes in median results between baseline 
and Week 6 or Week 26. Scores for patients in the placebo group at Week 6 
mostly declined in all but one (general health) of the domain scales that 
contribute mostly to the physical health summary outcome. At Week 26 patients 
in the placebo group either reported continued decline (physical functioning, 
role-physical) or remained unchanged (bodily pain). However there was a small 
improvement in median change from baseline for the general health domain. 
Overall for physical health there was no significant difference at week 6 or week 
26 apart from role physical mentioned above. There were no significant 
changes in the 4 mental health domains between the groups. The Health 
Transition Index showed improvement in the HCS group at week 6 and week 
26, while the placebo group showed initial improvement at week 6, with 
worsening at week 26, Table 3.9. See Appendix Section 8.3 for further details.  
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Table 3.8: SF-36 Role Physical with change from baseline by treatment and visit. 
Adjusted mean change is adjusted for number of patients. Lower scores indicate 
greater burden of disease. 
 
Treatment 
group Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 38.8 30.16 0 40.6 75  
 Week 6 Visit value 9 54.9 38.37 0 50.0 100  
  Change from 
baseline 
9 16.7 25.77 0 6.3 81  
  Adjusted mean 
change 
 14.5 (-5.7, 34.8)   0.1468 
 Week 
26 
Visit value 9 45.8 30.62 0 37.5 94  
  Change from 
baseline 
9 7.6 23.55 -25 0.0 56  
  Adjusted mean 
change 
 5.5 (-11.6, 22.6)   0.5044 
Placebo Baseline Visit value 10 48.8 31.29 6 50.0 100  
 Week 6 Visit value 10 42.5 27.76 0 40.6 88  
  Change from 
baseline 
10 -6.3 34.74 -56 -12.5 63  
  Adjusted mean 
change 
 -2.8 (-22.1, 16.5)   0.7609 
 Week 
26 
Visit value 9 27.1 23.18 0 25.0 69  
  Change from 
baseline 
9 -16.0 32.79 -75 -12.5 44  
  Adjusted mean 
change 
 -16.7 (-33.5, 0.2)   0.0520 
Difference 
between 
groups 
Week 6 Adjusted mean 
change 
 17.4 (-10.7, 45.4)   0.2084 
Week 
26 
Adjusted mean 
change 
 22.2 (-1.9, 46.3)   0.0685 
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Table 3.9:  
A) A summary of the individual SF-36 scales at baseline, week 6 and week 26. Lower scores indicate greater burden of disease. 
  Baseline Week 6 Week 26 
Adjusted mean 
change from 
Baseline to Week 26 95% Confidence Interval 
  HCS Placebo HCS Placebo HCS Placebo HCS Placebo HCS Placebo 
Physical functioning 39.5 33.5 45.6 37 40.6 26.9 0.9 -9.7 -8.9, 10.7 -19.9, 0.4 
Role Physical 38.8 48.8 54.9 42.5 45.8 27.1 5.5 -16.7 -11.6, 22.6 -33.5, 0.2 
Pain 36.4 52.4 42.2 45.6 38.8 35.6 -2.1 -9.7 -17.5, 13.3 -24.7, 5.5 
General Health Perception 36.8 31 40.1 27.3 36.2 24 2 -7.9 -10.4, 14.4 -19.8, 4.1 
Vitality 35.5 34 38.9 33.5 38.3 32 2.1 -2.8 -10.1, 14.3 -14.9, 9.2 
Social Functioning 53.8 48.8 61.1 51.3 56.9 36.1 6.9 -8.4 -12.4, 26.2 -27.4, 10.6 
Role Emotional 45.8 70 72.2 61.7 59.3 57.4 4.8 -4.2 -19.7, 29.3 -28.1, 19.7 
Mental Health 58.8 62 61.8 66.4 58.2 57.3 1 -1.7 -11.4, 13.4 -13.9, 10.4 
 
B) Health Transition Index at baseline, week 6 and week 26. 
  Baseline Week 6 Week 26 
  HCS Placebo HCS Placebo HCS Placebo 
Health Transition Index (n)             
Much better   1   2   1 
Somewhat better   2 2 1 3   
About the same 6 4 5 4 4 3 
Somewhat worse 4 2 2 2 2 2 
Much worse   1   1   3 
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3.3.4 Scleroderma Functional Score (SSc-FS) 
Each item of the Scleroderma Functional Score is scored from 0 (normal) to 4 
(impossible to achieve) with an overall sum score of 0 to 33, where a higher score 
indicates worse function. The median SSc-FS for patients taking HCS remained 
stable at both Week 6 and Week 26 however, the range of scores was large with 
the minimum score being 0 and maximum scores 27.0, 24.0 and 26.0 at baseline, 
Week 6 and Week 26, respectively. In the placebo group the median SSc-FS 
demonstrated a slight increase at Week 6 (0.50) and again at Week 26 (1.00) 
indicating worsening of function. Similarly, there was a wide spread in the scores 
in the placebo group with minimum and maximum scores of 4.0 to 23.0, 5.0 to 
22.0, and 6.0 to 19.8 at baseline, Week 6 and Week 26, respectively. No group 
had an adjusted mean change from baseline at either Week 6 or Week 26 that 
was significantly different to zero. Analysis of the adjusted mean change in the 
SSc-FS from baseline to Week 6 or to Week 26 in the ITT population indicates 
that there was no overall significant difference between the groups or between 
visit weeks, Table 3.10. 
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Table 3.10: SSc-FS with change from baseline by treatment and visit. Adjusted mean 
change is adjusted for patient numbers. Higher scores indicate greater disease burden. 
 
Treatment 
group Visit Value 
Summary statistics 
Prob n Mean SD Min Median Max 
HCS Baseline Visit value 10 10.73 8.460 0.0 13.00 27.0  
 Week 6 Visit value 9 11.56 9.475 0.0 10.00 24.0  
  Change from baseline 9 1.41 4.711 -4.0 0.00 11.0  
  Adjusted mean change  1.34 (-1.82, 4.51)   0.3822 
 Week 26 Visit value 9 11.78 9.985 0.0 14.00 26.0  
  Change from baseline 9 1.63 3.659 -1.0 0.00 10.0  
  Adjusted mean change  1.56 (-0.95, 4.08)   0.2061 
Placebo Baseline Visit value 10 11.38 6.246 4.0 10.00 23.0  
 Week 6 Visit value 10 10.40 4.904 5.0 10.00 22.0  
  Change from baseline 10 -0.98 4.508 -12.0 0.50 3.0  
  Adjusted mean change  -0.92 (-3.92, 2.08)   0.5253 
 Week 26 Visit value 9 11.87 5.697 6.0 13.00 19.8  
  Change from baseline 9 0.34 3.278 -5.0 1.00 5.0  
  Adjusted mean change  0.46 (-2.05, 2.96)   0.7036 
Difference 
between 
groups 
Week 6 Adjusted mean change  2.26 (-2.11, 6.63)   0.2885 
Week 26 Adjusted mean change  1.11 (-2.45, 4.66)   0.5189 
 
3.3.5 Neuropathic pain VAS 
Neuropathic pain VAS was indicated by patients on a horizontal line in mm on a 
scale of 0 (no pain) to 100 (severe pain), with the final score presented in cm. At 
baseline patients reported a median neuropathic pain of 4.50 cm in the HCS 
group and 0.60 cm in the placebo group. The median neuropathic pain decreased 
at Week 6 (-2.0 cm) and Week 26 (-0.90 cm) compared to baseline in the HCS 
group. There was no change in median pain VAS in the placebo group at Week 
6 and an increase (0.05 cm) at Week 26. The analysis of adjusted mean change 
from baseline in the neuropathic pain VAS indicates that there was significant 
difference between groups at week 26 with an improvement in the treatment 
group and no change in the placebo group, p=0.0461, Figure 3.7, Table 3.11. 
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Figure 3.7: Change in Neuropathic pain VAS from baseline to week 26. Horizontal 
bars show mean values.
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Table 3.11: Summary statistics for Neuropathic pain, baseline to week 26. Adjusted mean change is adjusted for patient numbers. Higher 
scores indicate worse pain. 
 
Treatment 
Group 
Visit Value 
Summary statistics Prob 
n Mean SD Min Median Max  
HCS Baseline Visit value 8 3.84 3.478 0 4.5 8   
  Week 6 Visit value 9 1.91 2.9 0 0.1 7.8   
    Change from baseline 7 -1.9 2.217 -6.1 -2 0   
    Adjusted mean change   -1.79 (-3.46, -0.13)       
  Week 26 Visit value 9 1.69 2.243 0 0.3 6.1   
    Change from baseline 7 -1.96 2.615 -6 -0.9 0.2   
    Adjusted mean change   -1.98 (-3.45, -0.51)       
Placebo Baseline Visit value 9 2.97 3.901 0 0.6 10   
  Week 6 Visit value 9 1 2.412 0 0 7.3   
    Change from baseline 9 -1.97 3.725 -10 0 0.2   
    Adjusted mean change   -2.05 (-3.52, -0.58)       
  Week 26 Visit value 9 3.47 3.207 0 3.5 8.3   
    Change from baseline 8 0.06 1.987 -3.2 0.05 3.6   
    Adjusted mean change   0.08 (-1.30, 1.46)       
Difference 
between 
groups 
Week 6 Adjusted mean change   0.25 (-1.97, 2.48)     0.8086 
Week 26 Adjusted mean change   -2.06 (-4.08, -0.04)     0.0461 
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3.3.6 MRC sum score 
No significant changes were noted of any of the six muscle groups (shoulder 
abduction, forearm flexion, wrist extension, hip flexion, knee extension and foot 
dorsiflexion) for patients in either group by Week 26. At baseline, pre- and post-
treatment administration the muscle strength of patients in both HCS and placebo 
groups was the same with median scores of 60.0. The MRC score remained 
unchanged at Week 6 and Week 26. While the scores ranged from 54 to 60 at 
most visits, there was one patient in the HCS group whose score declined to 33 
at Week 26 due to MCA infarction which caused the patient to withdraw from the 
study at Week 2, Table 3.12. 
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Table 3.12: Summary statistics MRC Sum score comparing Baseline to Week 0/Day 0, week 6, week 26. Lower scores indicate worse function. Adjusted for patient numbers. 
Treatment group Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 59.4 1.07 57 60 60   
  Week 0/Day 0 Visit value 10 59.6 0.7 58 60 60   
    Change from baseline 10 0.2 0.42 0 0 1   
    Adjusted mean change   0.3 (0.1, 0.5)       
  Week 6 Visit value 9 59.8 0.44 59 60 60   
    Change from baseline 9 0.1 0.6 -1 0 1   
    Adjusted mean change   0.3 (0.1, 0.5)       
  Week 26 Visit value 10 57.2 8.51 33   60 60   
    Change from baseline 10 -2.2 7.7 -24 0 2   
    Adjusted mean change   -2.3 (-5.9, 1.3)       
Placebo Baseline Visit value 10 59.2 1.87 54 60 60   
  Week 0/Day 0 Visit value 10 59.6 0.7 58 60 60   
    Change from baseline 10 0.4 1.26 0 0 4   
    Adjusted mean change   0.3 (0.1, 0.5)       
  Week 6 Visit value 10 59.8 0.63 58 60 60   
    Change from baseline 10 0.6 1.26 0 0 4   
    Adjusted mean change   0.5 (0.3, 0.6)       
  Week 26 Visit value 10 59.5 1.27 56 60 60   
    Change from baseline 10 0.3 0.82 -1 0 2   
    Adjusted mean change   0.4 (-3.2, 4.0)       
Difference between groups 
Week 0/Day 0 Adjusted mean change   -0.1 (-0.4, 0.2)     0.5537 
Week 6 Adjusted mean change   -0.2 (-0.5, 0.1)     0.2019 
Week 26 Adjusted mean change   -2.7 (-7.8, 2.4)     0.2808 
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3.3.7 Physician and patient global VAS 
There was no significant difference in change from baseline between patients’ 
VAS scores in either HCS or placebo groups in overall disease severity at week 
6 or week 26 (p=0.344), Table 3.13. 
 
Table 3.13: Summary statistics of the change in Patient global VAS scale of SSc-HAQ, 
baseline to week 26. Higher scores indicate increased disease burden. 
VAS item Group n Mean SD Min Median Max 
95% 
Confidence 
interval of 
mean 
Prob 
(t) 
Disease 
severity 
HCS 9 3.0 21.83 -24 3.0 54     
Placebo 9 10.9 24.85 -20 5.0 61     
  Difference   -10.4         (-32.9, 12.2) 0.3440 
 
 
In the HCS group the median physician disease severity at baseline decreased 
slightly at Week 6 (-0.3 cm) and further by Week 26 (-1.1 cm). In the placebo 
group the baseline median disease severity was higher than in the HCS group, 
decreased slightly at Week 6 (-0.1 cm) and then increased Week 26 (0.8 cm).  
The analysis of adjusted mean change from baseline in the global disease 
severity VAS indicates that there is no significant difference between treatment 
groups at either Week 6 (p=0.6515) or Week 26 (p=0.3451), Table 3.14.  
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Table 3.14: Summary statistics for physician global score. Higher scores indicate 
increasing disease burden. Adjusted for patient numbers. 
Treatment 
group 
Visit Value 
Summary statistics 
Prob 
n Mean SD Min Median Max 
HCS Baseline Visit value 10 4.7 1.82 2 4.8 8   
  Week 6 Visit value 9 4.7 1.88 1 5.1 7   
    
Change from 
baseline 
9 -0.2 1.19 -2 -0.3 2   
    
Adjusted 
mean change 
  -0.3 (-1.4, 0.8)       
  
Week 
26 
Visit value 10 4.4 2.51 1 3.3 8   
    
Change from 
baseline 
10 -0.3 2.77 -3 -1.1 6   
    
Adjusted 
mean change 
  -0.7 (-2.5, 1.1)       
Placebo Baseline Visit value 10 5.7 1.08 4 5.8 7   
  Week 6 Visit value 10 5.7 1.86 3 6 8   
    
Change from 
baseline 
10 0 1.79 -3 -0.1 4   
    
Adjusted 
mean change 
  0.1 (-1.0, 1.1)       
  
Week 
26 
Visit value 10 5.8 2.68 2 6.9 8   
    
Change from 
baseline 
10 0.1 2.96 -5 0.8 4   
    
Adjusted 
mean change 
  0.5 (-1.3, 2.4)       
Difference 
between 
groups 
Week 6 
Adjusted 
mean change 
  -0.3 (-1.9, 1.2)     0.6515 
Week 
26 
Adjusted 
mean change 
  -1.2 (-3.9, 1.4)     0.3451 
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4 Physiological studies 
4.1 Routine physiological studies 
4.1.1 Vital signs and clinical examination 
There were no significant changes between or within HCS and placebo groups 
in any of the vital signs parameters or clinical examination.  
4.1.2 Cardiological assessments 
There were no significant changes in ECG or echocardiogram findings between 
HCS and placebo groups throughout the study. Left ventricular ejection fraction 
(LVEF) was normal in all patients in both groups. Mean estimated pulmonary 
artery systolic pressure (PASP) was in the normal range in most patients. Mean 
PASP was slightly higher at baseline in the placebo group than the HCS group 
(26.1mmHg versus 19.3mmHg) but did not change significantly. Elevated PASP 
was reviewed by the assessor in the context of clinical symptoms and 
worsening lung function tests, particularly DLco. If the patient did not have 
symptoms and DLco was stable, the patient was monitored as per clinical 
protocol with a repeat echocardiogram in 6 months. If symptoms developed, a 
repeat echocardiogram was performed and depending on results the patient 
either continued to be monitored or was referred for further assessment. If lung 
function tests and/or clinical symptoms showed deterioration, the patient was 
referred for cardiological assessment including consideration for right heart 
catheterisation.  
 
PASP was found to be slightly elevated in 3 patients in the HCS group after the 
start of treatment, but it was not clinically significant and further tests were 
stable. PASP was significantly elevated at withdrawal visit in one patient in the 
placebo group who withdrew due to worsening lung disease. This patient was 
further assessed per clinical protocol and due to the significant change coupled 
with her dyspnoea, she went on to have a right heart catheter test which 
confirmed that her elevated PASP was pulmonary hypertension secondary to 
her lung disease and not due to PAH. 
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4.1.3 Chest radiograph and HRCT Chest  
Seventy percent of patients in the HCS group and 90% of patients in the 
placebo group had a normal chest radiograph at baseline. Abnormal findings 
were due to pre-existing lung fibrosis. 5 patients (2 in the HCS arm and 3 in the 
placebo arm) had HRCT chest performed due to either worsening of symptoms 
(dyspnoea, cough, worsening exercise tolerance) and/or worsening of 
pulmonary function tests (FVC or DLco decrease of 20% compared to last PFT 
readings), in line with usual clinical practice. HRCTs were reviewed with 
reference to extent of fibrotic changes i.e. definitely >20% or indeterminate (10-
30%) as per staging system suggested by Goh et al (202), which is routine 
practice. FVC <70% was used as the threshold in patients with indeterminate 
disease on HRCT.  Of the 5 patients who had a HRCT, 1 patient in the placebo 
group had confirmed worsening of lung fibrosis (when comparing her HRCT to 
previous scans and using the scoring system mentioned). She subsequently 
discontinued the study and started immunosuppression. 
4.1.4 Pulmonary function tests 
Lung function indices showed a trend of benefit for the HCS group compared to 
the placebo group for those variables that reflect respiratory effort (FVC and 
FEV1) for absolute values but not in % predicted values. At Week 26 FEV1 had 
increased in the HCS group and decreased in the placebo group resulting in 
5.83% difference between groups. A similar pattern was shown in FVC for a 
7.37% difference between the groups. This represents an interesting positive 
trend but did not reach statistical significance due to the small sample. In 
addition, no significant fold changes were noted in either group. However when 
background disease was taken into account (pre-existing lung disease 
worsened in 1 patient in the placebo group), there was no significant difference 
between the two treatment groups. DLco and TLC did not change during the 
study, Table 4.1. 
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Table 4.1, A&B: Descriptive statistics for change and percent change from Baseline to Week 26 for pulmonary function parameters.  
 
A 
Parameter Value Group n Mean 
95% Confidence 
limits for Mean SD SEM Prob (t) 
FEV1 (L) Raw change from Baseline HCS 9 -0.004 -0.128 - 0.119 0.1603 0.0534 0.9358 
  Placebo 10 -0.103 -0.225 - 0.019 0.1702 0.0538 0.0879 
  Group diff.  0.099 -0.062 - 0.259 0.1656 0.0761 0.2126 
FEV1 (L) Percent change from Baseline HCS 9 0.266 -4.658 - 5.191 6.4066 2.1355 0.9039 
  Placebo 9 -5.564 -11.375 - 0.246 7.5592 2.5197 0.0582 
  Group diff.  5.830 -1.171 - 12.832 7.0066 3.3029 0.0966 
Pred. FEV1 (%) Raw change from Baseline HCS 9 0.34 -4.10 - 4.79 5.780 1.927 0.8626 
  Placebo 10 -3.24 -7.78 - 1.30 6.349 2.008 0.1410 
  Group diff.  3.58 -2.32 - 9.49 6.088 2.797 0.2172 
FEV/FVC ratio (%) Raw change from Baseline HCS 9 -1.203 -4.096 - 1.690 3.7638 1.2546 0.3658 
  Placebo 10 0.200 -4.502 - 4.902 6.5730 2.0786 0.9255 
  Group diff.  -1.403 -6.671 - 3.866 5.4350 2.4972 0.5816 
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B 
Parameter Value Group n Mean 
95% Confidence 
SD SEM Prob (t) 
limits for Mean 
FVC (L) 
Raw change 
from Baseline 
HCS 9 0.027 -0.214 0.139 0.0463 0.5808 
    Placebo 10 -0.162 -0.392 0.2745 0.0868 0.0948 
    Group diff.   0.189 -0.429 0.2213 0.1017 0.0810 
FVC (L) 
Percent change 
from Baseline 
HCS 9 1.799 -7.871 5.1202 1.7067 0.3225 
    Placebo 10 -5.569 -13.922 9.7311 3.0772 0.1038 
    Group diff.   7.368 -15.323 7.9037 3.6315 0.0584 
Pred. FVC (%) 
Raw change 
from Baseline 
HCS 9 1.64 -7.29 4.74 1.58 0.3284 
    Placebo 10 -1.39 -10.18 7.119 2.251 0.5522 
    Group diff.   3.03 -11.85 6.116 2.81 0.2953 
DLCO (mmol/min/kPa) 
Raw change 
from Baseline 
HCS 9 -0.129 -0.452 0.2943 0.0981 0.2253 
    Placebo 10 -0.325 -0.796 0.5569 0.1761 0.0981 
    Group diff.   0.196 -0.878 0.4527 0.208 0.3590 
Pred. DLCO (%) 
Raw change 
from Baseline 
HCS 9 -1.48 -6.07 3.951 1.317 0.2944 
    Placebo 10 -3.76 -10.68 7.461 2.36 0.1455 
    Group diff.   2.28 -11.76 6.068 2.788 0.4244 
TLC (L) 
Raw change 
from Baseline 
HCS 9 -0.081 -1.011 0.6576 0.2192 0.7210 
    Placebo 10 -0.12 -0.524 0.3659 0.1157 0.3268 
    Group diff.   0.039 -1.016 0.5238 0.2407 0.8735 
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4.2 Exploratory physiological studies 
4.2.1 Sniff Nasal Inspiratory Pressure 
Sniff nasal inspiratory pressure (SNIP) was in the normal range (compared to 
reference values for normal subjects by age by Uldry et al (189)) for most 
patients Figure 4.1 and Table 4.2, A & B. SNIP was slightly low throughout 
compared to normal subjects for 3 patients, patients 2, 3 and 19, all of whom 
were women in their 70’s. There were no significant changes between the 
groups or within the groups throughout the study. This indicates that respiratory 
muscle function as measured by SNIP is normal in this group of SSc patients 
and remained normal throughout.  
 
Figure 4.1: Graphic representation of SNIP values at baseline, week 6 and week 26. 
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Table 4.2: Descriptive statistics for SNIP, A: Baseline, week 6 and week 26 
comparisons and B: Change from Baseline to Week 26. Normal values lie between 90-
110 cmH2O. 
A 
Descriptive Statistics 
Parameter 
Treatment 
Group Visit n Mean SD Min Median Max 
Sniff nasal inspiratory 
pressure (cmH2O) 
HCS Baseline 10 103.2 29.43 67 100.5 171 
 Week 6 9 99.0 23.73 67 96.0 148 
  Week 26 9 102.4 26.75 72 98.0 157 
 Placebo Baseline 10 103.3 24.10 54 105.5 146 
  Week 6 10 102.7 20.16 69 105.0 146 
  Week 26 10 105.7 23.06 61 111.0 145 
 
B Descriptive statistics 
Prob (t) Parameter Value Group n Mean 
95% 
Confidence 
limits for 
Mean SD SEM 
SNIP (cm H2O) Raw change from 
Baseline 
HCS 9 -3.8 -17.8 - 10.2 18.23 6.08 0.5514 
  Placebo 10 2.4 -2.3 - 7.1 6.62 2.09 0.2812 
  Group 
difference 
 -6.2 -19.2 - 6.8 13.40 6.16 0.3593 
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4.2.2 R-R interval 
Mean changes in R-R interval variation (also called heart rate variability, HRV) 
during normal breathing, deep breathing or Valsalva manoeuvre were similar for 
patients in both HCS and placebo groups throughout the study period. No 
clinically or statistically significant variations were noted. A number of patients in 
both groups demonstrated variation in association with ectopic beats or heart 
block. Patient 13 developed complete heart block at week 26, making his 
readings ineligible. Software is available to correct for occasional ectopic beats 
however, any patients who had numerous ectopic beats also had outlying 
readings, as these were impossible to correct for. The results compare SSc 
placebo patients to HCS treated patients before and after treatment, therefore 
patients act as their own controls. In this study there was no normal comparator 
control group. However, there is some published literature on HRV and 
autonomic dysfunction in SSc. These studies are mentioned in the relevant 
sections. 
4.2.2.1 Normal breathing 
Descriptive statistics for R-R interval are presented in Tables 4.3 and 4.4. Due 
to some outlying values, it is more useful to consider median rather than mean 
values. 
Placebo patients tended to have slightly lower values for SDRR and RMSSD 
but there was no significant change after treatment in either group. However, 
though there is no normal control group in this study, values for SDRR and 
RMSSD appear to be much lower than normal control groups in other studies, 
suggesting that autonomic neuropathy is present in these patients, in keeping 
with these and other studies showing evidence of significant autonomic 
neuropathy in SSc (195) (196) (203) (204). 
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Table 4.3: Descriptive statistics for normal breathing R-R interval. Normal control values for SDRR are reported to be 0.13-0.167sec and RMSSD are 0.032-0.057sec. 
  Descriptive Statistics 
Parameter 
Treatment 
Group Visit Time n Mean SD Min Median Max 
Max-min/ 
mean (%) 
HCS Day 0 pre dose 10 18.6 13.34 7 14.4 54 
  Day 0 post dose 10 16.7 11.43 7 13.4 47 
    Week 26 N/A 8 15.2 5.92 7 14 23 
  Placebo Day 0 pre dose 10 16.8 9.94 9 11.5 40 
    Day 0 post dose 10 18.3 14.24 8 14.1 56 
    Week 26 N/A 10 22.9 26.36 9 15.2 97 
SDRR (sec) HCS Day 0 pre dose 9 0.062 0.0474 0.01 0.053 0.16 
    Day 0 post dose 9 0.034 0.0224 0.02 0.028 0.09 
    Week 26 N/A 8 0.039 0.0221 0.02 0.033 0.08 
  Placebo Day 0 pre dose 10 0.04 0.0355 0.02 0.024 0.13 
    Day 0 post dose 10 0.044 0.0454 0.02 0.023 0.16 
    Week 26 N/A 10 0.055 0.0613 0.02 0.025 0.19 
RMSSD (sec) HCS Day 0 pre dose 9 0.07 0.0794 0 0.031 0.26 
    Day 0 post dose 9 0.033 0.0294 0.01 0.021 0.09 
    Week 26 N/A 8 0.046 0.0413 0.01 0.035 0.14 
  Placebo Day 0 pre dose 10 0.041 0.0443 0.01 0.018 0.15 
    Day 0 post dose 10 0.047 0.0617 0.01 0.019 0.18 
    Week 26 N/A 10 0.069 0.1009 0 0.024 0.28 
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Table 4.4: Change from baseline for normal breathing R-R interval. Normal control values for SDRR are reported to be 0.13-0.167sec and RMSSD are 0.032-0.057sec. 
  Change from Baseline 
Parameter 
Treatment 
Group Visit Time Mean SD Min Median Max 
Max-min/ mean 
(%) 
HCS Day 0 pre dose      
  Day 0 post dose -1.9 3.91 -8 -2 4 
    Week 26 N/A -4.2 13.78 -31 -4.2 14 
  Placebo Day 0 pre dose      
    Day 0 post dose 1.5 5.44 -5 0.7 15 
    Week 26 N/A 6.1 26.53 -21 -0.5 78 
SDRR (sec) HCS Day 0 pre dose      
    Day 0 post dose -0.028 0.042 -0.12 -0.018 0.02 
    Week 26 N/A -0.027 0.0358 -0.08 -0.033 0.03 
  Placebo Day 0 pre dose      
    Day 0 post dose 0.004 0.0224 -0.04 0.003 0.05 
    Week 26 N/A 0.015 0.0297 -0.01 0.001 0.08 
RMSSD (sec) HCS Day 0 pre dose      
    Day 0 post dose -0.037 0.0694 -0.19 -0.01 0.04 
    Week 26 N/A -0.03 0.0588 -0.12 -0.028 0.06 
  Placebo Day 0 pre dose      
    Day 0 post dose 0.006 0.0308 -0.05 0.001 0.07 
    Week 26 N/A 0.028 0.0643 -0.03 0.005 0.16 
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4.2.2.2 Deep breathing 
There was no significant difference between or within treatment groups for deep 
breathing HRV variables. Descriptive statistics are presented in Tables 4.5 and 
4.6. The published data on HRV deep breathing variables usually compares E/I 
ratio (the maximum expiration over the maximum inspiration) (205) (206). 
Unfortunately the software used does not record this variable, therefore 
conclusions can only be made comparing the values for each time period and 
comparing between groups. The HRV triangular index (HRV-TI) considers the 
major peak of the histogram as a triangle with its baseline width corresponding 
to the amount of RR interval variability, its height corresponds to the most 
frequently observed duration of RR intervals, and its area corresponds to the 
total number of all RR intervals used to construct it. The triangular HRV index is 
an estimate of the overall HRV. One study showed no difference in deep 
breathing variables (E/I) comparing SSc to controls (207).
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Table 4.5: Descriptive statistics for deep breathing R-R interval variables. No normal values are available for comparison on SDRR and HRV-
TI. Normal values for RMSSD vary between 0.0724 and 0.1288 depending on age group (208). 
  Descriptive Statistics 
Parameter 
Treatment 
Visit 
  
Mean SD Min Median 
  
Group Time Max 
SDRR (sec) HCS Day 0 pre dose 0.077 0.0541 0.03 0.052 0.18 
    Day 0 post dose 0.068 0.0402 0.02 0.061 0.14 
    Week 26 N/A 0.064 0.0509 0.02 0.059 0.18 
  Placebo Day 0 pre dose 0.062 0.0528 0.02 0.053 0.2 
    Day 0 post dose 0.073 0.0453 0.02 0.065 0.17 
   Week 26 N/A 0.088 0.0577 0.03 0.08 0.19 
RMSSD (sec) HCS Day 0 pre dose 0.08 0.091 0.02 0.039 0.3 
    Day 0 post dose 0.059 0.0461 0.01 0.043 0.13 
    Week 26 N/A 0.044 0.0481 0 0.039 0.16 
  Placebo Day 0 pre dose 0.062 0.0742 0.02 0.041 0.27 
    Day 0 post dose 0.07 0.0669 0.02 0.043 0.23 
    Week 26 N/A 0.099 0.1069 0.02 0.055 0.31 
HRV-TI HCS Day 0 pre dose 0.141 0.046 0.087 0.14 0.23 
    Day 0 post dose 0.134 0.073 0.066 0.12 0.32 
    Week 26 N/A 0.136 0.079 0.07 0.097 0.33 
  Placebo Day 0 pre dose 0.157 0.073 0.079 0.14 0.3 
    Day 0 post dose 0.135 0.046 0.077 0.125 0.23 
    Week 26 N/A 0.128 0.054 0.069 0.1 0.27 
 
 
151 
 
Table 4.6: Change from baseline for deep breathing R-R interval. No normal values are available for comparison. 
  Change from Baseline 
Parameter 
Treatment 
Visit 
      
Min Median Max Group Time Mean SD 
SDRR (sec) HCS Day 0 pre dose           
    Day 0 post dose -0.009 -0.0139 -0.01 0.009 -0.04 
    Week 26 N/A -0.013 -0.0032 -0.01 0.007 0 
  Placebo Day 0 pre dose           
    Day 0 post dose 0.009 -0.0075 0 0.012 -0.03 
    Week 26 N/A 0.026 0.0049 0.01 0.033 -0.01 
RMSSD (sec) HCS Day 0 pre dose           
    Day 0 post dose -0.021 -0.0449 -0.01 0.004 -0.16 
    Week 26 N/A -0.036 -0.0429 -0.02 0 -0.14 
  Placebo Day 0 pre dose           
    Day 0 post dose 0.008 -0.0073 0 0.002 -0.04 
    Week 26 N/A 0.037 0.0327 0 0.014 0.04 
HRV-TI HCS Day 0 pre dose           
    Day 0 post dose -0.007 0.027 -0.021 -0.02 0.09 
    Week 26 N/A -0.009 0.033 -0.017 -0.043 0.1 
  Placebo Day 0 pre dose           
    Day 0 post dose -0.022 -0.027 -0.002 -0.015 -0.07 
    Week 26 N/A -0.029 -0.019 -0.01 -0.04 -0.03 
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4.2.2.3 Valsalva manoeuvre 
The Valsalva ratio (VR) is calculated as the longest R-R interval within the 30 seconds after the manoeuvre divided by the shortest 
R-R interval during or within the first 5 seconds after the manoeuvre (max/min). There was no significant difference between or 
within the groups for VR, Tables 4.7 and 4.8. Compared to normal comparator control values in two studies, VR was between the 
normal values in patients in both groups (208) (207). 
Table 4.7: Descriptive statistics for Valsalva manoeuvre R-R interval. The mean normal value for VR reported in one study was 1.13-1.19 
depending on age group and in another study was 1.6 with no difference between SSc patients and controls. 
  Descriptive Statistics 
Parameter 
Treatment 
Visit 
  
n Mean SD Min Median 
  
Group Time Max 
Valsalva 
ratio 
HCS Day 0 pre dose 10 1.249 0.1658 1.02 1.228 1.49 
    Day 0 post dose 10 1.187 0.1986 1.02 1.11 1.55 
    Week 26 N/A 8 1.303 0.3281 1.01 1.22 1.97 
  Placebo Day 0 pre dose 10 1.305 0.2314 1.01 1.415 1.59 
    Day 0 post dose 10 1.354 0.2853 1.01 1.388 1.8 
    Week 26 N/A 10 1.435 0.3112 1.06 1.465 1.94 
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Table 4.8: Change from baseline for Valsalva manoeuvre R-R interval. The mean normal value for VR reported in one study was 1.13-1.19 
depending on age group and in another study was 1.6 with no difference between SSc patients and controls. 
 
  Change from Baseline 
Parameter 
Treatment 
Visit 
  
n 
    
Min Median Max Group Time Mean SD 
Valsalva ratio HCS Day 0 pre dose 10           
    Day 0 post dose 10 -0.063 0.1893 -0.43 -0.028 0.17 
    Week 26 N/A 8 0.099 0.2126 -0.11 0.04 0.51 
  Placebo Day 0 pre dose 10           
    Day 0 post dose 10 0.049 0.0923 -0.1 0.045 0.21 
    Week 26 N/A 10 0.13 0.2935 -0.18 0.05 0.89 
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5 Laboratory studies and candidate biomarker 
analysis 
5.1 Routine laboratory studies 
Biochemistry and haematology laboratory studies were largely within the normal 
range or just slightly abnormal but not clinically significant throughout the study. 
There were no significant changes between or within the groups for most 
values. One patient in the HCS group had significantly low calcium and 
magnesium levels at week 20 and 26, due to an increase in her proton pump 
inhibitor (PPI) for reflux. These went back to normal after stopping the PPI and 
recurred with restarting the PPI. One patient had high TSH and low T4 thyroid 
function tests at baseline due to undertreated concomitant hypothyroidism. 
These were normal at week 26. There were no other significant changes in 
thyroid function throughout the study in either group. Urinalysis and eGFR 
remained largely unchanged throughout the study. 
5.2 Trial specified candidate biomarkers 
5.2.1 PIIINP 
PIIINP is a marker of fibrosis. At week 26, PIIINP was significantly increased 
from baseline in the HCS group by 8.080 (4.445, 11.715) μg/L [adjusted mean 
change (95%CI)], (p=0.0002), and relatively unchanged in the placebo group, 
1.104 (-2.531, 4.739) μg/mL (p=0.5301). The difference between the groups at 
Week 26 was significant (p=0.0118) and the treatment groups were significantly 
different overall (p = 0.0118) Table 5.1, Figure 5.1. 
 
When looking at post hoc combined baseline to week 26 (i.e., 7 placebo 
patients who started on HCS at week 26 and 3 placebo patients who did not 
take medication, using week 26 as baseline and week 52 as week 26), the 
results were even more significant with p=0.0085, Figure 5.2. 
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Table 5.1: Descriptive statistics for PIIINP levels (μg/L) from baseline to week 26 in 
HCS and placebo groups. 
 
Treatment 
group Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 6.851 3.7638 3.88 5.630 16.31  
 Week 26 Visit value 10 15.442 10.1068 5.89 13.530 34.44  
  Change 
from 
baseline 
10 8.591 7.8340 0.75 5.955 23.31  
  Adjusted 
mean 
change 
(95% CI) 
 8.080 (4.445, 11.715)   0.0002 
Placebo Baseline Visit value 10 5.311 2.4068 2.17 5.330 9.41  
 Week 26 Visit value 10 5.904 2.7205 2.50 5.485 10.72  
  Change 
from 
baseline 
10 0.593 1.3078 -2.05 1.020 2.32  
  Adjusted 
mean 
change 
(95% CI) 
 1.104 (-2.531, 4.739)   0.5301 
Difference 
between 
groups 
Week 26 Adjusted 
mean 
change 
(95% CI) 
 6.975 (1.753, 12.198)   0.0118 
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Figure 5.1: Graphic representation of PIIINP levels from baseline to week 26. 
 
 
Figure 5.2: Graphic representation of PIIINP levels combined 26 week post hoc data, baseline 
to 26 weeks of treatment. Horizontal bars show mean values.
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Interestingly, the HCS group who continued HCS had a significant reduction in 
PIIINP from 26 weeks to 52 weeks (p=0.0078) though not back to baseline 
levels; comparing PIIINP levels at 52 weeks to baseline, there was a strong 
trend to significant increase in PIIINP (p=0.0527). The HCS patients who 
choose not to continue on HCS compassionate use also had a significant 
reduction of PIIINP level from 26 weeks to 52 weeks back to baseline levels, but 
there were only 2 patients in that group. The placebo patients who chose not to 
go on HCS at 26 weeks had no significant change in PIIINP levels (3 patients). 
In the group that switched from placebo to HCS at 26 weeks, significant 
increases from baseline (and from 26 weeks) were seen in PIIINP at 52 weeks 
(p=0.0008 compared to baseline). These results are shown graphically in 
Figure 5.3 (A-D). 
 
 
Figure 5.3: Graphic representation of PIIINP levels at baseline, week 26 and week 
52; A) HCS continuing on compassionate HCS for a further 6 months, B) HCS 
treatment discontinued after 6 month double-blind period, C) Placebo patients who 
decided not to go on compassionate HCS, D) Placebo patients who started 
compassionate HCS for 6 months. 
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5.2.2 sIL-2R 
At week 26, there was no significant difference between the groups for soluble 
IL-2 receptor (sIL-2R), p=0.7862 Table 5.2, Figure 5.4. The combined 26 week 
data from the post hoc analysis was also not significant, p=0.2218, Figure 5.5. 
 
Table 5.2: Descriptive statistics for sIL-2R (U/ml) from baseline to week 26 in 
HCS and placebo groups. 
 
  Summary statistics   
Treatment 
group Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit 
value 
10 1117.05 554.764 495.1 1077.95 2238.1   
  Week 26 Visit 
value 
10 1213.91 946.773 203.1 1177.35 2936.3   
    Change 
from 
baseline 
10 96.86 644.354 -
564.9 
-93.2 1738.1   
    Adjusted 
mean 
change 
(95% CI) 
  92.39 (-243.16, 
427.95) 
    0.5689 
Placebo Baseline Visit 
value 
10 966.18 496.8 430.3 797.75 2024.5   
  Week 26 Visit 
value 
10 1116.43 445.21 585.9 1011.3 2028.7   
    Change 
from 
baseline 
10 150.25 243.24 -
183.3 
115.4 655.9   
    Adjusted 
mean 
change 
(95% CI) 
  154.72 (-180.84, 
490.27) 
    0.3443 
Difference 
between 
groups 
Week 26 Adjusted 
mean 
change 
(95% CI) 
  -62.32 (-539.54, 
414.89) 
    0.7862 
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Figure 5.4: Graphic representation of sIL-2R levels from baseline to week 26. Horizontal bars 
show mean values. 
 
 
Figure 5.5: Graphic representation of combined 26 week post hoc data, sIL-2R levels 
from baseline to week 26. Horizontal bars show mean values. 
 
At week 52, there was no significant change in the HCS group who continued a 
further 26 weeks of treatment or in the HCS group who discontinued treatment. 
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In the placebo group, there was a trend to significant increase in the patients 
who did not take HCS (p=0.053). There were only 3 patients in this group and 2 
of these did not show a change; the third showed an increase in sIL-2R levels. 
sIL-2R is a marker for inflammation. The patient who had an increase in sIL-2R 
was extremely unwell throughout the study, particularly between week 26 and 
week 52, when he was an inpatient. He died soon after week 52 as a result of 
progression of his disease. There was a significant increase in sIL-2R in the 
placebo patients who opted for HCS compassionate treatment for 26 weeks 
(p=0.0311). This change was not seen in the double-blind HCS patients, 
mentioned above and the difference may be explained by fewer patients in the 
group (7 patients versus 10 patients in the original group) with a wider range of 
results. These results are shown graphically in Figure 5.6. 
 
 
Figure 5.6: Graphic representation of sIL-2R levels at baseline, week 26 and week 
52; A) HCS continuing on compassionate HCS for a further 6 months, B) HCS 
treatment discontinued after 6 month double-blind period, C) Placebo patients who 
decided not to go on compassionate HCS, D) Placebo patients who started 
compassionate HCS for 6 months. 
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5.2.3 vWF 
At week 26, there was no significant difference between the groups when comparing difference from baseline to week 26 for von 
Willebrand Factor (vWF), p=0.6875 Figure 5.7, Table 5.3.  
 
Table 5.3: Descriptive statistics for vWF (U/ml) from baseline to week 26 in HCS and placebo groups. 
Treatment group Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 27.08 24.2704 1.59 18.355 87.65  
 Week 26 Visit value 10 17.64 14.6770 2.65 14.135 52.86  
  Change from baseline 10 -9.43 13.0639 -34.79 -8.575 8.65  
  Adjusted mean 
change (95% CI) 
 -16.03 (-33.505, 1.440)   0.0697 
Placebo Baseline Visit value 10 61.48 75.4690 4.93 13.995 203.89  
 Week 26 Visit value 10 43.76 58.3372 4.60 14.780 183.00  
  Change from baseline 10 -17.72 44.5572 -140.51 -2.410 10.01  
  Adjusted mean 
change (95% CI) 
 -11.12 (-28.595, 6.350)   0.1969 
Difference between 
groups 
Week 26 Adjusted mean 
change (95% CI) 
 -4.91 (-30.226, 20.407)   0.6875 
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Figure 5.7: Graphic representation of vWF levels from baseline to week 26. Horizontal 
bars show mean values. 
 
Post hoc combined 26 week data for vWF also revealed no significant 
difference, p=0.35, Figure 5.8. 
 
 
 
Figure 5.8: Graphic representation of combined 26 week post hoc data, vWF levels 
from baseline to week 26. Horizontal bars show mean values.
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At week 52, there was no significant change in the HCS group who continued a 
further 26 weeks of treatment or in the HCS group who discontinued treatment. 
In the placebo group, there was no significant change in the patients who did 
not take HCS. There was a significant decrease in vWF in the placebo patients 
who did not take HCS, p=0.003; however, there were only 2 patients in this 
group. These 2 patients were unwell throughout the study and withdrew at week 
14 due to disease progression and/or worsening lung fibrosis. Both went on 
immunosuppressive agents after week 14, and their disease stabilised. As vWF 
is a marker for vasculopathy, this could explain the decrease in vWF levels. 
These data are presented in graphical form in Figure 5.9. 
 
 
 
Figure 5.9: Graphic representation of vWF levels at baseline, week 26 and week 52; 
A) HCS continuing on compassionate HCS for a further 6 months, B) HCS treatment 
discontinued after 6 month double-blind period, C) Placebo patients who decided not to 
go on compassionate HCS, D) Placebo patients who started compassionate HCS for 6 
months. 
164 
 
5.3 Multiplex cytokine analysis 
The following sections describe individual results, followed by a cluster analysis 
of the data. The first 3 analytes (MSH, ACTH and FGF) and PIIINP were the top 
4 upregulated hormones/growth factors in the HCS group according to cluster 
analysis, whereas the remainder were downregulated. 
5.3.1 α-Melanocyte Stimulating Hormone (αMSH) 
At week 26, αMSH was significantly increased from baseline in the HCS group 
compared to placebo, p=0.0395, Figure 5.10, Table 5.4. Post hoc combined 26 
week data for MSH revealed a more significant difference, p=0.005, Figure 
5.11. 
 
 
 
 
 
Figure 5.10: Graphic representation of αMSH levels from baseline to week 26. 
Horizontal bars show mean values.
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Table 5.4: Descriptive statistics for αMSH (pg/ml) from baseline to week 26 in HCS 
and placebo groups. 
 
Treatment 
group 
Visit Value n Mean SD Min Median Max Prob 
HCS Baseline 
Visit 
value 
10 3.71 3.573 0.2 2.03 11.9   
  
Week 
26 
Visit 
value 
9 31.13 35.782 0.2 15.06 101.3   
    
Change 
from 
baseline 
9 27.16 34.206 -6 9.58 89.5   
    
Adjusted 
mean 
change 
(95% 
CI) 
  24.96 (9.42, 40.49)     0.0035 
Placebo Baseline 
Visit 
value 
10 1.78 0.896 0.9 1.55 3.6   
  
Week 
26 
Visit 
value 
10 2.18 1.869 0.8 1.27 6.4   
    
Change 
from 
baseline 
10 0.39 1.365 -0.8 -0.03 3   
    
Adjusted 
mean 
change 
(95% 
CI) 
  2.27 (-12.50, 17.03)     0.7498 
Difference 
between 
groups 
Week 
26 
Adjusted 
mean 
change 
(95% 
CI) 
  22.69 (1.23, 44.14)     0.0395 
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Figure 5.11: Graphic representation of combined 26 week post hoc data, αMSH 
levels from baseline to week 26. Horizontal bars show mean values. 
 
At week 52, in the HCS group who continued treatment, there was a decrease 
in αMSH levels compared to week 26, but not back to baseline and the 
difference was not statistically significant compared to baseline or week 26. The 
HCS group who did not continue treatment had a significant drop in αMSH back 
to baseline levels (only 2 patients). There was no change in the placebo group 
who did not take HCS and in the placebo to HCS group a significant increase 
from baseline (and week 26) was seen in αMSH, p=0.0014, Figure 5.12. 
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Figure 5.12: Graphic representation of αMSH levels at baseline, week 26 and week 
52; A) HCS continuing on compassionate HCS for a further 6 months, B) HCS 
treatment discontinued after 6 month double-blind period, C) Placebo patients who 
decided not to go on compassionate HCS, D) Placebo patients who started 
compassionate HCS for 6 months. 
5.3.2 Adrenocorticotrophic Hormone (ACTH) 
Mirroring MSH, at 26 weeks ACTH levels showed a strong trend to increase 
from baseline in the HCS group compared to placebo, p=0.0532, Figure 5.13, 
Table 5.5. Post hoc combined 26 week data for ACTH revealed a more 
significant difference, p=0.0208, Figure 5.14. 
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Figure 5.13: Graphic representation of ACTH levels from baseline to week 26. 
Horizontal bars show mean values. 
 
 
Figure 5.14: Graphic representation of combined 26 week post hoc data, ACTH 
levels from baseline to week 26. Horizontal bars show mean values. 
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Table 5.5: Descriptive statistics for ACTH (pg/ml) from baseline to week 26 in HCS 
and placebo groups 
 
Treatment 
Group 
Visit Value n Mean SD Min Median Max Prob 
HCS Baseline 
Visit 
value 
10 1.94 2.434 0.2 0.96 8.2   
  
Week 
26 
Visit 
value 
9 27.63 42.282 0.4 3.94 114.6   
    
Change 
from 
baseline 
9 25.54 40.374 -1.8 2.95 106.4   
    
Adjusted 
mean 
change 
(95% 
CI) 
  25.41 (6.95, 43.87)     0.0099 
Placebo Baseline 
Visit 
value 
10 1.14 1.074 0.4 0.76 3.9   
  
Week 
26 
Visit 
value 
10 0.99 0.679 0.4 0.82 2.8   
    
Change 
from 
baseline 
10 -0.15 0.61 -1.2 -0.24 0.7   
    
Adjusted 
mean 
change 
(95% 
CI) 
  0.28 (-17.33, 17.89)     0.9736 
Difference 
between 
groups 
Week 
26 
Adjusted 
mean 
change 
(95% 
CI) 
  25.13 (-0.39, 50.65)     0.0532 
 
 
At week 52, again similar to the αMSH results, in the HCS group who continued 
treatment, there was a decrease in ACTH levels compared to week 26, but not 
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back to baseline and the difference was not statistically significant compared to 
baseline or week 26. The HCS group who did not continue treatment had a 
significant drop in ACTH back to baseline levels (only 2 patients). There was no 
change in the placebo group who did not take HCS and in the placebo to HCS 
group a significant increase from baseline (and week 26) was seen in ACTH, 
p=0.0022, Figure 5.15. 
 
 
 
Figure 5.15: Graphic representation of ACTH levels at baseline, week 26 and week 
52; A) HCS continuing on compassionate HCS for a further 6 months, B) HCS 
treatment discontinued after 6 month double-blind period, C) Placebo patients who 
decided not to go on compassionate HCS, D) Placebo patients who started 
compassionate HCS for 6 months. 
5.3.3 basic Fibroblast Growth Factor (bFGF) 
At 26 weeks bFGF (or FGF-basic) levels showed an increase from baseline in 
the HCS group compared to placebo, but this was not statistically significant, 
p=0.148, Figure 5.16, Table 5.6. Post hoc combined 26 week data for FGF 
also showed an increase, but again it was not statistically significant, Figure 
5.17. 
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Figure 5.16: Graphic representation of bFGF levels from baseline to week 26. 
Horizontal bars show mean values. 
 
 
 
 
Figure 5.17: Graphic representation of combined 26 week post hoc data, bFGF levels 
from baseline to week 26. Horizontal bars show mean values. 
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Table 5.5: Descriptive statistics for bFGF (pg/ml) from baseline to week 26 in HCS 
and placebo groups. 
 
Treatment 
group 
Visit Value n Mean SD Min Median Max Prob 
HCS Baseline 
Visit 
value 
10 3.37 6.483 0.3 0.3 16   
  
Week 
26 
Visit 
value 
9 21.52 21.921 0.3 19.76 57   
    
Change 
from 
baseline 
9 17.8 24.753 -15.1 19.28 56.7   
    
Adjusted 
mean 
change 
(95% 
CI) 
  17.03 (3.24, 30.81)     0.0185 
Placebo Baseline 
Visit 
value 
10 21.29 43.34 0.3 7.59 142.3   
  
Week 
26 
Visit 
value 
10 23.64 51.652 0.3 7.04 169.3   
    
Change 
from 
baseline 
10 2.35 11.892 -13.5 0 27   
    
Adjusted 
mean 
change 
(95% 
CI) 
  3.22 (-10.10, 16.54)     0.6165 
Difference 
between 
groups 
Week 
26 
Adjusted 
mean 
change 
(95% 
CI) 
  13.81 (-5.43, 33.05)     0.1484 
 
 
At week 52, in the HCS group who continued treatment, there was a non-
significant increase in bFGF levels compared to week 26. The HCS group who 
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did not continue treatment had a significant drop in bFGF back to baseline 
levels (only 2 patients). There was a significant decrease in the placebo group 
who did not take HCS (only 3 patients) and in the placebo to HCS group a non-
significant increase from baseline (and week 26) was seen in bFGF, Figure 
5.18. 
 
 
 
Figure 5.18: Graphic representation of bFGF levels at baseline, week 26 and week 
52; A) HCS continuing on compassionate HCS for a further 6 months, B) HCS 
treatment discontinued after 6 month double-blind period, C) Placebo patients who 
decided not to go on compassionate HCS, D) Placebo patients who started 
compassionate HCS for 6 months. 
5.3.4 Transforming Growth Factor-β1 (TGF-β1) 
At 26 weeks, both groups showed a decrease in TGF-β1 levels while the HCS 
group showed a slightly bigger decrease. This was not significant with 
p=0.6009, Figure 5.19, Table 5.6. The post hoc combined 26 week data 
showed an increase in the HCS group but no change in the placebo group and 
the difference again was not significant, Figure 5.20. 
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Figure 5.19: Graphic representation of TGF-β1 levels from baseline to week 26. 
Horizontal bars show mean values. 
 
 
 
 
Figure 5.20: Graphic representation of combined 26 week post hoc data, TGF-β1 
levels from baseline to week 26. Horizontal bars show mean values. 
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Table 5.6: Descriptive statistics for TGF-β1 (pg/ml) from baseline to week 26 in HCS 
and placebo groups. 
 
  Summary statistics   
Treatment 
group 
Visit Value n Mean SD Min Median Max Prob 
HCS Baseline 
Visit 
value 
10 29450.8 7931.31 18623 30691.5 39011   
  
Week 
26 
Visit 
value 
10 27777.1 4309.86 19000 28182 33190   
    
Change 
from 
baseline 
10 -1673.7 9751.16 -17545 -1188 9479   
    
Adjusted 
mean 
change 
(95% CI) 
  -329.3 (-5838.7, 5180.2)     0.9011 
Placebo Baseline 
Visit 
value 
10 26408 4385.31 21367 26988 34587   
  
Week 
26 
Visit 
value 
10 25424.8 10364.98 6877 25868 37341   
    
Change 
from 
baseline 
10 -983.2 9692.93 -17114 816 11626   
    
Adjusted 
mean 
change 
(95% CI) 
  -2327.6 (-7837.1, 3181.8)     0.3852 
Difference 
between 
groups 
Week 
26 
Adjusted 
mean 
change 
(95% CI) 
  1998.4 (-5910.6, 9907.4)     0.6009 
 
At 52 weeks, the group of placebo patients who were followed up only with no 
other treatment showed an increase in TGF-β1 levels but there were only 3 
patients in this group. None of the other 3 groups showed statistically significant 
changes compared to baseline or week 26, Figure 5.21. 
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Figure 5.21: Graphic representation of TGF-β1 levels at baseline, week 26 and week 
52; A) HCS continuing on compassionate HCS for a further 6 months, B) HCS 
treatment discontinued after 6 month double-blind period, C) Placebo patients who 
decided not to go on compassionate HCS, D) Placebo patients who started 
compassionate HCS for 6 months. 
5.3.5 Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) 
At 26 weeks there was a slight decrease in TIMP-2 levels compared to baseline 
in the HCS group and a slight increase in the placebo group. However, the 
difference was not statistically significant, p=0.1044, Figure 5.22, Table 5.7. 
The combined 26 week post hoc analysis showed a less significant difference, 
Figure 5.23. 
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Figure 5.22: Graphic representation of TIMP-2 levels from baseline to week 26. 
Horizontal bars show mean values.  
 
 
 
Figure 5.23: Graphic representation of combined 26 week post hoc data, TIMP-2 
levels from baseline to week 26. Horizontal bars show mean values. 
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Table 5.7: Descriptive statistics for TIMP-2 (pg/ml) from baseline to week 26 in HCS 
and placebo groups. 
 
Treatment 
group 
Visit Value Mean SD Min Median Max Prob 
HCS Baseline 
Visit 
value 
13458.24 1880.143 11046.8 12733.52 17217.1   
  
Week 
26 
Visit 
value 
13038.63 1821.765 10978.2 12713.92 15636.3   
    
Change 
from 
baseline 
-573.59 663.711 -1580.8 -329.67 63.6   
    
Adjusted 
mean 
change 
(95% 
CI) 
-630.36 (-1934.2, 673.45)     0.322 
Placebo Baseline 
Visit 
value 
13058.01 1825.532 11124.7 12561.83 16082.6   
  
Week 
26 
Visit 
value 
13850.66 2311.337 9901.6 14400.88 16558.6   
    
Change 
from 
baseline 
792.65 2239.923 -3280.8 951.43 4810.8   
    
Adjusted 
mean 
change 
(95% 
CI) 
834.62 (-400.72, 2069.96)     0.1721 
Difference 
between 
groups 
Week 
26 
Adjusted 
mean 
change 
(95% 
CI) 
-1464.98 (-3266.4, 336.40)     0.1044 
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At 52 weeks, there were no statistically significant changes in any of the 4 
groups compared to baseline or week 26, Figure 5.24. 
 
 
 
Figure 5.24: Graphic representation of TIMP-2 levels at baseline, week 26 and week 
52; A) HCS continuing on compassionate HCS for a further 6 months, B) HCS 
treatment discontinued after 6 month double-blind period, C) Placebo patients who 
decided not to go on compassionate HCS, D) Placebo patients who started 
compassionate HCS for 6 months. 
5.3.6 Fractalkine (CX3CL1) 
At 26 weeks, there was a decrease in Fractalkine levels in both groups. The 
HCS group had a bigger decrease, however the difference was not statistically 
significant with p=0.3179, Figure 5.25, Table 5.8. The combined 26 week post 
hoc analysis showed an even smaller difference, Figure 5.26. 
 
At week 52, there were no significant changes in any of the 4 groups compared 
to baseline or week 26, Figure 5.27. 
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Figure 5.25: Graphic representation of Fractalkine levels from baseline to week 26. 
Horizontal bars show mean values. 
 
 
 
Figure 5.26: Graphic representation of combined 26 week post hoc data, Fractalkine 
levels from baseline to week 26. Horizontal bars show mean values. 
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Table 5.8: Descriptive statistics for Fractalkine (pg/ml) from baseline to week 26 in 
HCS and placebo groups. 
 
Treatment 
group 
Visit Value n Mean SD Min Median Max Prob 
HCS Baseline 
Visit 
value 
10 3736.54 6396.612 734.7 1301.59 21512.1   
  
Week 
26 
Visit 
value 
9 3272.08 6131.862 439.9 1012.26 19418.2   
    
Change 
from 
baseline 
9 -685.9 1965.505 
-
4833.7 
-170.83 2344   
    
Adjusted 
mean 
change 
(95% 
CI) 
  -793.29 (-1778.1, 191.55)     0.1075 
Placebo Baseline 
Visit 
value 
10 1148.46 653.894 485.4 1184.58 2700.9   
  
Week 
26 
Visit 
value 
10 998.76 638.248 333.1 752.29 1952.1   
    
Change 
from 
baseline 
10 -149.69 478.468 -855.1 -232.89 573.3   
    
Adjusted 
mean 
change 
(95% 
CI) 
  -123.44 (-1079.3, 832.37)     0.7885 
Difference 
between 
groups 
Week 
26 
Adjusted 
mean 
change 
(95% 
CI) 
  -669.86 (-2043.4, 703.73)     0.3179 
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Figure 5.27: Graphic representation of Fractalkine levels at baseline, week 26 and 
week 52; A) HCS continuing on compassionate HCS for a further 6 months, B) HCS 
treatment discontinued after 6 month double-blind period, C) Placebo patients who 
decided not to go on compassionate HCS, D) Placebo patients who started 
compassionate HCS for 6 months. 
5.3.7 Cartilage Oligomeric Matrix Protein (COMP) 
At 26 weeks, there was a decrease in COMP levels in HCS group and a slight 
increase in the placebo group, though the difference between groups was not 
statistically significant with p=0.2651, Figure 5.28, Table 5.9. The combined 26 
weeks post hoc data showed a smaller difference between the groups, Figure 
5.29. 
 
At 52 weeks, there were no significant changes in any of the 4 groups 
compared to baseline or week 26, Figure 5.30. 
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Figure 5.28: Graphic representation of COMP levels from baseline to week 26. 
Horizontal bars show mean values. 
 
 
 
Figure 5.29: Graphic representation of combined 26 week post hoc data, COMP 
levels from baseline to week 26. Horizontal bars show mean values. 
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Table 5.9: Descriptive statistics for COMP (ng/ml) from baseline to week 26 in HCS 
and placebo groups. 
 
Treatment 
group 
Visit Value n Mean SD Min Median Max Prob 
HCS Baseline 
Visit 
value 
10 1821 1138.11 707 1451 4598   
  
Week 
26 
Visit 
value 
10 1364.3 348 808 1333 2028   
    
Change 
from 
baseline 
10 -456.7 895.93 -2770 -84.5 144   
    
Adjusted 
mean 
change 
(95% 
CI) 
  -267 (-540.8, 6.8)     0.0553 
Placebo Baseline 
Visit 
value 
10 1260.5 537.64 445 1389.5 1952   
  
Week 
26 
Visit 
value 
10 1400.1 588.1 553 1206.5 2501   
    
Change 
from 
baseline 
10 139.6 473.94 -521 40.5 1131   
    
Adjusted 
mean 
change 
(95% 
CI) 
  -50.1 (-323.9, 223.7)     0.7043 
Difference 
between 
groups 
Week 
26 
Adjusted 
mean 
change 
(95% 
CI) 
  -216.9 (-614.1, 180.2)     0.2651 
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Figure 5.30: Graphic representation of COMP levels at baseline, week 26 and week 
52; A) HCS continuing on compassionate HCS for a further 6 months, B) HCS 
treatment discontinued after 6 month double-blind period, C) Placebo patients who 
decided not to go on compassionate HCS, D) Placebo patients who started 
compassionate HCS for 6 months. 
5.3.8 Growth-Related Oncogene-α (GROα) 
At 26 weeks, there was a decrease in GROα levels in HCS group and a slight 
increase in the placebo group, though the difference between groups was not 
statistically significant with p=0.2061, Figure 5.31, Table 5.10. The combined 
26 weeks post hoc data showed a smaller difference between the groups, 
Figure 5.32. 
 
At 52 weeks, there were no significant differences in any of the 4 groups 
compared to baseline. The HCS group who stopped treatment at 26 weeks (2 
patients) had a significant increase GROα levels compared to week 26, Figure 
5.33. 
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Figure 5.31: Graphic representation of GROα levels from baseline to week 26. 
Horizontal bars show mean values. 
 
 
 
Figure 5.32: Graphic representation of combined 26 week post hoc data, GROα 
levels from baseline to week 26. Horizontal bars show mean values. 
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Table 5.10: Descriptive statistics for GROα (pg/ml) from baseline to week 26 in HCS 
and placebo groups. 
 
Treatment 
group 
Visit Value n Mean SD Min Median Max Prob 
HCS Baseline 
Visit 
value 
10 35.02 97.233 0.9 2.88 311.4   
  
Week 
26 
Visit 
value 
9 10.66 17.118 0.9 1.25 50.5   
    
Change 
from 
baseline 
9 -27.3 88.278 -260.9 0 23.3   
    
Adjusted 
mean 
change 
(95% 
CI) 
  -19.27 (-40.82, 2.28)     0.0764 
Placebo Baseline 
Visit 
value 
10 3.62 5.549 0.9 0.9 18.7   
  
Week 
26 
Visit 
value 
10 10.19 15.088 0.9 2.96 47   
    
Change 
from 
baseline 
10 6.57 14.452 -1.4 0.92 46.1   
    
Adjusted 
mean 
change 
(95% 
CI) 
  -0.76 (-21.20, 19.69)     0.9387 
Difference 
between 
groups 
Week 
26 
Adjusted 
mean 
change 
(95% 
CI) 
  -18.51 (-48.23, 11.20)     0.2061 
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Figure 5.33: Graphic representation of GROα levels at baseline, week 26 and week 
52; A) HCS continuing on compassionate HCS for a further 6 months, B) HCS 
treatment discontinued after 6 month double-blind period, C) Placebo patients who 
decided not to go on compassionate HCS, D) Placebo patients who started 
compassionate HCS for 6 months. 
5.3.9 Cluster analysis 
To strengthen and extend the analysis of individual serum analytes, cluster 
analysis was performed to better understand the changes that occurred in the 
patients during this study, focusing on the effects at 26 and 52 weeks compared 
with baseline.  This approach is now well established for large datasets and was 
first developed and validated for analysis of microarray gene expression data.  
The advantage of this approach is that it takes account of the multiple factors 
that are analysed and permits analysis of normalized and scaled data so that 
different levels within the cohort and the range of change can be taken into 
account is defining patterns of change associated with treatment using HCS or 
placebo. 
 
First, significance analysis of microarray testing (SAM®) was used to further 
interrogate the dataset and determine the significance of the findings observed 
in each analyte when examined separately as outlined earlier in this chapter.  
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Fold change >2 was taken as a cut-off point and the 4 most significant positive 
and 5 most significant negative serum factors were analysed separately. The 
results of this analysis are summarised in Tables 5.11 and 5.12 included below.  
 
Tale 5.11: SAM results for positive or upregulated serum factors; difference between 
baseline and 26 weeks for 10 HCS and 10 placebo patients. Top 4 values (in bold) 
were further defined individually. 
 
Positive serum factors (20) 
Gene ID Score(d) Numerator(r) Denominator(s+s0) Fold Change q-value (%) 
PIIINP 2.640433 8.04325 3.046186311 14.56365936 0 
FGF Basic 2.366466 19.35974445 8.180866024 65.03317217 0 
MSH 1.950008 23.09005523 11.84100502 298.5833202 0 
ACTH 1.755792 24.67471113 14.05332342 -176.6136588 20 
PARC 1.623022 104588.3975 64440.52994 -3.103386906 43.07692308 
VEGF 1.411976 72.34451238 51.23634762 4.767420819 46.89655172 
I309 1.261012 8.5671673 6.793884919 5.508246003 46.89655172 
IL12p70 1.239963 5.0243342 4.05200181 2.642028734 46.89655172 
MMP 9 0.732223 34106.7405 46579.69077 -5.850080076 46.89655172 
TIMP1 0.658503 1216.991525 1848.118263 -0.9899809 46.89655172 
vWF 0.630152 10.4645 16.60630987 0.409519242 46.89655172 
PDGFBB 0.530864 372.60309 701.8806505 -0.456093176 46.89655172 
POMC 0.418754 0.424928775 1.014745138 -1.096768388 46.89655172 
TNFβ 0.415387 0.317667 0.764749815 0 46.89655172 
IL13 0.347142 1.30916645 3.771269521 -0.442608135 46.89655172 
IL17 0.253017 0.132916625 0.525326243 Inf 46.89655172 
CRH-CRF 0.23087 3.942164275 17.07523796 1.663474069 46.89655172 
Cortisol 0.182868 1.07700025 5.88950338 0.1083206 46.89655172 
RANTES 0.140456 1797.2911 12796.09594 1.205590518 46.89655172 
IL2 0 0 0.40737444 NaN 46.89655172 
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Table 5.12: SAM results for negative or downregulated serum factors; difference 
between baseline and 26 weeks for 10 HCS and 10 placebo patients. Top 5 values (in 
bold) were further defined individually. 
 
Negative serum factors (25) 
Gene ID Score(d) Numerator(r) Denominator(s+s0) Fold Change q-value (%) 
MCP1 -1.9592 -150.4625425 76.79810154 -0.516892076 36 
COMP -1.7311 -611.35 353.1576161 -3.379297994 36 
Eotaxin -1.47442 -45.661062 30.96874403 -0.893550124 36 
sIL-2R -1.46475 -175.825 120.0378606 -0.170216306 36 
TARC -1.39961 -122.7552213 87.70684383 -1.250242361 36 
IL6 -1.29356 -14.15866368 10.94553866 -0.039524253 36 
GROα -1.26918 -19.73091858 15.54617371 -2.299208472 36 
TNFα -1.25196 -15.3312874 12.24578508 0.014255288 36 
IL8 -1.23829 -17.85924148 14.42254707 -0.112771771 36 
MMP 1 -1.16512 -2794.828925 2398.749522 -0.215739357 36 
MCP2 -1.15495 -10.05505555 8.706025497 -0.228473599 36 
IL15 -1.10331 -10.99097028 9.96183907 0.088592258 36 
IL23 -1.02728 -279.0776533 271.6674578 -0.553160336 36 
IL1α -0.98516 -8.0595833 8.180948623 -0.035825212 36 
IL4 -0.93619 -1.1429165 1.220819809 -0.636635387 36 
HGF -0.87733 -175.42056 199.9483156 -0.360281534 36 
FRACT -0.71827 -427.7533475 595.5317395 6.103113065 43.07692308 
IL1β -0.70907 -13.71445425 19.34133528 0.154455043 43.07692308 
ANG2 -0.61767 -29.71100025 48.10206386 0.250561152 43.07692308 
TIMP2 -0.58747 -817.65725 1391.817976 12.68181916 43.07692308 
TGF-β1 -0.58689 -2726.425 4645.526243 3.773011595 43.07692308 
IP10 -0.308 -6.67869775 21.684043 -0.124359133 56.77419355 
IFNγ -0.2878 -1.95020915 6.776181521 0.656905046 56.77419355 
IL10 -0.26974 -0.9372499 3.474623409 0.718346281 56.77419355 
IL5 -0.04987 -0.051832775 1.039392444 0.926058746 56.77419355 
 
 
 
When SAM was used to interrogate the data for the combined dataset, different 
serum factors appeared to be up- or down-regulated compared to the original 
dataset, summarised in Tables 5.13 and 5.14. 
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Table 5.13: SAM results for positive or upregulated serum factors; difference between 
baseline and 26 weeks for 17 HCS and 13 placebo patients, post hoc combined 
analysis. The top 4 values (in bold) had a fold change > 2. 
 
Positive serum factors (26) 
Gene ID Score(d) Numerator(r) Denominator(s+s0) Fold Change 
q-value 
(%) 
MCP1 1.832005807 98.93034282 54.00110768 -2.414793365 34.2 
IL6 1.594572399 16.08315559 10.08618712 -1.777216259 34.2 
IL15 1.540105361 13.64949101 8.862699501 -2.507476277 34.2 
IL1α 1.242893284 8.412820513 6.768739219 -2.091054689 34. 2 
IL1β 1.239217255 27.16116587 21.91800168 -0.921342864 34.2 
TIMP2 1.220226809 1149.487974 942.0281258 -0.126599233 34.2 
IL23 1.207957322 243.5651758 201.6339248 -1.305592763 34.2 
TNFα 1.207041383 13.9251183 11.53657074 -5.085633024 34.2 
IL8 1.172059278 12.57138449 10.72589478 -27.31706687 34.2 
RANTES 1.094252363 14154.29901 12935.13222 5.138355352 34.2 
COMP 0.915849974 262.9435897 287.1033434 -1.040431374 34.2 
Eotaxin 0.853774696 22.98585421 26.92262293 -7.03641438 34.2 
IL4 0.814276379 1.787897221 2.195688426 -0.565584165 34.2 
GROα 0.787870405 8.892838528 11.28718438 -0.876170181 34.2 
TGF-β1 0.771378672 2938.548718 3809.476234 -1.430695421 34.2 
IL13 0.76105448 5.308623713 6.975353079 -0.098386497 34.2 
TARC 0.75677734 49.04613026 64.8091951 -2.228194437 34.2 
MMP-1 0.695902737 1220.623755 1754.014878 7.543422795 34.2 
IL10 0.663175198 2.664394641 4.01763312 3.794170837 34.2 
HGF 0.606078117 84.17718051 138.8883349 5.93737534 34.2 
CRH/CRF 0.490188983 11.42492441 23.30718317 2.070046832 36.7677 
MCP2 0.470832152 3.737037508 7.937090725 4.791922553 36.7677 
IL12p70 0.424284411 3.097389831 7.300267817 3.14269436 36.7677 
IFNγ 0.065101446 0.403957369 6.205044502 1.077264764 36.7677 
IP10 0.055224539 0.966713077 17.50513626 1.575263514 36.7677 
FRACT 0.036052922 14.36885487 398.548972 0.885803128 36.7677 
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Table 5.14: SAM results for negative or downregulated serum factors; difference 
between baseline and 26 weeks for 17 HCS and 13 placebo patients, posthoc 
combined analysis. The values in bold show fold change > 2. 
 
Negative serum factors (19) 
Gene ID Score(d) Numerator(r) Denominator(s+s0) Fold Change 
q-value 
(%) 
PDGFBB -1.629334901 -907.1397467 556.754628 -0.952471327 39.40741 
VEGF -1.486551442 -54.57591307 36.71310088 0.141891823 39.40741 
PARC -1.447486142 -75276.6 52005.05749 -0.229573828 39.40741 
MMP-9 -1.22883471 -39991.07967 32543.90467 -1.160871013 39.40741 
TIMP1 -1.149488678 -2084.084764 1813.053756 -0.262435512 39.40741 
MSH -1.111615105 -11.58038906 10.41762478 0.312294243 39.40741 
ANG2 -1.099532478 -172.3082403 156.7104598 0.245481556 39.40741 
ACTH -1.090291169 -12.95268792 11.88002645 0.268928548 39.40741 
vWF -0.898412866 -13.66287154 15.20778704 4.96886555 41.48148 
sIL-2R -0.84630143 -147.9358974 174.8028446 0.277891812 41.48148 
PIIINP -0.823018236 -2.994358974 3.638265647 0.45623021 41.48148 
Cortisol -0.6719399 -4.502067439 6.700104338 5.379335653 43.92157 
IL17 -0.610398442 -2.007110867 3.288197884 0 44.4 
I309 -0.427784987 -2.707607103 6.329364479 0.662205925 44.4 
bFGF -0.309302754 -4.507010338 14.57151699 0.415828654 44.4 
TNFβ -0.24523127 -1.894325487 7.724649026 -0.129666371 44.4 
IL2 -0.199250177 -0.3062222 1.536872913 0 44.4 
POMC -0.186659577 -0.319989169 1.714292799 0.220812678 44.4 
IL5 -0.053787807 -0.195530631 3.635222235 0.830448463 44.4 
 
Next, unsupervised cluster analysis was used to explore the patterns of co-
ordinately up or down-regulated serum factors.  The results of these analyses 
are included in Figures 5.34-5.37 below.  There were patterns that seem to 
confirm what was observed at the individual analyte level.  As can be seen in 
Figure 5.34, most of the patients had similar serum profiles at baseline. It is 
interesting to note that the patients who had upregulated serum factors while 
most other patients were down regulated, were patients 2, 13 and 17. Patient 2 
withdrew at week 2 due to a MCA infarction. Patient 13 had panenteric 
dysmotility and progression of disease with major GI and cardiac complications 
and patient 17 withdrew at week 14 due to worsening of lung disease.  
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Figure 5.34: Unsupervised cluster analysis heat map, baseline, 10 HCS patients and 
10 placebo patients. 
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Figure 5.35: Unsupervised cluster analysis heat map, Week 26, 10 HCS patients and 
10 placebo patients. 
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Figure 5.35 shows week 26 in the original cohort. Placebo patients align mainly 
on the left and HCS patients mainly on the right. The top half of the cohort 
shows the most change. Figure 5.36 shows the difference between baseline 
and week 26 for the original cohort. In this figure, HCS patients align mainly on 
the left and placebo on the right.  Many of the serum factors that are 
upregulated in the HCS patients, are downregulated in the placebo patients.  
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Figure 5.36: Unsupervised cluster analysis heat map, difference between baseline 
and Week 26, 10 HCS patients and 10 placebo patients. 
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Finally, supervised cluster analysis was used to better define the cluster of 
serum factors that could be defined as an HCS induced signature of change.  
This was a successful approach and the resulting annotated heat map is shown 
below, Figure 5.37. 
 
 
Figure 5.37: Supervised cluster analysis heat map, difference between baseline and 
Week 26, 10 HCS patients and 10 placebo patients. Yellow box highlights HCS 
patients. 
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In this figure, HCS patients align on the left and placebo on the right.  A more 
consistent pattern is identifiable in HCS patients compared to placebo patients, 
with increasing serum factors at the top and decreasing factors at the bottom.  
This could be referred to as a “HCS induced signature” and the main serum 
factors that are increasing or decreasing extrapolated from the supervised 
cluster analysis are shown in Table 5.15. This echoes the SAM analysis tables 
shown earlier.  
 
Table 5.15: This table shows the main increasing and decreasing serum factors 
extrapolated from the supervised cluster analysis. 
 
“HCS induced signature" 
Increasing ACTH 
  αMSH 
  bFGF 
  PIIINP 
  VEGF 
Decreasing TIMP-2 
  MMP-1 
 TGF-β1 
  Eotaxin 
  IL-8 
  MCP-1 
  FRACT 
  TARC 
  IL-23 
  COMP 
  GROα 
  TNFα 
 
 
The post-hoc combined cohort shows less change than the original cohort. This 
is also reflected in the analysis of separate serum factors seen in the preceding 
sections. Figure 5.38 shows the difference between baseline and week 26 the 
post-hoc combined 26 week data in unsupervised cluster analysis. In this figure, 
HCS patients align mainly on the left and placebo on the right. The serum 
factors that are up/down regulated are different between this and the original 
cohort.  
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Figure 5.38: Unsupervised cluster analysis heat map, difference between baseline 
and Week 26, post-hoc combined data, 17 HCS patients and 13 placebo patients. 
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Supervised cluster analysis was used to better define the cluster of serum 
factors that could be defined as an HCS induced signature of change.  The 
resulting annotated heat map for the post-hoc cohort is shown in Figure 5.39, 
below.  
 
A more consistent pattern is identifiable in HCS patients compared to placebo 
patients, though again the post-hoc combined cohort show different changes 
than original cohort. An identifiable treatment signature is not as significant in 
the post-hoc cohort, although some increasing and decreasing serum factors 
are seen, extrapolated from the supervised analysis, Table 5.16. 
 
 
Table 5.16: This table shows the main increasing and decreasing serum factors 
extrapolated from the supervised cluster analysis for the post-hoc cohort. 
 
"HCS combined cohort signature" 
Increasing ACTH 
  αMSH 
  PIIINP 
  ANG2 
Decreasing TIMP-2 
  FRACT 
  TARC 
  IL-8 
  MCP-1 
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Figure 5.39: Supervised cluster analysis heat map, difference between baseline and 
Week 26, post-hoc combined data, 17 HCS patients and 13 placebo patients. Yellow 
box highlights HCS patients. 
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6 Discussion 
This thesis describes the conduct and results of a clinical trial of a novel 
biological therapy in a cohort of established diffuse systemic sclerosis.  The 
value of the study is that it explores treatment in a stage and subset of this 
disease with high unmet medical need and also that it provides valuable 
information about the safety and tolerability of this novel agent in a disease 
setting and within the framework of a placebo controlled clinical trial.  Finally, 
the demonstration of treatment effect provides a powerful opportunity to better 
understand relevant aspects of disease biology.  Central to this is the use of a 
contemporary trial design that reflects many aspects that have been discussed 
in expert groups.  This is the first of a series of recent studies that are 
encouraging with evidence of effect of treatment on skin thickening.  This study 
is unique in demonstrating effect in later stage disease and may inform future 
clinical studies. In this final discussion key aspects of the work described in the 
thesis are integrated and areas for future study are highlighted. 
 
6.1 Primary endpoints and key secondary endpoints 
6.1.1 Safety endpoints 
Established dcSSc has a high morbidity, and as such, provides a unique “safety 
platform” to assess HCS, a novel immunomodulatory agent. There were 
frequent AEs in both groups, in keeping with the high morbidity associated with 
established SSc. Although not statistically significant, there were numerically 
more AEs and SAEs in the placebo group compared to the HCS group, 
supporting the conclusion that the study medication is safe and well tolerated.  
 
The frequency of specific AEs were similar in both groups with the exception of 
injection site reactions which were much more common in the HCS group, both 
in the double-blind phase (9 of 10 patients) and also in the compassionate 
medication extension phase (5 of 7 patients). These reactions were self-limiting 
in the majority of patients, though a few patients with more severe reactions 
required a short course of anti-histamine and steroid to relieve symptoms. 
Injection site reactions had also previously been reported in other HCS studies 
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{Investigator Brochure, Daval International, personal communication}. None of 
the SAEs were considered to be treatment related. 
 
Immunosuppression withdrawal prior to enrolment in a study is an important 
consideration. Once patients have established disease, it is thought that 
inflammation plays a less important role in the disease process, and therefore 
immunosuppression may also be less important. However, individual patients 
may still have complications, such as lung fibrosis, which require 
immunosuppressive agents.  
 
All patients enrolled into the study were considered to have stable and 
established disease. Half of the study patients were required to stop 
immunosuppression prior to enrolment. Only 3 of these had to restart 
immunosuppression after the double-blind period and 1 patient started 
immunosuppression after having been off it for a number of years. All patients 
were in the placebo group and 2 of the 4 started immunosuppression for lung 
disease. This underlines the importance of regular monitoring for complications 
and may indicate a continuing role for inflammation even in established disease. 
6.1.2 Efficacy endpoints 
6.1.2.1 MRSS 
Skin thickening usually peaks within the first 2 years of disease (163) and skin 
score declines overall during the course of a trial (164), but in one study 
patients enrolled with a disease duration <6 months had a small but significant 
increase in skin score before a subsequent decline and patients with a disease 
duration >2 years had a greater rate of skin score decline than the other groups 
(165).  
 
Baseline characteristics show the mean disease duration between 10 and 11 
years, no difference between the groups. Median disease duration was 8 years 
in the HCS group and 11 years in the placebo group. Mean MRSS at baseline 
was 16.9 in the HCS group and 13.2 in the placebo group, with median MRSS 
being almost identical at 12 and 12.5 in the HCS and placebo groups 
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respectively. Skin thickening was therefore mild to moderate in keeping with 
longstanding dcSSc, and there were no significant differences in baseline 
characteristics between the groups. 
 
The HCS treated group had a slight improvement in skin score by mean 1.4 
units and the placebo group worsened by mean 2.1 units (though the difference 
was not significant, p=0.18). We then looked at the number of responders in 
each group with the definition of a responder being MRSS improvement ≥4 
units (minimum clinically important difference). There were more responders 
(50% vs 10%) at 26 weeks in the HCS group compared to the placebo group, 
responder frequency analysis with a z-pooled test, p=0.067. Furthermore we 
assessed an extended dataset; combining the original dataset with the results 
of placebo patients who started HCS at week 26 and using week 26 as baseline 
and week 52 as week 26. This shows a statistically significant improvement in 
MRSS in the HCS group (mean -2 units) compared to placebo (mean +2.39 
units), p=0.025.  
 
Furthermore, looking at the 4 groups separately, though the results are not 
statistically significant, the patients who continued on HCS for a further 6 
months and the patients who had HCS in the first 6 months but chose not to 
continue treatment appear to have stabilisation or slight improvement of MRSS. 
The patients who had no treatment overall (placebo to no treatment) seemed to 
have a slight worsening of MRSS, while the patients who were on placebo and 
changed to HCS overall seemed to have a slight improvement in MRSS. 
 
The study on tolerance to human Type 1 collagen (27) was used to generate a 
hypothesis and plan setup for our trial. It showed significant reduction in MRSS 
in late-stage dcSSc patients, but not in early-stage patients, suggesting that the 
processes that cause or promote skin sclerosis and inflammation may be 
different in early versus late-stage disease. In this study, there was a significant 
decrease in the MRSS from baseline to 15 months (p=0.0063) with a mean 
change in MRSS of -7.9 in the 20 active-treated patients with late-stage or 
established dcSSc compared with a mean change of -2.9 in the 30 placebo-
treated patients with late-stage dcSSc. This difference became apparent after 8 
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months of treatment. It is, therefore, very interesting to note a similar 
improvement in MRSS in our cohort of patients with late-stage disease treated 
with HCS. Other possible reasons for this improvement are suggested below. 
6.1.2.2 HAQ and HAQ-DI 
There was no significant difference between the groups for HAQ-DI, though the 
placebo group was slightly worse. Mean ±SD at baseline was 1.2±0.07 for the 
HCS group and 1.6±0.63 for placebo group and at 26 weeks was 1.2±0.98 for 
HCS and 1.6±0.55 for placebo (p=0.47). In the eight functional activity category 
scores in the HAQ, no changes were seen in median values for any of these 
categories for patients in both groups at 26 weeks and no overall statistically 
significant difference was seen. The disease-specific VAS items showed no 
significant differences between HCS and placebo for 4 of 5 scales. The only 
significant difference found was in the scale for finger ulcers with the HCS group 
(percentage change) showing an improvement with treatment (p=0.0466). 
However there was large variability in a small sample size and the absolute 
change was not significant. Variability may be explained by the time of year the 
patients were seen as finger ulcers tend to be worse in colder months. 
 
In one study, HAQ-DI shows a small improvement in early dcSSc in a meta-
analysis of clinical trials, but the range of change was wide and HAQ-DI also 
rose slightly with longer disease duration (in keeping with morbidity associated 
with the disease). The authors’ conclusion was the HAQ-DI in general remained 
stable throughout the course of a trial, with wide individual variation (164). The 
placebo patients in our study had slightly longer median disease duration than 
the HCS patients, which could account for the slightly higher HAQ-DI scores.  
 
Minimal clinically important difference (MCID) for worsening of HAQ-DI in SSc 
was reported as 0.14 by Sekhon et al (209). A longitudinal study by a Canadian 
group (210) shows that in SSc patients HAQ-DI increases (worsens) over time, 
but only by a small amount. Their data shows an increase of 0.12 units over 3 
years, by conservative estimates, almost at a clinically significant level. 
Considering that our study was only one year and with a small sample size, it is 
not surprising therefore, that there was no significant change in HAQ-DI. 
206 
 
 
Schnitzer et al (210) also reported the longitudinal results of the SSc-HAQ VAS 
scales. In comparison to the patients in that study, our patients had more 
severe disability in all the categories, particularly the HCS patients. Their 
patients had a mean disease duration of 11 years and 41% dcSSc patients in 
comparison to 100% patients in our study who had dcSSc, which may explain 
worse morbidity in our patients. A summary of comparison of the HAQ VAS 
scales is given in Table 6.1. 
 
Table 6.1: A summary of HAQ VAS scales in HCS and Placebo patients at baseline 
and week 26, compared to the baseline results from Schnitzer et al (210). 
 
  Mean score in cm (standard deviation) 
  HCS Baseline  
HCS 26 
weeks 
Placebo 
Baseline 
Placebo 26 
weeks 
Schnitzer et al 
Baseline 
Intestinal VAS 3.83 (3.49) 4.67 (3.42) 2.96 (3.03) 3.28 (3.42) 1.92 (2.86) 
Breathing VAS 3.35 (2.83) 3.98 (2.96) 3.75 (3.69) 2.27 (2.44) 2.08 (2.57) 
Raynaud's VAS 4.74 (3.76) 4.42 (3.87) 3.43 (4.14) 4.19 (2.78) 3.01 (2.98) 
Finger ulcers VAS 3.21 (4.11) 2.91 (4.21) 1.47 (3.20) 1.41 (2.54) 2.10 (3.03) 
Pain VAS 5.56 (2.88) 5.00 (3.28) 3.49 (3.22) 4.94 (2.59) 3.71 (2.79) 
 
6.1.2.3 SF-36 
In the 8 domains of SF-36, the only domain to show some change was Role 
Physical, which showed a worsening in the placebo group and maintenance or 
stabilisation in the treatment group between baseline and week 26, with trend to 
significance between the groups (p=0.0685). For the SF-36 domain scales that 
mostly contribute to the scoring of the physical health summary outcome, 
patients in the HCS group showed no change from baseline median to week 26. 
Scores for patients in the placebo group declined (physical functioning, role-
physical) or remained unchanged (bodily pain) from baseline to week 26. 
However there was a small improvement in median change from baseline for 
the general health domain. Overall for physical health there was no significant 
difference at week 6 or week 26 apart from role physical. There were no 
significant changes in the 4 mental health domains between the groups. The 
Health Transition Index showed improvement in the HCS group at week 6 and 
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week 26, while the placebo group showed initial improvement at week 6, with 
worsening at week 26. 
 
In a study by Rannou et al (211), SF-36, SSc-HAQ and other quality of life 
outcome measures were assessed. They included 50 SSc patients (23 patients 
had dcSSc) with a mean disease duration of 9.1 years. The dcSSc patients in 
their study had a poor Role Physical score (mean 25.89) which correlated to the 
placebo patients score at week 26 in our study (mean 27.1). The placebo 
patients had a higher baseline score than the HCS patients (mean 48.8 vs 38.8 
for HCS patients) but their scores declined whereas the HCS patients score 
improved at 26 weeks (mean 45.8).  
 
In another study by Hudson et al (212) with 504 patients, mean disease 
duration 10.5 years, 44% dcSSc, the Role Physical mean score was 40.1, 
closer to the baseline scores for our patients. This study also compares results 
to US general female population norms and other chronic conditions. The 
results show significantly worse scores in SSc patients compared to US norms 
for most of the components and scores were comparable to or worse than other 
chronic conditions. The authors found the biggest impairments in the Physical 
Functioning, Role Physical and General Health domains in SSc patients. This is 
also reflected in the placebo patients of our study. The full results for the 8 
categories of the SF-36 and comparisons with both the Rannou and Hudson 
studies are shown in Table 6.2. 
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Table 6.2: Comparison of the 8 categories of the SF-36 to the Rannou (211) and 
Hudson (212) study results for SSc patients. 
 
  Mean scores (standard deviation) 
  
HCS 
Baseline 
HCS 
Week 26 
Placebo 
Baseline 
Placebo 
Week 26 
Rannou 
et al 
Hudson 
et al 
Role 
Physical 
38.8 
(30.16) 
45.8 
(30.62) 
48.8 
(31.29) 
27.1 
(23.18) 
25.89 
(25.89) 
40.1 
(12.1) 
Physical 
Functioning 
39.5 
(31.49) 
40.6 
(36.18) 
33.5 
(20.69) 
26.9 
(20.69) 
55.43 
(23.09) 
36.4 
(11.8) 
Bodily pain 
36.4 
(28.12) 
38.8 
(31.27) 
52.4 
(32.38) 
35.6 
(23.17) 
50.52 
(23.57) 
43 
(10.0) 
General 
Health 
36.8 
(19.76) 
36.2 
(26.51) 
31 
(18.47) 
24 
(16.12) 
36.66 
(15.14) 
37.7 
(10.7) 
Vitality 
35.5 
(14.62) 
38.3 
(21.51) 
34 
(20.92) 
32.2 
(23.33) 
38.45 
(13.03) 
45.5 
(10.9) 
Social 
Functioning 
53.8 
(28.9) 
56.9 
(27.32) 
48.8 
(33.57) 
36.1 
(34.49) 
60.78 
(19.69) 
42.8 
(11.8) 
Role 
Emotional 
45.8 
(36.69) 
59.3 
(34.72) 
70 
(34.96) 
57.4 
(40.71) 
42.26 
(43.15) 
44.9 
(12.4) 
Mental 
Health 
58.8 
(21.42) 
58.2 
(20.89) 
62 
(18.31) 
57.3 
(22.09) 
51.86 
(17.42) 
47.6 
(10.3) 
 
6.1.2.4 SSc-FS 
There was no significant change in the SSc-FS from baseline to week 26 in 
either group. However, the range of scores was large. The placebo group 
appeared to have slightly worse median scores than the HCS group, though 
mean scores were similar. Adjusted mean change from baseline was 1.56 in the 
HCS group and 0.46 in the HCS group. In a previous study a change of 3 units 
was deemed clinically relevant (184). Mean SSc-FS was between 10.7 and 11.4 
at baseline and between 11.7 and 11.9 at week 26 for both groups. This is 
consistent with previously reported studies (184) (185), though disease duration 
was shorter in these studies. These studies also showed very good correlation 
between SSc-FS and HAQ-DI.  
6.1.2.5 Other outcomes 
Pain in SSc is often multifactorial and can be difficult to treat. Pain in SSc is 
more common than previously recognised. Between 60 and 83% of SSc 
patients report some element of pain (213) (214) (215) (216) and about 10% of 
patients report severe pain (213) (214). In one recent study by Perrot et al 
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(216), neuropathic pain was detected in almost half of SSc patients and just 
over one third of RA patients. Pain frequency and intensity were higher in 
dcSSc than lcSSc patients and dcSSc patients tended to have more joint, 
visceral and diffuse pain. Neuropathic pain has not been extensively studied in 
SSc.  
 
For the neuropathic pain VAS, the HCS group were worse at baseline with a 
median score of 4.5cm compared to 0.6cm in the placebo group. The analysis 
of adjusted mean change from baseline in the neuropathic pain VAS indicates 
that there was significant difference between groups at week 26 with an 
improvement in the treatment group and no change in the placebo group, 
p=0.0461. Though the sample size is small, this is an interesting outcome as 
neuropathic pain seems to be more common than previously recognised and 
HCS may have the potential to improve neuropathic pain due to its sodium 
channel opening effect. 
 
MRC sum score, a measure of muscle strength, did not change throughout the 
study apart from one patient with a middle cerebral artery infarct. All of the 
patients also had normal creatinine kinase levels, indicating that no patients had 
acute inflammatory myositis.  
6.2 Physiological studies 
6.2.1 Pulmonary function tests 
Lung function indices showed a trend of benefit for the HCS group compared to 
the placebo group for those variables that reflect respiratory effort (FVC and 
FEV1) for absolute values but not in % predicted values. At Week 26 FEV1 had 
increased in the HCS group and decreased in the placebo group resulting in 
5.83% difference between groups. A similar pattern was shown in FVC for a 
7.37% difference between the groups. However when background disease was 
taken into account (pre-existing lung disease worsened in 1 patient in the 
placebo group), there was no significant difference between the two treatment 
groups. DLco and TLC did not change during the study.  
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This was an interesting positive trend in a small sample size. In most studies in 
lung function in SSc, % predicted values are used for comparison and these did 
not show a change. This study was not powered for lung function changes and 
while interesting, a bigger and properly powered trial would be needed to 
confirm lung function changes and benefit with treatment. 
6.2.2 Exploratory physiological studies 
Sniff nasal inspiratory pressure (SNIP) is a non-invasive method to assess 
respiratory muscle function and is used in patients with neuromuscular disease 
such as motor neurone disease and muscular dystrophies as well as chronic 
obstructive pulmonary disease. Theoretically, SSc patients may have 
respiratory muscle weakness due to myositis which can contribute to dyspnoea 
in some patients. As HCS has a potential sodium channel opening effect, and if 
there was respiratory muscle weakness, it may have been possible to record a 
therapeutic effect using SNIP pressures. SNIP has not been previously 
assessed in SSc patients in published literature. However, SNIP was normal in 
most of our patients and no treatment effect was detected. This confirms that 
there was no detectable respiratory muscle myositis in our group of patients. It 
may be interesting to study SNIP in SSc patients who have documented 
myositis or who have dyspnoea of unknown etiology as it is easy to perform and 
non-invasive. 
 
Heart rate variability (HRV) is a normal physiological response governed by 
vagal tone which is controlled by the autonomic nervous system. Therefore, 
HRV can be a surrogate marker or biomarker of autonomic dysfunction. HRV 
dysfunction is well recognised in SSc and is characterised by parasympathetic 
dysfunction combined with sympathetic overactivity and depression of the 
circadian rhythm of heart rate (203) (204) (195). SDRR gives an overall 
impression of HRV and sinus node activity, while higher values for RMSSD 
indicate higher vagal tone. Sympathetic activation is also indicated by lower 
values in SDRR (204) (203). HRV was performed on our patients as a non-
invasive test to assess HRV and to look for potential therapeutic effect from 
HCS via its sodium channel opening effect. 
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There were no clinically or statistically significant changes within or between the 
treatment groups before and after treatment for any of the 3 separate modes 
assessed (normal breathing, deep breathing and Valsalva manoeuvre). The 
Valsalva results appear normal in comparison to controls in one study and there 
were no changes with HCS. The Deep Breathing results again show no change 
with treatment. However, our results in the Normal Breathing mode, when 
compared to controls in other published studies, show reduction in both SDRR 
and RMSSD, indicating sympathetic overdrive and parasympathetic 
dysfunction, in keeping with other published data in SSc.  
6.3 Laboratory studies and candidate biomarker analysis 
The pathogenesis of SSc is a complex interplay between vasculopathy, 
inflammation and fibrosis. In order to assess these three areas, potential 
biomarkers representative of these areas were studied. PIIINP was used to 
assess fibrosis, vWF for endothelial damage and vasculopathy and sIL-2R for 
lymphocyte activation and inflammation. 
6.3.1 Trial specified candidate biomarkers 
6.3.1.1 PIIINP 
PIIINP is a marker for collagen synthesis, and therefore fibrosis and there has 
been interest in it since the 1980’s as a possible surrogate biomarker for SSc. 
Many studies have shown that PIIINP increases in SSc and is higher in dcSSc 
than lcSSc (217) (218) (219) (220). Some studies have shown that PIIINP is a 
marker for disease activity (219) (221) and is responsive to change in SSc 
(218). Studies have also shown that PIIINP is higher in early disease compared 
to late disease and predicts mortality (222) (223) and that treatment reduces 
PIIINP levels (224). PIIINP also appears to correlate with lung involvement 
(225) (221). 
 
In our study, at week 26, PIIINP was significantly increased from baseline in the 
HCS group by 8.080 μg/L, (p=0.0002), and relatively unchanged in the placebo 
group, 1.104 μg/mL, (p=0.5301). The difference between the groups at Week 
26 was significant (p=0.0118). The post hoc combined baseline to week 26 
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showed an even more significant result with p=0.0085. In the group that 
switched from placebo to HCS at 26 weeks, significant increases from baseline 
(and from 26 weeks) were seen in PIIINP at 52 weeks (p=0.0008 compared to 
baseline). The HCS group who continued HCS had a significant reduction in 
PIIINP from 26 weeks to 52 weeks (p=0.0078) though not back to baseline 
levels. 
 
These data are intriguing considering that MRSS improved on treatment with 
HCS and PIIINP correlates with MRSS in most previously published studies, as 
seen above. There were no statistical differences between the groups for AEs 
and SAEs and lung involvement appeared to be worse in the placebo group, 
therefore PIIINP does not appear to be associated with adverse events or 
worse prognosis in this group. It is also interesting that after 6 months on HCS, 
the group who continued HCS had a reduction in PIIINP, though not back to 
baseline levels. As the HCS group did not have evidence of worsening fibrosis, 
it is unknown why the PIIINP levels increased in this group. 
6.3.1.2 vWF 
vWF is a marker for endothelial damage and vasculopathy. A number of studies 
report increased levels of vWF in SSc (226) (227) (228) (229) (230) and higher 
levels of vWF correlate with more extensive disease (230) (228) or visceral 
complications (227) (231). Raised vWF levels have also been associated with 
the development of PAH (222) (232). 
 
In our study, at week 26, overall there was no significant difference between the 
groups for vWF, p=0.6875 and post hoc combined 26 week data for vWF also 
revealed no significant difference, p=0.35. At week 52, there was a significant 
decrease in vWF in the placebo patients who did not take HCS, p=0.003; 
however, there were only 2 patients in this group. These 2 patients were unwell 
throughout the study and withdrew at week 14 due to disease progression 
and/or worsening lung fibrosis. Both went on immunosuppressive agents after 
week 14, and their disease stabilised which could explain the decrease in vWF 
levels. 
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6.3.1.3 sIL-2R 
sIL-2R is a marker for lymphocyte activation. sIL-2R levels are increased in SSc 
and higher levels are associated with mortality, more extensive disease and 
earlier disease (233) (234) (235) (221) (236) (237). Some studies have shown a 
reduction in sIL-2R with treatment (88) while others haven’t (234) (238). 
 
In our study, at week 26, there was no significant difference between the groups 
for sIL-2R, p=0.7862. The combined 26 week data from the post hoc analysis 
was also not significant, p=0.2218. At week 52, there was no significant change 
in the HCS group who continued a further 26 weeks of treatment or in the HCS 
group who discontinued treatment. In the placebo group, there was a trend to 
significant increase in the patients who did not take HCS (p=0.053). There were 
only 3 patients in this group and 2 of these did not show a change; the third 
showed an increase in sIL-2R levels. The patient who had an increase in sIL-2R 
was extremely unwell throughout the study, particularly between week 26 and 
week 52, when he was an inpatient. He died soon after week 52 as a result of 
progression of his disease and sIL-2R is associated with mortality, therefore this 
explains the increased levels in this patient.  
 
There was a significant increase in sIL-2R in the placebo patients who opted for 
HCS compassionate treatment for 26 weeks (p=0.0311). This change was not 
seen in the double-blind HCS patients, mentioned above and the difference 
may be explained by fewer patients in the group (7 patients versus 10 patients 
in the original group) with a wider range of results. There was one patient who 
had a particularly high level a week 52, which skewed the results somewhat. 
This patient had significant issues with finger ulcers, which may have increased 
her levels. 
6.3.2 Multiplex cytokine analysis 
6.3.2.1 Cluster analysis 
Multiplex cytokine analysis is increasingly being reported in inflammatory 
diseases, including SSc, and is being used as a tool to improve understanding 
of pathophysiology of disease as well as identifying potential biomarkers and 
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assessing response to therapy. Some examples of multiplex cytokine analysis 
in SSc are given below.  
 
In a report by Beirne et al (239) looking at sarcoidosis and SSc patients, the 
authors found increased levels of IP-10, MIG, MIP-1α, MIP-1β, MCP-1, eotaxin 
and IL-17 in SSc patients but there was considerable overlap with cytokines that 
were elevated in sarcoidosis patients. When the authors looked at 
complications, they observed elevated levels in EGF in SSc patients with anti-
topoisomerase antibody compared to those negative for the antibody. bFGF 
was higher in untreated SSc patients than treated patients and eotaxin was 
elevated in untreated SSc patients compared to controls. They also performed a 
correlation analysis to assess correlations between cytokines and found that the 
most complex inflammatory network was in SSc patients. They identified a 
group of 17 mediators that could be used to group cases into controls, 
sarcoidosis or SSc correctly in 89.5% cases and even with reduction to 6 core 
analytes, the model showed 78.9% accuracy. Using another group of analytes, 
they could also correctly identify patients with SSc with or without lung fibrosis. 
 
In another study, Vettori et al (240) looked at cytokine profiles in early SSc and 
showed increased sICAM-1, CCL2, CXCL8 and IL-13 in early SSc patients 
compared to controls and lower levels than in definite SSc patients. IL-33 levels 
were highest in early SSc patients and lowest in lcSSc patients. sVCAM-1 and 
TGF-β were elevated in dcSSc and lcSSc but not in early SSc or controls.  
 
Gourh et al (241) looked at plasma multiplex cytokine profiles in SSc and found 
that after adjusting for age and gender, TNFα, IL-6 and IFN-γ levels were raised 
in SSc patients compared to controls and IL-17 and IL-23 were reduced 
compared to controls. When looking at disease duration, TNFα and IL-6 were 
increased in SSc patients with disease duration 0-5 years and 5-10 years 
compared to controls and IL-5, IL-10 and IFN-γ were increased in patients with 
disease duration >10 years. IL-13 was increased in patients with disease 
duration <5 years and IL-17 was decreased in all SSc patients independent of 
disease duration. IL-23 was reduced in patients with disease duration 0-5 years 
and 5-10 years but not >10 years. Comparing autoantibody subsets, increased 
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TNFα and reduced IL-23 were found in all autoantibody subsets. IL-6 was 
increased in all subsets apart from ACA positive and IL-17 was reduced in all 
but the autoantibody negative group. They also noted associations with 
complications; increased IL-6 was associated with ILD and PAH patients were 
more likely to have high IL-6. IL-6 was also correlated to MRSS. The authors 
conclude that many factors influence cytokine profiles in SSc, particularly 
disease duration and autoantibody profile. They didn’t, however, comment on 
dcSSc versus lcSSc. 
 
Schiopu et al (242) looked at subclinical atherosclerosis in SSc patients and 
assessed carotid intima media thickness (CIMT) and plaque formation with 
ultrasound as well as a multiplex serum profile. They found 8 cytokines 
associated with plaque and 5 different cytokines associated with CIMT. Only 2 
proteins were associated with both, NT-proBNP and IL-6. They looked at a 
composite score of the 8 proteins associated with plaque and found that 5 or 
more had a high sensitivity and specificity, suggesting that it could be used in 
clinical practise to pick up patients with subclinical atherosclerosis. 
 
Clark et al (243) compared cytokine profiles in dermal blister fluid to plasma 
multiplex cytokine profiles. In dermal blister fluid, the authors found increased 
levels of IL-6, IL-15, MCP-3, FGF-2, and PDGF-AA in SSc patients compared to 
controls and IL-17 was only detected in dcSSc blisters and not in lcSSc or 
controls. IL-6 and MCP-3 were higher but not significantly higher in dcSSc 
compared to lcSSc in blister fluid samples. In plasma multiplex samples, the 
authors found increased levels of IL-1RA, TNFα, RANTES and GMCSF in SSc 
patients compared to controls. They also found greater than 1.5 fold higher 
levels of MCP-3, IL-12p40, VEGF, IL-10, IL-4, IL-2 and IL-1α in SSc samples 
compared to controls using significance analysis of microarrays (SAM®) 
software. IL-4, IL-5, IL-6 and IL-13 were only detectable in SSc plasma but not 
at significant levels. Comparing blister fluid and plasma samples in SSc, there 
were no significant correlations, reflecting local inflammatory processes in the 
blister fluid samples and not leakage from serum. However, the health control 
samples did show some correlations between blister fluid and plasma samples. 
Using hierarchical clustering on the blister fluid, the authors identified 3 groups; 
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an inflammatory group (group 1) with high IL-6, IL-10, TNFα and IL-1α, an IFN-γ 
group (group2) with high IFN-γ, IL-2, IL-4, IL-5, MCP-3, IL-12p40 and IL-12p70 
and a quiescent group (group 3) with low levels of cytokines and chemokines. 
Group 1 was early dcSSc, group 2 late dcSSc and group 3 lcSSc or dcSSc with 
low skin score. 
 
In our study, using SAM® we identified 4 cytokines in the original dataset (6 
month double-blind cohort) that were increased by more than 2 fold in the HCS 
treated patients compared to placebo treated patients. These were α-MSH, 
ACTH, bFGF and PIIINP. PIIINP is already mentioned above. We also identified 
5 cytokines that were reduced more than 2 fold in HCS treated patients 
compared to controls; TGF-β1, TIMP-2, Fractalkine, COMP and GROα. Apart 
from α-MSH, ACTH and PIIINP, the differences between HCS and placebo 
patients for individual cytokines are not statistically significant. However, 
analysing the data using this method gives us very interesting and useful data.  
 
Interestingly, all of the cytokines that were more than 2 fold reduced with HCS 
treatment have been reported to be elevated in SSc patients versus controls 
with TGF-β1 being one of the most important cytokines involved in the 
pathophysiology of SSc. Increased levels of α-MSH and ACTH with treatment 
point to a possible mechanism of action for HCS treatment. However, it is 
difficult to explain increased levels of bFGF and PIIINP with HCS treatment. 
Different cytokines were increased or decreased in the post hoc 26 week 
combined cohort and results were less significant. Each of the cytokines 
identified by SAM® are discussed separately below. 
6.3.2.2 α-MSH and ACTH 
α-MSH is a 13-amino acid peptide hormone produced from the processing of 
pro-opiomelanocortin (POMC). POMC is also a precursor for at least 4 other 
peptides including β-MSH, γ-MSH, ACTH and β-endorphin. They bind to 
melanocortin receptors, of which 5 have been identified, (MC1-5R). α-MSH is 
known to have a number of anti-inflammatory and anti-microbial properties. It 
suppresses TNF production and inhibits activation of I- and E-selectin, as well 
as NF-κB (244). POMC and ACTH are produced from the pituitary gland in 
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response to CRH stimulation. CRH has also been found to stimulate POMC 
activity and ACTH production and release in human dermal fibroblasts (HDF). 
CRH and ACTH stimulate the production of corticosterone in fibroblasts, with 
ACTH being more potent (245). 
 
Previous reports have looked into melanocortins, primarily β-MSH (246) and 
adrenal deficiency (247) as a cause for abnormal pigmentation in SSc, but 
found no evidence for either theory. In an interesting series of studies, Bohm et 
al described that HDF express the MC1 receptor (MC1R) that binds α-MSH with 
high affinity and they found that α-MSH suppressed TGF-β induced collagen 
synthesis in HDF in vitro (248) (249).  
 
Furthermore, the authors used a bleomycin mouse model (systemic sclerosis 
mouse model) to investigate the effects of α-MSH on skin fibrosis and found 
that simultaneous administration of α-MSH with bleomycin supressed the 
effects of bleomycin on HDF. ACTH was also found to have similar suppressive 
effects. α-MSH exerts its effects via a cAMP driven pathway and not via Smad 
2/3. α-MSH upregulates superoxide dismutase 2 and hemeoxygenase 1 which 
is protective against the effects of bleomycin on reactive oxygen species. They 
also confirmed the presence of POMC and the MC1R in affected skin from 
patients with SSc and that HDF from these patients strongly expressed both 
POMC and MC1R (as well as in normal skin), making α-MSH a potential 
therapeutic target in the future according to the authors (250). In a recent study, 
the same group also conclude that MC1-signalling deficient mice with a 
C57BL/J6 background exhibit experimentally induced fibrosis in response to 
bleomycin, whereas wildtype animals with the same genetic background do not 
(251). The authors conclude that it would be fascinating to investigate 
expression and function of MC1R in patients with fibrotic skin disorders such as 
SSc. 
 
There is one interesting case report on one patient (252), who was enrolled in 
the CAT-192 clinical trial (253), which shows that before treatment, the patient 
had increased TGF-β mRNA expression and suppressed POMC mRNA 
expression and MCR 1-3 and 5 receptor subtypes in the skin lesion compared 
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to controls. After treatment there was rebound expression of POMC, MCR 2, 3 
and 5 receptors, which may indicate a role for the melanocortin system in SSc.  
 
As mentioned in the introduction, HCS contains a multi-protein complex which 
includes CRH. It is not surprising, therefore, that both α-MSH and ACTH were 
significantly increased in the HCS treated patients compared to the placebo 
patients during the double-blind part of the trial. α-MSH and ACTH decreased 
again between 26 weeks and 52 weeks, though not to baseline levels. This may 
have been, in part, due to poorer compliance in the compassionate use part of 
the trial where patients were not monitored as frequently. The action of α-MSH 
and ACTH on the MC1R is one possible mechanism by which the MRSS in 
HCS treated patients may have improved. As mentioned, CRH also stimulates 
the production of corticosterone in HDF, so this may also have some relevance 
due to an additional anti-inflammatory effect. 
6.3.2.3 bFGF 
Basic FGF (bFGF, also called FGF-2) is a growth factor and chemotactic factor 
for fibroblasts and endothelial cells. It is a key molecule in the induction of 
angiogenesis. It stimulates proliferation, migration and differentiation of 
endothelial cells and synergises with vascular endothelial growth factor (VEGF) 
in its angiogenic actions (254) (255). In SSc, data on serum levels of bFGF are 
conflicting with some groups finding elevated levels in SSc but not in controls 
(256) (257) while others did not find any difference in serum levels between SSc 
and controls (258) (259). Lawrence et al did find increased expression on bFGF 
in the skin of SSc patients however they found only a few patients with SSc had 
high serum levels of bFGF (259).  
 
In our study, at 26 weeks bFGF levels showed an increase from baseline in 
both groups but a larger increase in the HCS group. The difference was not 
statistically significant, p=0.148. Post hoc combined 26 week data for FGF also 
showed an increase in the HCS group and slight decrease in the placebo group, 
but again the difference was not statistically significant. The separate groups 
showed that the HCS group continuing HCS and the placebo group who started 
on HCS had some increase in bFGF levels but again it was not significant. The 
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effect of treatment on serum bFGF in SSc has not yet been studied, but it is 
interesting but difficult to explain increase in bFGF with HCS treatment. 
6.3.2.4 TGF-β1 
TGF-β is the pre-eminent signal for connective tissue synthesis and is 
considered the core pathway in wound healing and pathological fibrosis. TGF-β 
promotes fibroblast proliferation, differentiation, migration, adhesion and 
survival, induces cytokine secretion and upregulates synthesis of collagen and 
extracellular matrix (260). TGF-β is secreted from monocytes, lymphocytes and 
fibroblasts in an inactive form and sequestered in the ECM. Data on serum 
TGF-β1 levels in SSc are conflicting with some groups find elevated levels (261) 
(262) and some no difference from controls (263) (264) (265). One group found 
a reduction in active TGF-β1 in dcSSc compared to lcSSc and controls and 
levels correlated inversely with MRSS (266). These conflicting results may be 
due to a number of issues including type of SSc (dcSSc or lcSSc), disease 
duration, heterogenous population, the assays used and/or the form of TGF-β 
studied (active versus latent).  
 
In this study, at 26 weeks, both groups showed a decrease in TGF-β1 levels 
while the HCS group showed a slightly bigger decrease but this was not 
significant with p=0.6009. The post-hoc combined 26 week data showed a very 
slight increase in the HCS group but no change in the placebo group and the 
difference again was not significant. At 52 weeks, the group of placebo patients 
who were followed up only with no other treatment showed an increase in TGF-
β1 levels but there were only 3 patients in this group, p=0.0118 compared to 
baseline. None of the other 3 groups showed statistically significant changes 
compared to baseline or week 26. Though not significant, it is interesting 
nonetheless, that there was a slight decrease in TGF-β1 with HCS treatment 
that may coincide with decrease in MRSS. 
6.3.2.5 TIMP-2 
Fibroblasts produce matrix metalloproteinases (MMPs) which digest all the 
ECM products. They also produce tissue inhibitors of MMPs (TIMPs) and the 
quantity of ECM is determined by the balance between the MMPs and TIMPs. 
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Previous studies report contradictory results about serum TIMP-2 levels in SSc. 
Yazawa et al found elevated levels of TIMP-2 in 22.7% patients with SSc. They 
also found that TIMP-2 levels were significantly correlated with skin score and 
significantly higher in active disease (267).  
 
Others found no difference in TIMP-2 levels in SSc compared to controls (268) 
(269). Dziankowska-Bartkowiak et al however, did note that patients with lcSSc 
and a restrictive lung defect on PFTs had high or borderline high levels of TIMP-
2. In a follow-up study, Dziankowska-Bartkowiak et al again found that TIMP-2 
levels were not significantly different in patients compared to controls in the 
group as a whole, but did find elevated levels in SSc patients who had 
cardiovascular disease (270). Shahin et al found that in patients with disease 
duration of more 2 years, TIMP-2 levels were higher in SSc, particularly dcSSc, 
than in controls. They also found a correlation between TIMP-2 levels in dcSSc 
patients and CT scoring for fibrosis and also between TIMP-2 levels in lcSSc 
patients and cardiovascular problems, in agreement with the studies by 
Dziankowska-Bartkowiak et al (271). 
 
In our study, at 26 weeks there was a slight decrease in TIMP-2 levels 
compared to baseline in the HCS group and a slight increase in the placebo 
group. However, the difference was not statistically significant, p=0.1044, and 
the combined 26 week post hoc analysis showed a less significant difference. 
At 52 weeks, there were no statistically significant changes in any of the 4 
groups compared to baseline or week 26.  
6.3.2.6 Fractalkine 
Fractalkine is a member of the CX3C chemokine family and is found on TNFα 
and IL-1 stimulated endothelial cells (272) (273). It has a soluble form 
(consisting of the extracellular domain and a mucin-like stalk) and a membrane 
bound form and it binds to its receptor CX3CR1. The soluble form is generated 
by enzymatic cleavage of the extracellular part of the membrane bound form by 
TNFα converting enzyme (TACE/ ADAM-17). The membrane bound form 
promotes leucocyte activation and can mediate in each step in the leucocyte 
adhesion cascade and the soluble form is a powerful chemoattractant for 
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monocytes, macrophages, NK cells and T cells expressing its receptor (274) 
(272) (275) (276). 
 
Hasegawa et al found an increase in CXCR1 in skin and lung tissue samples 
compared to controls, with higher number in dcSSc compared to lcSSc as well 
as increased levels of CX3CR1 on peripheral macrophages/monocytes and T 
cells in dcSSc. Fractalkine was strongly expressed in endothelial cells in 
affected skin and lung tissues. Serum fractalkine was 4 times higher in SSc 
patients than controls and patients who had pulmonary fibrosis had levels 4 
times higher than patients without. Raised serum fractalkine levels also reduced 
after treatment with immunosuppressants (277). In another study, fractalkine 
was again found to be higher in SSc than controls and higher in dcSSc than 
lcSSc. After treatment with prostaglandin E1, fractalkine levels dropped at day 3 
and remain reduced after a month (278). Increased susceptibility to SSc has 
also been shown to be associated with a polymorphism in the fractalkine 
receptor and is associated with PAH (279). 
 
In our study, at 26 weeks, there was a decrease in fractalkine levels in both 
groups. The HCS group had a bigger decrease, however the difference was not 
statistically significant with p=0.3179 and the combined 26 week post hoc 
analysis showed an even smaller difference. At week 52, there were no 
significant changes in any of the 4 groups compared to baseline or week 26. As 
previous studies have shown reduction of fractalkine with immunosuppressants, 
it is likely that there is some treatment effect with HCS treatment but not big 
enough for a significant result. 
6.3.2.7 COMP 
Cartilage oligomeric matrix protein (COMP, Thrombospondin 5) is a large 
disulphide linked pentameric extracellular glycoprotein member of the 
thrombospondin family found mainly in cartilage and tendon extracellular matrix 
(280) (281). It can also be produced by dermal and synovial fibroblasts (282) 
and can bind to several extracellular proteins including type I, type II and type IX 
collagen (283) (284) (285). 
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COMP accumulates in SSc skin but not normal skin and cultured fibroblasts 
from SSc skin demonstrate more staining for COMP than normal controls (286). 
Serum COMP levels are increased in SSc patients compared to controls and 
higher in dcSSc than lcSSc (287) (288). Serum COMP correlates with skin 
involvement measure by MRSS (289) and is higher in SSc patients with arthritis 
(288). High serum COMP levels in early disease are associated with an 
increased risk of mortality (290). Complexes between COMP and complement 
C3b in the serum are elevated in SSc but no co-localisation was found in skin 
biopsies indicating that complexes are formed after release of COMP into 
circulation and COMP does not drive complement activation in SSc (291). 
 
In our study, at 26 weeks, there was a decrease in COMP levels in HCS group 
and a slight increase in the placebo group, though the difference between 
groups was not statistically significant with p=0.2651 and the combined 26 
weeks post hoc data showed a smaller difference between the groups. At 52 
weeks, there were no significant changes in any of the 4 groups compared to 
baseline or week 26. 
6.3.2.8 GROα 
Growth-related oncogene α (GROα), also called CXCL1, is related to IL-8 and 
attracts and activates neutrophil and basophil leucocytes (292) (293). GROα is 
produced by macrophages, neutrophils, epithelial cells, endothelial cells and 
fibroblasts (294). GROα levels are elevated in SSc patients compared to 
controls, SLE patients and dermatomyositis patients. GROα levels were similar 
in dcSSc and lcSSc patients. There is a correlation between GROα levels and 
IL-8 levels. When elevated GROα levels were defined as the mean plus 2 
standard deviations of control serum samples, patients with elevated GROα 
levels had increased frequency of decreased lung function indices, kidney 
involvement, muscle involvement and anti-topoisomerase 1 antibody (295). 
 
In our study, at 26 weeks, there was a decrease in GROα levels in HCS group 
and a slight increase in the placebo group, though the difference between 
groups was not statistically significant with p=0.2061. The combined 26 weeks 
post hoc data showed a smaller difference between the groups. At 52 weeks, 
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there were no significant differences in any of the 4 groups compared to 
baseline. The HCS group who stopped treatment at 26 weeks (2 patients) had a 
significant increase GROα levels compared to week 26, though this was due to 
one patient of the two and she had significant digital ulcers with infection and 
severe vasculopathy.  
6.4 Conclusions 
Systemic sclerosis is a complex multisystem autoimmune disorder that has a 
very high morbidity and the highest case-specific mortality of any rheumatic 
disorder with 50% of patients dying or developing major internal organ 
complications within 3 years of diagnosis (1). Currently, no treatment is proven 
to be effective in preventing progression of disease, reversing fibrosis or 
improving long-term outcome. Therefore there is a huge unmet clinical need for 
targeted and effective novel therapies.  
 
In this study, we found that HCS is safe and well tolerated with few side effects. 
MRSS improved in the HCS group and worsened in the placebo group, with 
more responders in the HCS group at 26 weeks. Neuropathic pain, which is 
more common in SSc than previously recognised, also improved in the HCS 
group compared to placebo. We found a trend to benefit for lung function 
indices but as the study was not powered to look at lung outcomes, a larger 
study would be needed to confirm. SNIP testing may be useful in SSc patients 
with myositis or in patients who have dyspnoea of unknown origin. HRV testing 
confirmed autonomic dysfunction in our cohort of SSc patients but did not show 
a treatment effect.  
 
A key strength of this study is the opportunity to analyse serum levels of 
candidate biomarkers that can be correlated with clinical change and also with 
administration of HCS.   Although the approach taken in this study is essentially 
hypothesis generating it provides information that may lead to further 
exploration of the potential mechanisms of action of this novel agent and also 
help to define the serological changes that accompany clinically meaningful 
change in skin thickness in SSc.  This has implications for future clinical trials 
but the findings described in this thesis will need further confirmation and 
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validation in SSc and also in different stages and subsets of disease.  The most 
interesting results are the cytokine analyses. Using SAM® we identified 4 
cytokines and proteins that were more than 2 fold increased in HCS patients 
compared to placebo patients and 5 that were more than 2 fold reduced. We 
found that α-MSH and ACTH were significantly increased with HCS treatment. 
The action of α-MSH and ACTH on the MC1R is one possible mechanism by 
which the MRSS in HCS treated patients may have improved as well as a local 
anti-inflammatory effect. MC1R is a potentially important novel target recently 
identified in SSc. PIIINP and bFGF were increased with HCS treatment and 
TGF-β1, TIMP-2, fractalkine, COMP and GROα were reduced with HCS 
treatment indicating that there may be different processes contributing to 
ongoing inflammation in established SSc compared to early SSc. 
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7 Concluding comments 
In this chapter the overall implications of the work described in the thesis is 
considered and put into the context of other potential clinical strategies for HCS 
and also the emerging landscape of possible targets for therapy in systemic 
sclerosis.  Future direction for study of HCS in systemic sclerosis is also 
considered. 
7.1 Clinical implications 
On reflection, a number of points can be made about the results of the trial. 
Firstly, the medication is relatively safe. Secondly, there is some signal of 
efficacy both clinically with change in MRSS and neuropathic pain score and in 
parallel, changes in serum proteins which is evident even with the small sample 
size. Thirdly, we hypothesize that we may have found a potential novel 
mechanism of action of HCS through the melanocortin system and that this 
system may explain the improvement in MRSS and neuropathic pain and the 
changes in the serum proteins in these patients. 
 
Another clinical trial in secondary progressive MS, Chapter 1, Section 1.2.5.3 
(conducted at the same time as our trial but the results were reported later) also 
confirmed safety and reported some efficacy in MS patients. Serum cytokines 
have not been reported as yet, but it would be interesting to correlate our 
findings with the serum protein findings in that trial, in spite of different disease 
processes.  
 
Animal studies performed in the scleroderma bleomycin mouse model after the 
completion of our trial (Chapter 1, Sections 1.2.4.2-4) show a non-significant 
increase in serum α-MSH and a non-significant decrease in serum MMP-1 and 
MMP-13, while a significant decrease was found in serum MMP-9, BAL fluid IL-
12p70, MCP-1 and TNFα in the HCS treated group. Lung function improved in 
the HCS treated bleomycin lung model. In the bleomycin mouse skin model, α-
MSH levels were increased or maintained in the HCS treated group. MC1R 
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expression did not change but MC4R expression decreased in the HCS treated 
group. Hydroxyproline levels and expression was lower in the HCS treated 
group indicating less fibrosis. PIIINP and TGFβ showed no significant change 
and TIMP-1 analysis revealed a strong trend in reduction in expression in the 
HCS treated group. These results are in keeping with some of the changes 
described in our study, though the bleomycin mouse model does not have all 
the features seen in human SSc, and therefore cannot be compared directly. 
7.2 Suggestions for future studies 
Some questions remain after analysing the results of the study. Future clinical 
trials in a larger cohort of SSc patients will be needed to 1) confirm the efficacy 
of HCS in reducing MRSS, 2) confirm the cytokine changes, 3) investigate the 
mechanism of action of HCS and/or confirm that the melanocortin system is 
involved by assessing melanocortin receptor expression and function in skin 
and serum samples, 4) investigate lung function changes in a cohort powered 
for assessment of lung function outcomes, and 5) consideration of a dose 
finding study as higher doses may improve MRSS outcomes . Our current study 
was in late-stage SSc patients. Other studies could potentially look at other 
stages or subsets of disease and other diseases including inflammatory 
diseases and diseases where the melanocortin system is implicated. Other 
scientific research could include experiments using HCS treatment on human 
dermal fibroblasts and looking at changes in fibrosis markers and melanocortin 
receptors. Other animal models of SSc could also be investigated.  
 
In the first instance, a phase III double-blind clinical trial with a larger cohort of 
dcSSc patients should be considered. This would probably need to be a 
multicentre clinical trial due to challenges involved in recruiting the required 
number of patients. Some of these challenges include: the number of patients 
seen in a single centre, competing studies, eligibility criteria, patient consent 
and logistic challenges such as travel and childcare. There are now many 
studies recruiting or in planning stages because of the identification of new 
targets, as mentioned in the section below, and as the number of patients seen 
each year in a single centre is relatively constant, patients can be eligible for 
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more than one study but usually can be recruited into only one at a time causing 
competition for clinical trials. However, recruitment is possible with a well-
designed study with clear objectives and outcomes. 
Systemic sclerosis is considered a rare disease and to date, there is no 
effective treatment approved by the European Medicines Agency (EMA). 
Therefore SSc is designated an orphan disease and medications under 
development for treatment of SSc could potentially be eligible for orphan 
medicinal product designation. An orphan designation application may be 
submitted at any time in the development of a drug but has to be submitted 
before marketing authorisation. In the EU, this is submitted to the Committee for 
Orphan Medicinal Products in the EMA and the process can take up to 6 
months. In the US, the corresponding office is the Food and Drugs 
Administration (FDA). There are a number of incentives in applying for orphan 
drug status, namely protocol assistance and follow-up, reduced or waived 
regulatory fees, tax credits or subsidies on clinical trials and of course, market 
exclusivity, which is granted only after marketing authorisation (296). An 
application for orphan medicinal product status should be submitted for HCS as 
the next step. If approved, this would provide assistance with other trials and 
would fast-track development of this novel medication. 
7.3 Targeted therapies and future clinical development of HCS 
Systemic sclerosis is a multisystem autoimmune rheumatic disorder with a high 
morbidity and case specific mortality. To date, no treatment has been proven to 
be unequivocally effective. In the past, immunosuppressive treatments have 
been borrowed from other diseases, but these treatments are broadly 
immunosuppressant with many unwanted side effects and toxicities. In recent 
years, as our understanding of the pathophysiological processes that cause 
SSc grows, there has been much interest in developing more targeted 
treatments in an attempt to modify one or more pathological processes in 
disease while restricting toxicity. There are now a huge number of possible 
targets of interest and many of these have specific medications that are 
currently in ongoing clinical trials, being considered for trials or could be 
considered in future trials, Table 7.1, (129) (297).  
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Table 7.1: Potential therapeutic targets in SSc. 
Targets Existing or potential drugs 
TGF-β CAT-192, Fresolimumab, GC1008, LY2382770 
IL-1 Rilonacept 
IL-6 Tocilizumab 
IL-13 Tralokinumab, QAX576 
IL-17 Ixekizumab, Brodalumab 
CCL2 NOX-E36, CNTO 888 
MCP-1/CCR2 PF-04136309, BMS-741672, MLN1202 
CXCL12/CRCR4 AMD3100 
PPARγ Rosiglitazone, Pioglitazone 
Endothelin Bosentan, Ambrisentan, Macitentan 
LPA AM966 and AM095, SAR100842 
Serotonin Terguride, Cyproheptadine, SB 204741 
Adenosine Targeting the relevant adenosine receptor might be a novel therapeutic 
option in SSc, No current treatment. 
Phosphodiesterases Sildenafil, Tadalafil 
Prostanoids Iloprost, Treprostinil 
Leukotrienes Montelukast, Zileuton 
Cannabinoids Synthetic analogues of tetrahydrocannabinol such as ajulemic acid 
Morphogen (Wnt, Notch, 
Hedgehog) 
PRI-724, CWP232291, Resveratrol, DAPT, Vismodegib 
PDGF Imatinib, Nilotinib, Dasatinib, SU6656 
CTGF FG3019 
Th17 Halofuginone 
T-cell costimulation Abatacept 
Immunomodulatory Pomalidomide, HSCT 
Antioxidant N-acetylcysteine 
IL-2 receptor Basiliximab 
mTOR Rapamycin 
B cell Rituximab, anti-CD19 
BAFF/BlyS Belimumab 
STAT4 Statins 
FRA-2 (AP-1 family) T5224, small-molecule inhibitor of AP-1 
Epigenetic pathways HDAC inhibitors include trichostatin A, SAHA;  DNA methyltransferase 
inhibitors such as 5-aza-2-deoxycytidine 
Integrin signalling Monoclonal antibody therapies against α5β6, α1β1 and α2β1 integrins 
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Although not in this list, the melanocortin pathway is an emerging pathway that 
should be explored further as a potential target for treatment in SSc. Recent 
evidence suggests that the melanocortin pathway and MC1R may be important 
in SSc (250) (251) (252).  
 
The melanocortin pathway is an emerging pathway in a number of other 
diseases and there is renewed interest in using ACTH and other melanocortin 
peptides for new indications, based on recent discoveries about the 
melanocortin receptors, their functions and mechanisms of action. Unlike 
targeted therapies specifying one pathway, α-MSH could be considered a pro-
resolving therapy, modulating a number of different pathways such as TNFα, IL-
1β, prostaglandins, adhesion molecules, neutrophils, monocytes and 
phagocytosis (298). 
 
Melanocortins have adrenal and extra-adrenal actions. Adrenal-based actions 
are mediated only by the action of ACTH on the MC2R receptor in the adrenals. 
This mechanism is also responsible for the unwanted side-effects of 
glucocorticoids and ACTH. Extra-adrenal actions are mediated by 
melanocortins (including ACTH) on the remaining 4 receptors. The receptors 
and their functions and agonist profiles are further explained in Table 7.2, (298) 
(299) (300). 
 
Apart from α-MSH and ACTH, over the past decade a number of agonists, 
selective antagonists and small molecules have been developed, some of which 
may have therapeutic benefits (299). Melanocortins have been shown to be 
involved in many diseases, and therefore medications modulating the 
melanocortin pathway may have implications for some or all of these diseases. 
Besides SSc mentioned above, other rheumatological conditions such as RA 
and gout have previously benefited from α-MSH and ACTH treatment and 
improvement of gout has been associated with MC3R separate to the effect on 
adrenal MC2R. All of the following diseases have been associated with the 
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melanocortin pathway in recent published literature; bronchial asthma, 
inflammatory bowel disease, cardiac reperfusion injury, erectile dysfunction 
(associated with MC4R), infections/antimicrobial action, melanoma (associated 
with MC1R) (301), inflammatory brain disorders such as MS, meningitis, brain 
reperfusion injury (associated with MC3 and 4R), septic shock, allergic 
inflammation, obesity (associated with MC4R), neuropathic pain syndromes 
(associated with MC4R in rat model) (302) (303) and some degenerative brain 
disorders such as Alzheimer’s disease (298) (299) (300). 
Table 7.2: Melanocortin receptors, distribution, function and agonists 
 
Receptor Distribution and cell 
receptors 
Function Agonist profile 
MC1R Macrophages, neutrophils, 
endothelial cells, fibroblasts, 
chondrocytes, osteoblasts, 
osteoclasts, lymphocytes 
Pigmentation, anti-inflammatory, 
anti-pyretic, pain modulation, 
regulation of skin physiology 
α-MSH > ACTH 
>> γ-MSH 
MC2R Adrenals, skin, melanoma 
cells, osteoblasts, 
chondrocytes 
Steroidogenesis ACTH 
MC3R CNS, stomach, kidneys, 
heart, gut,  thymus, 
placenta, macrophages, 
chondrocytes, osteoclasts 
Cardiovascular, anti-
inflammatory, energy 
homeostasis, feeding 
γ-MSH = ACTH = 
α-MSH 
MC4R CNS, osteoblast Feeding control, energy 
homeostasis, sexual function, 
anti-pyretic, neuropathic pain 
α-MSH = ACTH 
>> γ-MSH 
MC5R Many peripheral tissues 
including exocrine glands, 
spleen, adipose tissue, skin, 
muscle, gut, lung, sexual 
organs, macrophages, T 
and B cells, chondrocytes 
Exocrine secretion, lipolysis, 
sebaceous secretion, 
immunoregulatory functions 
α-MSH > ACTH > 
γ-MSH 
 
HCS increases α-MSH and ACTH and can potentially modulate the 
melanocortin system. HCS is already approved for motor neurone disease and 
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a number of other neurological diseases. Potentially, HCS could be used to 
treat some of the diseases listed above, depending on outcome of future 
studies and confirmation of mechanism of action/ which receptor it modulates 
and is a possible novel therapeutic agent for late-stage SSc and for neuropathic 
pain.  
 
In conclusion, HCS is a potentially exciting novel therapeutic agent. In this 
thesis we have explored safety and possible efficacy of this agent as well as 
forming a hypothesis on a potential new mechanism of action and on an 
emerging exciting novel therapeutic target in SSc. 
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Appendix 
8.1 Questionnaires 
8.1.1 Scleroderma Health Assessment Questionnaire 
 
In this section we are interested in learning how your illness affects your 
ability to function in daily life.  Please feel free to add comments. 
 
Please tick the one response that best describes your usual abilities  
IN THE PAST SEVEN DAYS: 
 Without 
ANY 
difficulty 
With SOME 
difficulty 
With MUCH 
difficulty 
 
UNABLE 
to do 
DRESSING & GROOMING 
Are you able to: 
    
 Dress yourself, including tying 
shoelaces and doing buttons? 
 
 
_____ 
 
_____ 
 
_____ 
 
_____ 
 Shampoo your hair? 
 
_____ _____ _____ _____ 
ARISING 
Are you able to: 
    
 Stand up from an armless 
straight chair? 
 
_____ 
 
_____ 
 
_____ 
 
_____ 
 Get in and out of bed? 
 
_____ _____ _____ _____ 
EATING     
Are you able to:     
 Cut your meat? _____ _____ _____ _____ 
 Lift a full glass to your mouth? _____ _____ _____ _____ 
 
 Open a new milk carton? _____ _____ _____ _____ 
WALKING     
Are you able to:     
 Walk outdoors on flat ground? _____ _____ _____ _____ 
 Climb up five stairs? _____ _____ _____ _____ 
     
Please tick any AIDS or DEVICES that you usually use for any of these 
activities: 
 Cane  Devices for dressing (button hook, zipper pull,  
long-handled shoe horn, etc.) 
 Walker  Special Utensils 
 Crutches  Special or built-up chair 
 Wheelchair  Other (specify: ________________________ ) 
    
Please tick any categories for which you usually need ASSISTANCE FROM  
ANOTHER PERSON 
 Dressing & Grooming  Eating 
 Arising  Walking 
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Please tick the one response which best describes your usual abilities 
IN THE PAST SEVEN DAYS: 
     
 Without 
ANY 
difficulty 
With SOME 
difficulty 
With MUCH 
difficulty 
 
UNABLE 
to do 
 
HYGIENE 
Are you able to: 
     
 Wash and dry your entire body?  
 
_____ 
 
 
_____ 
 
 
_____ 
 
 
_____ 
 
 Take a tub bath? 
 
_____ _____ _____ _____  
 Get on and off the toilet? 
 
     
REACH 
Are you able to: 
     
 Reach and get down a 2 kilo 
object (such as a bag of sugar) 
from just over your head? 
 
_____ 
 
_____ 
 
_____ 
 
_____ 
 
 Bend down and pick up clothing 
off the floor? 
 
 
_____ 
 
_____ 
 
_____ 
 
_____ 
 
GRIP      
Are you able to:      
 Open car doors? _____ _____ _____ _____  
 
 Open jars that have been 
previously opened? 
 
_____ 
 
_____ 
 
_____ 
 
_____ 
 
 
 
 Turn taps on and off? _____ _____ _____ _____  
 
 
ACTIVITIES      
Are you able to:      
 Run errands and shop? _____ _____ _____ _____  
 
 Get in and out of a car? _____ _____ _____ _____  
      
 Do everyday household 
cleaning? 
_____ _____ _____ _____  
 
Please tick any AIDS or DEVICES that you usually use for any of these 
activities: 
 Raised Toilet Seats  Bathtub Seat 
 Long-handled appliances 
for reach 
 Jar Opener (for jars previously opened) 
 Long-handled appliances in 
bathroom 
  
 
 Bath tub bar  Other (specify: ________________________) 
 
 
Please tick any categories for which you usually need ASSISTANCE FROM 
ANOTHER PERSON 
 Hygiene  Gripping and opening things 
 Reach  Errands and chores 
234 
 
We are also interested in learning whether or not you are affected by pain because of your 
illness. 
 
How much pain have you had because of your illness IN THE PAST WEEK? 
 
PLACE A MARK ON THE LINE TO INDICATE THE SEVERITY OF THE PAIN. 
  NO PAIN                                                                                                                   VERY SEVERE                 
                                                                                                                                                   PAIN 
 
     0                                                                                                                                 100 
 
IN THE PAST WEEK how much have your intestinal problems interfered with your daily 
activities? 
 
PLACE A MARK ON THE LINE TO INDICATE THE LIMITATION OF ACTIVITY. 
INTESTINAL PROBLEMS                                                                                VERY SEVERE                 
DO NOT LIMIT ACTIVITIES                                                                               LIMITATION 
 
     0                                                                                                                                 100 
 
IN THE PAST WEEK how much have your breathing problems interfered with your daily 
activities? 
 
PLACE A MARK ON THE LINE TO INDICATE THE LIMITATION OF ACTIVITY. 
BREATHING PROBLEMS                                                                          VERY SEVERE                 
DO NOT LIMIT ACTIVITIES                                                                        LIMITATION 
 
     0                                                                                                                                 100 
 
IN THE PAST WEEK how much has your Raynaud’s interfered with your daily activities? 
 
PLACE A MARK ON THE LINE TO INDICATE THE LIMITATION OF ACTIVITY. 
RAYNAUD’S  DOES                                                                                   VERY SEVERE                 
NOT LIMIT ACTIVITIES                                                                             LIMITATION 
 
     0                                                                                                                                 100 
 
IN THE PAST WEEK how much have your finger ulcers interfered with your daily 
activities? 
 
PLACE A MARK ON THE LINE TO INDICATE THE LIMITATION OF ACTIVITY. 
FINGER ULCERS                                                                                          VERY SEVERE                 
DO NOT LIMIT ACTIVITIES                                                                        LIMITATION 
 
     0                                                                                                                                 100 
 
Overall, considering how much pain, discomfort, limitations in your daily life and other 
changes in your body and life, how severe would you rate your disease today? 
 
PLACE A MARK ON THE LINE TO INDICATE THE LIMITATION OF ACTIVITY. 
NO DISEASE                                                                                                          VERY SEVERE                 
                                                                                                                                     LIMITATION 
     0                                                                                                                                 100 
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8.1.2 Short Form-36, version 2 
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8.1.3 Systemic Sclerosis Functional Score 
 
 
ITEM Please tick one 
(please see key 
below) 
  0 1 2 3 
1 Can you lift and pour water (about 3 
pints) from a saucepan? 
    
2 Can you unscrew a jam-jar lid from a jar 
which has been opened? 
    
3 Can you take money (20p and £1) out of 
a purse with a thumb and second digit? 
    
4 Can you hold a pen and write your 
name? 
    
5 Can you hold a pen and write half a 
sheet of typing paper (A4)? 
    
6 Can you do and undo shirt buttons?     
7 Can you tuck your shirt or blouse into 
the waistband? 
    
8 Can you comb the back of your hair?     
9 Can you wash your hair? 
 
    
10 Can you get up from the toilet without 
using your hands? 
    
11 Can you walk up to 20 steps without 
using a banister?  
    
 
 
 
  
 
0 = Able to perform in normal manner 
1 = Able to perform with alteration in style 
2 = Can only manage with difficulty  
3 = Impossible to achieve 
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8.2 HAQ and HAQ-DI additional results 
 
There are eight functional activity category scores in the HAQ; dress and 
groom, arise, eating, walking, hygiene, reach, grip and activity. The descriptive 
statistics of each category are illustrated in the following tables, Tables 8.1-8. 
 
At 26 weeks, no changes were seen in median values for any of these 
categories for patients in both groups. Statistically there was no overall 
significant difference between the groups in any of the eight categories: groom 
and dress, arise, eating, walking, hygiene, reach, grip and activity (p=0.6139, 
p=0.6560, p=0.3927, p=0.8015, p=0.2506, p=0.5363, p=0.5628, p=0.8133 
respectively). 
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Table 8.1: Summary statistics for HAQ Dress and Groom scale, baseline to week 6 and week 26. 
 
  Summary statistics   
Treatment group Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 1 0.67 0 1 2   
  Week 6 Visit value 9 1 0.87 0 1 2   
    Change from baseline 9 0 0.5 -1 0 1   
    Adjusted mean change   -0.1 (-0.7, 0.4)     0.5982 
  Week 26 Visit value 9 1.3 0.87 0 2 2   
    Change from baseline 9 0.3 0.5 0 0 1   
    Adjusted mean change   0.2 (-0.2, 0.6)     0.3174 
Placebo Baseline Visit value 10 1.7 0.95 0 2 3   
  Week 6 Visit value 10 1.2 0.92 0 1 3   
    Change from baseline 10 -0.5 0.97 -3 0 0   
    Adjusted mean change   -0.4 (-0.9, 0.1)     0.1236 
  Week 26 Visit value 9 1.8 0.67 1 2 3   
    Change from baseline 9 0 0.71 -1 0 1   
    Adjusted mean change   0.2 (-0.2, 0.6)     0.4251 
Difference 
between groups 
Week 6 Adjusted mean change   0.3 (-0.5, 1.0)     0.4898 
Week 26 Adjusted mean change   0 (-0.6, 0.6)     0.8782 
Treatment groups were not significantly different (p = 0.6139) overall. 
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Table 8.2: Summary statistics for HAQ Arise scale, baseline to week 6 and week 26. 
 
  Summary statistics   
Treatment group Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 0.7 0.67 0 1 2   
  Week 6 Visit value 9 0.9 0.93 0 1 2   
    Change from baseline 9 0.2 0.67 -1 0 1   
    Adjusted mean change   0.1 (-0.4, 0.7)     0.5674 
  Week 26 Visit value 9 1 1.12 0 1 3   
    Change from baseline 9 0.3 0.87 -1 0 2   
    Adjusted mean change   0.3 (-0.3, 0.8)     0.3806 
Placebo Baseline Visit value 10 0.9 0.99 0 1 3   
  Week 6 Visit value 10 1 0.67 0 1 2   
    Change from baseline 10 0.1 0.99 -2 0 1   
    Adjusted mean change   0.1 (-0.3, 0.6)     0.5239 
  Week 26 Visit value 9 0.9 0.6 0 1 2   
    Change from baseline 9 -0.1 1.05 -2 0 1   
    Adjusted mean change   -0.1 (-0.6, 0.5)     0.8104 
Difference 
between groups 
Week 6 Adjusted mean change   0 (-0.7, 0.7)     0.982 
Week 26 Adjusted mean change   0.3 (-0.5, 1.1)     0.4271 
Treatment groups were not significantly different (p = 0.6560) overall. 
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Table 8.3: Summary statistics for HAQ Eating scale, baseline to week 6 and week 26. 
 
  Summary statistics   
Treatment group Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 0.9 0.88 0 1 2   
  Week 6 Visit value 9 1.1 1.05 0 1 3   
    Change from baseline 9 0.1 0.6 -1 0 1   
    Adjusted mean change   0.1 (-0.4, 0.6)     0.7015 
  Week 26 Visit value 9 1.1 1.05 0 1 3   
    Change from baseline 9 0.1 0.6 -1 0 1   
    Adjusted mean change   0.1 (-0.3, 0.5)     0.6031 
Placebo Baseline Visit value 10 1.2 1.03 0 1 3   
  Week 6 Visit value 10 0.9 0.88 0 1 2   
    Change from baseline 10 -0.3 0.82 -2 0 1   
    Adjusted mean change   -0.3 (-0.8, 0.2)     0.2073 
  Week 26 Visit value 9 1.2 0.83 0 1 2   
    Change from baseline 9 -0.1 0.33 -1 0 0   
    Adjusted mean change   0 (-0.4, 0.3)     0.9867 
Difference 
between groups 
Week 6 Adjusted mean change   0.4 (-0.3, 1.1)     0.2532 
Week 26 Adjusted mean change   0.1 (-0.4, 0.6)     0.6999 
Treatment groups were not significantly different (p = 0.3927) overall.  
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Table 8.4: Summary statistics for HAQ Walking scale, baseline to week 6 and week 26. 
 
  Summary statistics   
Treatment group  Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 0.7 0.95 0 0 2   
  Week 6 Visit value 9 0.8 0.97 0 0 2   
    Change from baseline 9 0 0 0 0 0   
    Adjusted mean change   0 (-0.4, 0.4)     0.9689 
  Week 26 Visit value 9 1 1.22 0 0 3   
    Change from baseline 9 0.2 0.44 0 0 1   
    Adjusted mean change   0.2 (-0.3, 0.7)     0.4044 
Placebo Baseline Visit value 10 0.9 0.88 0 1 2   
  Week 6 Visit value 10 1 0.82 0 1 2   
    Change from baseline 10 0.1 0.88 -1 0 2   
    Adjusted mean change   0.1 (-0.3, 0.5)     0.5345 
  Week 26 Visit value 9 1 0.87 0 1 2   
    Change from baseline 9 0.2 0.97 -2 0 1   
    Adjusted mean change   0.2 (-0.3, 0.7)     0.3688 
Difference between 
groups 
Week 6 Adjusted mean change   -0.1 (-0.7, 0.5)     0.6477 
Week 26 Adjusted mean change   0 (-0.8, 0.7)     0.9703 
Treatment groups were not significantly different (p = 0.8015) overall. 
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Table 8.5: Summary statistics for HAQ Hygiene scale, baseline to week 6 and week 26. 
 
  Summary statistics   
Treatment group  Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 1.8 1.23 0 2 3   
  Week 6 Visit value 9 1.4 1.01 0 2 3   
    Change from baseline 9 -0.2 0.44 -1 0 0   
    Adjusted mean change   -0.3 (-0.7, 0.2)     0.2828 
  Week 26 Visit value 9 1.6 1.13 0 2 3   
    Change from baseline 9 -0.1 0.33 -1 0 0   
    Adjusted mean change   -0.1 (-0.5, 0.2)     0.4067 
Placebo Baseline Visit value 10 2 1.05 0 2 3   
  Week 6 Visit value 10 1.9 1.2 0 2 3   
    Change from baseline 10 -0.1 0.88 -1 0 2   
    Adjusted mean change   -0.1 (-0.5, 0.4)     0.7706 
  Week 26 Visit value 9 2.1 0.93 1 2 3   
    Change from baseline 9 0.2 0.67 -1 0 1   
    Adjusted mean change   0.3 (-0.1, 0.6)     0.1356 
Difference 
between groups 
Week 6 Adjusted mean change   -0.2 (-0.8, 0.5)     0.5573 
Week 26 Adjusted mean change   -0.4 (-0.9, 0.1)     0.108 
Treatment groups were not significantly different (p = 0.2506) overall. 
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Table 8.6: Summary statistics for HAQ Reach scale, baseline to week 6 and week 26. 
 
  Summary statistics   
Treatment group  Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 1.3 0.95 0 2 2   
  Week 6 Visit value 9 1.4 1.13 0 2 3   
    Change from baseline 9 0.2 0.83 -1 0 2   
    Adjusted mean change   0.1 (-0.4, 0.6)     0.5809 
  Week 26 Visit value 9 1.2 1.2 0 2 3   
    Change from baseline 9 0 1.12 -2 0 2   
    Adjusted mean change   -0.1 (-0.7, 0.6)     0.7845 
Placebo Baseline Visit value 10 2 0.67 1 2 3   
  Week 6 Visit value 10 1.6 0.7 1 1.5 3   
    Change from baseline 10 -0.4 0.52 -1 0 0   
    Adjusted mean change   -0.3 (-0.8, 0.2)     0.1828 
  Week 26 Visit value 9 1.8 0.97 0 2 3   
    Change from baseline 9 -0.2 0.67 -2 0 0   
    Adjusted mean change   -0.1 (-0.7, 0.5)     0.7451 
Difference between 
groups 
Week 6 Adjusted mean change   0.5 (-0.3, 1.2)     0.2126 
Week 26 Adjusted mean change   0 (-0.9, 1.0)     0.9758 
Treatment groups were not significantly different (p = 0.5363) overall. 
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Table 8.7: Summary statistics for HAQ Grip scale, baseline to week 6 and week 26. 
 
  Summary statistics   
Treatment group  Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 1.7 0.67 0 2 2   
  Week 6 Visit value 9 1.3 1 0 2 2   
    Change from baseline 9 -0.3 0.71 -2 0 0   
    Adjusted mean change   -0.3 (-0.9, 0.2)     0.246 
  Week 26 Visit value 9 1.3 1 0 2 2   
    Change from baseline 9 -0.3 0.71 -2 0 0   
    Adjusted mean change   -0.3 (-0.9, 0.2)     0.2073 
Placebo Baseline Visit value 10 2.1 0.32 2 2 3   
  Week 6 Visit value 10 1.4 0.84 0 2 2   
    Change from baseline 10 -0.7 0.82 -2 -0.5 0   
    Adjusted mean change   -0.7 (-1.3, -0.2)     0.0147 
  Week 26 Visit value 9 1.8 0.83 0 2 3   
    Change from baseline 9 -0.3 0.71 -2 0 0   
    Adjusted mean change   -0.4 (-0.9, 0.2)     0.1587 
Difference 
between groups 
Week 6 Adjusted mean change   0.4 (-0.4, 1.2)     0.3435 
Week 26 Adjusted mean change   0 (-0.7, 0.8)     0.9318 
Treatment groups were not significantly different (p = 0.5628) overall. 
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Table 8.8: Summary statistics for HAQ Activity scale, baseline to week 6 and week 26. 
 
  Summary statistics   
Treatment group  Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 1.1 0.99 0 1.5 2   
  Week 6 Visit value 9 1.1 0.93 0 1 2   
    Change from baseline 9 0.1 0.33 0 0 1   
    Adjusted mean change   0 (-0.4, 0.4)     0.9259 
  Week 26 Visit value 9 1.3 1.12 0 2 3   
    Change from baseline 9 0.3 0.71 0 0 2   
    Adjusted mean change   0.2 (-0.3, 0.8)     0.3381 
Placebo Baseline Visit value 10 1.9 0.57 1 2 3   
  Week 6 Visit value 10 1.7 0.67 1 2 3   
    Change from baseline 10 -0.2 0.63 -1 0 1   
    Adjusted mean change   -0.1 (-0.5, 0.3)     0.5332 
  Week 26 Visit value 9 1.9 0.78 1 2 3   
    Change from baseline 9 0 0.5 -1 0 1   
    Adjusted mean change   0.2 (-0.3, 0.7)     0.3514 
Difference between 
groups 
Week 6 Adjusted mean change   0.1 (-0.4, 0.7)     0.6426 
Week 26 Adjusted mean change   0 (-0.7, 0.8)     0.9701 
Treatment groups were not significantly different (p = 0.8133) overall. 
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8.3 SF- 36 additional results 
 
The SF-36 is split into 8 domains, 4 for physical health (Physical functioning, 
Role Physical, Bodily pain and General Health) and 4 for mental health (Vitality, 
Social Functioning, Role Emotional and Mental Health). Role Physical has 
already been discussed in Chapter 3. The descriptive statistics of each of the 
other categories are illustrated in the following tables, Tables 8.9-15. 
 
 For the SF-36 domain scales that mostly contribute to the scoring of the 
physical health summary outcome, patients in the HCS group reported 
improvement between baseline and Week 6 in role-physical and general health, 
however this was not maintained at Week 26 as results indicate that there had 
been no change from baseline median in role-physical and a worsening in 
general health. For the two other domain scales, physical functioning and bodily 
pain in this category there were no changes in median results between baseline 
and Week 6 or Week 26. Scores for patients in the placebo group at Week 6 
mostly declined in all but one (general health) of the domain scales that 
contribute mostly to the physical health summary outcome. At Week 26 patients 
in the placebo group either reported continued decline (physical functioning, 
role-physical) or remained unchanged (bodily pain). However there was a small 
improvement in median change from baseline for the general health domain. 
Overall for physical health there was no significant difference at week 6 or week 
26 apart from role physical mentioned above. There were no significant 
changes in the 4 mental health domains between the groups.
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Table 8.9: Summary statistics for SF-36 Physical Functioning scale, baseline to week 6 and week 26. 
 
  Summary statistics   
Treatment group  Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 39.5 31.49 0 32.5 90   
  Week 6 Visit value 9 45.6 33.21 0 50 95   
    Change from baseline 9 5.6 12.36 -10 0 30   
    Adjusted mean change   5.9 (-6.3, 18.1)     0.3209 
  Week 26 Visit value 9 40.6 36.18 0 35 100   
    Change from baseline 9 0.6 13.79 -20 0 20   
    Adjusted mean change   0.9 (-8.9, 10.7)     0.8509 
Placebo Baseline Visit value 10 33.5 20.69 5 32.5 85   
  Week 6 Visit value 10 37 20.3 10 30 70   
    Change from baseline 10 3.5 21.35 -15 -7.5 45   
    Adjusted mean change   3.1 (-8.5, 14.7)     0.5782 
  Week 26 Visit value 8 26.9 20.69 0 20 70   
    Change from baseline 8 -8.1 13.35 -25 -12.5 10   
    Adjusted mean change   -9.7 (-19.9, 0.4)     0.0596 
Difference between 
groups 
Week 6 Adjusted mean change   2.8 (-14.0, 19.6)     0.7301 
Week 26 Adjusted mean change   10.6 (-3.6, 24.8)     0.1319 
Higher values indicate better functioning. 
Treatment groups were not significantly different (p = 0.3003) overall. 
249 
 
Table 8.10: Summary statistics for SF-36 Pain scale, baseline to week 6 and week 26. 
 
  Summary statistics   
Treatment group  Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 36.4 28.12 0 32 100   
  Week 6 Visit value 9 42.2 29.65 0 41 100   
    Change from baseline 9 4.2 29.76 -49 0 50   
    Adjusted mean change   1.3 (-17.1, 19.7)     0.8821 
  Week 26 Visit value 9 38.8 31.27 0 41 100   
    Change from baseline 9 0.8 14.92 -32 0 19   
    Adjusted mean change   -2.1 (-17.5, 13.3)     0.7728 
Placebo Baseline Visit value 10 52.4 32.38 0 46.5 100   
  Week 6 Visit value 10 45.6 25.13 12 41 80   
    Change from baseline 10 -6.8 33.52 -50 -6 72   
    Adjusted mean change   -2.8 (-20.4, 14.8)     0.7362 
  Week 26 Visit value 9 35.6 23.17 12 22 74   
    Change from baseline 9 -11.6 30.59 -69 0 22   
    Adjusted mean change   -9.7 (-24.9, 5.5)     0.1944 
Difference between 
groups 
Week 6 Adjusted mean change   4.2 (-21.6, 29.9)     0.7363 
Week 26 Adjusted mean change   7.6 (-14.2, 29.4)     0.4722 
Higher values indicate better functioning. 
Treatment groups were not significantly different (p = 0.5522) overall. 
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Table 8.11: Summary statistics for SF-36 General Health scale, baseline to week 6 and week 26. 
 
  Summary statistics   
Treatment group  Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 36.8 19.76 5 35 67   
  Week 6 Visit value 9 40.1 27.31 5 30 77   
    Change from baseline 9 4.8 10.39 -12 5 25   
    Adjusted mean change   5.9 (-7.6, 19.3)     0.3707 
  Week 26 Visit value 9 36.2 26.51 10 25 77   
    Change from baseline 9 0.9 11.27 -10 -5 15   
    Adjusted mean change   2 (-10.4, 14.4)     0.7408 
Placebo Baseline Visit value 10 31 18.47 0 26 62   
  Week 6 Visit value 10 27.3 14.41 5 26 52   
    Change from baseline 10 -3.7 26.03 -47 0 47   
    Adjusted mean change   -4.1 (-16.9, 8.6)     0.4996 
  Week 26 Visit value 9 24 16.12 0 20 57   
    Change from baseline 9 -3.6 19.53 -42 5 20   
    Adjusted mean change   -7.9 (-19.8, 4.1)     0.1813 
Difference between 
groups 
Week 6 Adjusted mean change   10 (-8.6, 28.6)     0.2706 
Week 26 Adjusted mean change   9.8 (-7.4, 27.1)     0.2451 
Higher values indicate better functioning. 
Treatment groups were not significantly different (p = 0.2342) overall. 
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Table 8.12: Summary statistics for SF-36 Vitality scale, baseline to week 6 and week 26. 
 
  Summary statistics   
Treatment group  Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 35.5 14.62 15 37.5 60   
  Week 6 Visit value 9 38.9 21.91 10 30 70   
    Change from baseline 9 2.2 23.33 -25 -5 50   
    Adjusted mean change   2.6 (-10.2, 15.5)     0.6678 
  Week 26 Visit value 9 38.3 21.51 15 30 75   
    Change from baseline 9 1.7 21.65 -25 0 35   
    Adjusted mean change   2.1 (-10.1, 14.3)     0.7221 
Placebo Baseline Visit value 10 34 20.92 10 27.5 70   
  Week 6 Visit value 10 33.5 15.82 15 35 60   
    Change from baseline 10 -0.5 17.23 -20 0 40   
    Adjusted mean change   -1.1 (-13.2, 11.1)     0.8537 
  Week 26 Visit value 9 32.2 23.33 10 20 65   
    Change from baseline 9 -2.8 10.93 -20 0 15   
    Adjusted mean change   -2.8 (-14.9, 9.2)     0.6222 
Difference between 
groups 
Week 6 Adjusted mean change   3.7 (-14.0, 21.4)     0.6619 
Week 26 Adjusted mean change   4.9 (-12.2, 22.1)     0.5505 
Higher values indicate better functioning. 
Treatment groups were not significantly different (p = 0.5617) overall. 
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Table 8.13: Summary statistics for SF-36 Social Functioning scale, baseline to week 6 and week 26. 
 
  Summary statistics   
Treatment group  Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 53.8 28.9 0 50 100   
  Week 6 Visit value 9 61.1 32.74 0 50 100   
    Change from baseline 9 9.7 27.08 -13 0 75   
    Adjusted mean change   11.1 (-9.1, 31.2)     0.2609 
  Week 26 Visit value 9 56.9 27.32 25 37.5 100   
    Change from baseline 9 5.6 24.3 -25 0 50   
    Adjusted mean change   6.9 (-12.4, 26.2)     0.4588 
Placebo Baseline Visit value 10 48.8 33.57 0 56.3 100   
  Week 6 Visit value 10 51.3 29.14 0 50 100   
    Change from baseline 10 2.5 37.64 -38 0 88   
    Adjusted mean change   2.5 (-16.5, 21.6)     0.7805 
  Week 26 Visit value 9 36.1 34.49 0 25 100   
    Change from baseline 9 -6.9 34.86 -63 0 50   
    Adjusted mean change   -8.4 (-27.4, 10.6)     0.3629 
Difference between 
groups 
Week 6 Adjusted mean change   8.5 (-19.2, 36.3)     0.524 
Week 26 Adjusted mean change   15.3 (-11.8, 42.4)     0.2491 
Higher values indicate better functioning. 
Treatment groups were not significantly different (p = 0.3082) overall. 
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Table 8.14: Summary statistics for SF-36 Role Emotional scale, baseline to week 6 and week 26. 
 
  Summary statistics   
Treatment group  Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 45.8 36.69 0 41.7 100   
  Week 6 Visit value 9 72.2 33.59 0 83.3 100   
    Change from baseline 9 24.1 28.7 0 25 83   
    Adjusted mean change   17.8 (-3.6, 39.1)     0.0973 
  Week 26 Visit value 9 59.3 34.72 0 66.7 100   
    Change from baseline 9 11.1 34.86 -25 0 83   
    Adjusted mean change   4.8 (-19.7, 29.3)     0.6836 
Placebo Baseline Visit value 10 70 34.96 25 87.5 100   
  Week 6 Visit value 10 61.7 30.23 25 62.5 100   
    Change from baseline 10 -8.3 42.67 -75 -8.3 67   
    Adjusted mean change   -1.4 (-21.8, 19.0)     0.8862 
  Week 26 Visit value 9 57.4 40.71 0 50 100   
    Change from baseline 9 -9.3 43.39 -100 0 50   
    Adjusted mean change   -4.2 (-28.1, 19.7)     0.7144 
Difference between 
groups 
Week 6 Adjusted mean change   19.2 (-11.1, 49.4)     0.1977 
Week 26 Adjusted mean change   9 (-25.8, 43.8)     0.591 
Higher values indicate better functioning. 
Treatment groups were not significantly different (p = 0.3391) overall. 
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Table 8.15: Summary statistics for SF-36 Mental Health scale, baseline to week 6 and week 26. 
 
  Summary statistics   
Treatment group  Visit Value n Mean SD Min Median Max Prob 
HCS Baseline Visit value 10 58.8 21.42 20 68 80   
  Week 6 Visit value 9 61.8 21.83 20 68 88   
    Change from baseline 9 5.3 8.94 -8 0 20   
    Adjusted mean change   4.5 (-4.9, 14.0)     0.3225 
  Week 26 Visit value 9 58.2 20.89 24 68 88   
    Change from baseline 9 1.8 14.16 -28 4 20   
    Adjusted mean change   1 (-11.4, 13.4)     0.868 
Placebo Baseline Visit value 10 62 18.31 28 62 80   
  Week 6 Visit value 10 66.4 14.87 40 62 84   
    Change from baseline 10 4.4 18.03 -24 4 32   
    Adjusted mean change   5.5 (-3.5, 14.4)     0.2157 
  Week 26 Visit value 9 57.3 22.09 20 64 88   
    Change from baseline 9 -2.7 22.54 -40 0 32   
    Adjusted mean change   -1.7 (-13.9, 10.4)     0.7675 
Difference 
between groups 
Week 6 Adjusted mean change   -0.9 (-14.0, 12.2)       0.8835 
Week 26 Adjusted mean change   2.7 (-14.7, 20.1)     0.7456 
Higher values indicate better functioning. 
Treatment groups were not significantly different (p = 0.8934) overall. 
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